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High-risk human papillomaviruses (HPV) infect squamous epithelia and cause 
hyperproliferative lesions that can progress to cancer. During infection, the virus interacts 
with and regulates the host kinome, which has important implications for viral and cellular 
protein function. The cyclic AMP (cAMP) dependent protein kinase A (PKA) 
phosphorylates several viral proteins and altered activity of this pathway may be relevant 
for oncogenic progression of HPV infections; however, whether the virus modulates the 
activity of PKA during infection is unclear. Using a bioluminescent resonance energy 
transfer-based approach, HPV18 replication was consistently associated with increased 
activity of the PKA pathway, occurring concomitantly with increased levels of cAMP; this 
was partially dependent on the HPV E5 oncoprotein. Additionally, biochemical analysis 
showed that the virus interacted with a nuclear regulator of PKA-RII signalling, the 
A-kinase-anchoring protein 95 (AKAP95). This interaction was mediated by the 
PSD95/DLG/ZO-1 (PDZ)-binding motif of the E6 oncoprotein, requiring the polarity 
protein hScrib and PKA. Intriguingly, E6 regulated AKAP95-PKA binding and silencing 
of the AKAP in a physiological HPV18 replication model showed that it regulated 
expression of E6 targets Dlg1, hScrib and p53. Thus, E6 targeting of AKAP95 may be 
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CHAPTER 1 INTRODUCTION 
1.1 Virus infection and cancer 
The first suggestion that viral infections could lead to the development of cancer came 
from studies in the early 20th century that showed a filterable agent (later termed Rous 
sarcoma virus) in cell extracts taken from a chicken tumour could transmit tumour 
formation to a healthy chicken (Rous, 1911). The first evidence of virus-induced human 
cancers came from Epstein-Barr virus (EBV). In the 1950s, the British surgeon Denis 
Burkitt described a childhood tumour while working in East Africa that he suspected was 
due to a virus being spread by arthropods (Burkitt, 1962). Subsequently, the virologists 
Tony Epstein and Yvonne Barr established the first cell line from Burkitt’s lymphoma and 
showed that it was possible to observe the virus by electron microscopy (Epstein et al., 
1964). Although met with initial scepticism by the scientific community, there is now 
significant evidence that EBV plays a central role in the development of Burkitt’s 
lymphoma, as well as other malignancies such as nasopharyngeal and post-transplant 
carcinomas, thus establishing it as the first human tumour virus (reviewed in Javier and 
Butel, 2012).  
Since then, the number of viruses causally associated with human cancers has risen 
considerably, with seven viruses being defined by the International Agency for Research 
on Cancer (IARC) as carcinogenic in humans. These include EBV, hepatitis B virus, 
hepatitis C virus (HCV), Kaposi sarcoma-associated herpesvirus (KSHV), human 
immunodeficiency virus, type-1 (HIV-1), human T cell lymphotropic virus type-1 and 
several human papillomavirus types (HPV). In addition to these viruses, bacteria such as 




infections cause approximately 16% of human cancers (Akram et al., 2017; Chen et al., 
2014; Liao, 2006; Plummer et al., 2016). This list is constantly evolving and it is likely that 
additional agents will be added as evidence accumulates. One such example is the Merkel 
cell polyomavirus, a small double-stranded DNA virus that has received increasing 
research attention due to its link with Merkel cell carcinoma, a rare but often fatal 
cutaneous malignancy (Feng et al., 2009). 
These viruses can persist for many years either as a result of integration into the host 
genome or by expressing viral proteins that segregate the viral genome into daughter cells 
during cell division, resulting in latent infection. During this time, they can contribute to 
the carcinogenic process through either direct or indirect mechanisms. Direct-acting 
tumour viruses such as EBV and HPV encode oncoproteins whose expression leads to the 
immortalisation and transformation of infected cells. Indirect-acting tumour viruses, such 
as HIV and HCV, however, cause cancer by other means, including virus-mediated 
induction of chronic inflammation and immunosuppression (reviewed in Morales-Sánchez 
and Fuentes-Pananá, 2014). For example, the mechanisms behind HCV-associated 
carcinogenesis include the acquisition of DNA damage as a result of immune-mediated 
hepatic inflammation as well as the induction of oxidative stress, both of which are thought 
to contribute to the development of hepatocellular carcinoma (Tarocchi et al., 2014). HIV 
contributes towards cancer risk by inducing a state of immunosuppression in the host. This 
virus-induced immunosuppression is thought to predispose individuals to opportunistic 
infection(s) by other viruses such as KSHV, which gives rise to a 500-fold increase in the 
risk of Kaposi sarcoma compared to the general population (Hernández-Ramírez et al., 
2017), as well as reducing immune-mediated surveillance and clearance of malignant cells 




1.2 Human papillomaviruses 
1.2.1 Human papillomaviruses 
HPVs are a group of small, non-enveloped, double-stranded DNA viruses that belong to 
the Papillomaviridae family and are associated with the development of both benign and 
malignant lesions at mucosal and cutaneous squamous epithelial sites. There have been 
more than 210 HPV types identified to date and the complete genome sequence has been 
determined for more than 180 of these viruses (https://pave.niaid.nih.gov). Despite the 
large range of HPV types, only a small subset of these viruses have been defined as 
carcinogenic and are associated with the development of cancer in the anogenital region 
(e.g. cervical, anal, penile, vulvar, vaginal cancer) as well as in the oropharynx (tonsil and 
base of tongue) (International Agency for Research on Cancer, 2007). These viruses have 
also been linked to cancers at other anatomical sites, such as the breast, lung and liver; 
however, strong causal evidence is lacking (Cheau-Feng et al., 2016; Simoes et al., 2012; 
Tulay and Serakinci, 2016) 
1.2.2 HPV classification 
HPV classification is based on the DNA sequence of the L1 open reading frame (ORF) 
where differences in L1 DNA sequence of 10% or more define a new HPV type, while 
2-10% define a subtype and <2% a new variant. This definition came from scientists 
working on HPV taxonomy and was agreed at the International Papillomavirus Workshop, 
Quebec 1995. HPVs are classified into one of five genera—alpha (α), beta (β), gamma (γ), 
mu (µ) and nu (ν)—based on viral genome sequence, tissue tropism and association with 
disease, and members of the same genus share >60% DNA sequence identity in the L1 




number of known HPV types and attract the vast majority of research attention due to their 
association with cancer.  
The alpha genus contains 66 HPV types and is divided into both high- or low-risk mucosal 
viruses depending on their propensity to cause cancer, as well as low-risk cutaneous 
viruses commonly associated with benign skin lesions and warts. Of these high-risk 
mucosal types, the alpha genus contains HPV types 16 and 18 that together cause around 
70 to 76% of cervical cancer cases worldwide, with estimated prevalence rates of 57% and 
16% for HPV16 and HPV18, respectively (Li et al., 2011). HPV16 is associated with the 
development of squamous cell carcinomas while HPV18 is linked with the development of 
adenocarcinomas (Bulk et al., 2006). The remaining cases are associated with infection by 
one of the other high-risk HPVs. These include the six most frequently encountered after 
HPV16 and HPV18 in cervical cancers - HPV31, 33, 35, 45, 52 and 58 – as well as other 
HPV types (e.g. HPV51, 56, 66, 39 and 59) (IARC Working Group, 2012)  
The low-risk alpha-HPV types, such as HPV types 6 and 11, are not commonly associated 
with cancer development but nevertheless carry a small (1-3%) risk of cancer progression 
(Egawa and Doorbar, 2017). In addition, these viruses cause genital and oral warts as well 
as recurrent respiratory papillomas that tend to be difficult to treat clinically (Lacey et al., 
2006; De Villiers et al., 2004). The beta genus contains 64 virus types that are associated 
with the development of cutaneous benign lesions, though there is evidence that some of 
these viruses are carcinogenic in the immunosuppressed (HPV8: Schaper et al., 2005) or 
co-operate with ultraviolet light in the development of non-melanoma skin cancer (HPV38: 
Viarisio et al., 2011, 2016). Additionally, individuals with the genetic disorder 
epidermodysplasia verruciformis (EV) are highly susceptible to infection by beta HPV 




squamous cell carcinomas of the skin, particularly on sun-exposed sites. EV is a primary 
immunodeficiency disorder where sufferers have compromised innate and cell-mediated 
immunity, thought to arise due to mutations in two genes (EVER1/TCM6 and 
EVER2/TCM8) whose gene products function in zinc metabolism and T cell activation 
(Lazarczyk et al., 2009; Ramoz et al., 2002). The remaining gamma, mu and nu viruses all 
target the cutaneous epithelia and are associated with the development of papillomas and 



















Figure 1.1: HPV phylogenetic tree. HPV types are classified into one of five genera—alpha, 
beta, gamma, mu and nu—where alpha and beta represent the largest group of HPV types. 
Within the alpha genus, HPVs can be classified as low-risk cutaneous viruses (grey), low-risk 
mucosal viruses (orange) or high risk mucosal viruses (pink). Those alpha-types highlighted 
in red are known carcinogenic virus types while the others are either probably or possibly 
carcinogenic, in line with the classification by the International Agency for Research on 





1.2.3 HPV genome organisation 
HPVs contain a double-stranded DNA genome of approximately 8 kb in size, encapsidated 
by an icosahedral capsid around 50-60 nm in diameter. The viral genome contains both 
early and late gene regions as well as a non-protein coding region known as the long 
control region (LCR). The early promoter lies within the E6 ORF, with the late promoter 
within the E7 ORF. An illustration of the viral genome is given in Figure 1.2. 
The LCR, sometimes known as the upstream regulatory region, does not encode any 
known proteins but instead houses the viral origin of replication, the early promoter and a 
variety of binding sites both for the viral E2 protein and cellular transcription factors, both 
of which are important for controlling early oncoprotein expression (Hoppe-Seyler and 
Butz, 1994; Thierry, 2009). The viral genome encodes multiple ORFs, yielding either early 
or late proteins, so named for the timing of their expression during the viral life cycle. In 
addition, alternative splicing of these ORFs leads to viral fusion proteins, such as E8^E2 
and E1^E4, that have important functions in the viral life cycle. The early region encodes 
E6, E7, E8, E1, E2, E4 and E5, which play roles in viral transcription, viral genome 
replication and host cell transformation. Despite its name, E4 expression coincides with the 
differentiation-dependent aspect of the HPV life cycle. The late region encodes the major 
(L1) and minor (L2) structural proteins, which together make up the virus coat (Longworth 
and Laimins, 2004). L2 also has multiple other functions in the viral life cycle, including 
encapsidation (see section 1.2.4). The viral capsid is an icosahedral capsid composed of 
360 copies of the L1 protein arranged into 72 capsomeres, with a variable number of L2 
molecules per capsid. The precise number of L2 molecules in each capsid is unclear; 
however, estimates range from 36 to 72 L2 molecules per capsid depending on the exact 




Figure 1.2: HPV genome organisation. The HPV genome is organised into early, late 
and the LCR. The early region encodes E6, E7, E8, E1, E2, E4 and E5 while the late 
region encodes the structure proteins L1 and L2. The early promoter (PE; p105 in HPV18) 
sits within the E6 ORF and the late promoter (PL; p811 in HPV18) within the E7 ORF. 
The promoter PE8, from which the E8^E2 fusion protein is expressed, is contained within 
the E1 ORF. The early (pAE) and late (PAL) polyadenylation sites are shown between the 








1.2.4 HPV life cycle  
The HPV life cycle is closely linked to the differentiation status of the host cell that it 
infects – the keratinocyte. In a natural infection of the cervix, it is likely that the virus 
reaches the transformation zone, an area of metaplastic tissue between the squamous 
epithelium of the ectocervix and the glandular or columnar tissue of the endocervical canal 
that appears to be particularly susceptible to HPV carcinogenesis – the squamocolumnar 
junction – following epithelial injury (Elson et al., 2000; Kines et al., 2009). This region 
contains a discrete population of non-stratified cuboidal cells of embryonic origin that 
express a junction cell-specific expression profile. It is thought that these junctional cells 
are progenitors of cervical cancers by the phenotypic similarities between these cells and 
high-grade cancers (Herfs et al., 2012, 2013; Mirkovic et al., 2015) After the virus reaches 
this area, it interacts with heparin sulphate proteoglycans such as syndecan-1 via the L1 
protein to facilitate internalisation (Joyce et al., 1999; Kines et al., 2009; Shafti-Keramat et 
al., 2003). This binding event leads to a conformational change in the virus capsid, 
exposing L1 residues for cleavage by the serine protease kallikrein-8 and resulting in 
exposure of the amino terminus of L2 (Cerqueira et al., 2015; Richards et al., 2013). 
Following this, cyclophilin B, a peptidyl-prolyl cis-trans isomerase that is involved in 
protein folding and maturation (Lang et al., 1987), binds to this exposed region of L2 and 
induces a further conformational change to reveal a binding site for the proprotein 
convertase furin (Cerqueira et al., 2015; Day et al., 2008; Richards et al., 2013). These 
events result in the transfer of the virus to a secondary entry receptor. The identity of this 
secondary receptor has not been firmly established but attractive candidates include the 




among others (Evander et al., 1997; Fast et al., 2018; Scheffer et al., 2013; Yoon et al., 
2001).  
The exact mechanism of virus internalisation is not completely understood and appears to 
vary between different HPV types. For example, internalisation of HPV16 is dependent on 
actin polymerisation and tetraspanin-enriched microdomains but is independent of clathrin, 
caveolin and lipid rafts (Scheffer et al., 2013; Schelhaas et al., 2012; Selinka et al., 2002; 
Spoden et al., 2008). By contrast, HPV31 is dependent on caveolin and dynamin but 
independent of clathrin-mediated endocytosis (Smith et al., 2007). Nevertheless, the virus 
is endocytosed in an asynchronous fashion over a number of hours, with the exact timing 
depending on the cell cycle stage of the target cell during infection (Broniarczyk et al., 
2015). 
Following internalisation, the virus is disassembled in the endosomal compartment to L1 
and L2-viral DNA complexes. This L2-viral complex is trafficked, via the trans-Golgi 
network, to the nucleus where, upon breakdown of the nuclear envelope during mitosis, the 
virus associates with host chromatin (Aydin et al., 2017; Bienkowska-Haba et al., 2012; 
Calton et al., 2017; DiGiuseppe et al., 2014). Finally, the L2-viral genome accumulates in 
nuclear domain 10 (ND10) bodies where L2 relocalises the ND10 body proteins Sp100 and 
Daxx to drive early viral transcription and viral DNA replication (Florin et al., 2002; Stepp 
et al., 2013) 
Replication of viral genomes requires the actions of the viral E1 and E2 proteins. These 
viral proteins are necessary and sufficient for viral replication and bind to specific binding 
sites in the viral origin of replication to initiate viral replication (Chiang et al., 1992; Ustav 
et al., 1991). E2 binds to specific sites in the viral origin of replication and facilitates the 




assembles into a double hexameric helicase and catalyses the melting of the DNA both to 
allow for access to the cellular replication machinery and to provide a template for the 
synthesis of viral DNA (Sedman and Stenlund, 1998; Enemark and Joshua-Tor, 2006; 
Stenlund, 2003). During this process, the virus relies extensively on host factors for viral 
DNA replication, including replication protein A, proliferating cell nuclear antigen 
(PCNA), topoisomerase I and the DNA polymerases polα and polϵ (Chojnacki and 
Melendy, 2018; Loo and Melendy, 2004; Melendy et al., 1995). This initial amplification 
stage generates around 50 to 100 episomal HPV genomes per cell with minimal viral 
transcription, which is thought to evade detection by the host immune system (Maglennon 
et al., 2011; McBride, 2017). This limited viral genome replication is thought to be largely 
due to expression of the E8^E2 protein, a conserved fusion protein derived from the E8 
ORF and E2 C-terminal sequences, which inhibits viral gene expression and genome 
replication (Dreer et al., 2017). In addition, E2 is involved in the partitioning of viral 
genomes during mitotic cell division by tethering the virus genome to host chromosomes. 
A plethora of E2 interactions are thought to anchor the viral genome to host chromosomes, 
including bromodomain-containing protein 4, mitotic kinesin-like proteins 2, ChlR1 and 
DNA topoisomerase 2-binding protein 1, ensuring viral persistence in dividing cells 
(Donaldson et al., 2007; Harris et al., 2017; Parish et al., 2006; You et al., 2004; Yu et al., 
2007).  
In the next stage of the viral life cycle, the infected cell population expands through the 
actions of E6 and E7. How exactly this switch from low levels of viral transcription in 
basal cells to increased oncoprotein expression during differentiation is unclear, however, 
recent studies have identified a role for the cellular transcriptional regulators CCCTC-




between YY1 bound at the viral transcriptional enhancer and CTCF bound at the E2 ORF 
regulates E6/E7 expression via epigenetic repression of the early promoter. During 
keratinocyte differentiation, however, there is a decrease in the level of YY1 protein which 
disrupts this repressive chromatin loop, allowing for increased expression of E6 and E7 
(Pentland et al., 2018).  
In uninfected cells, basal keratinocytes undergo either symmetrical cell division to produce 
a daughter cell with the same fate that remains in the basal layer or asymmetrical cell 
division to produce cells with different fates; one remaining in the basal cell layer with 
mitotic potential and the other daughter cell entering differentiation, which involves 
exiting the cell cycle (Koster and Roop, 2007). In HPV-infected cells, the virus subverts 
this process and pushes post-mitotic differentiating cells back into the cell cycle, delaying 
differentiation and allowing for amplification of the viral genome to thousands of copies 
per cell.  
One key mechanism by which the virus amplifies its genomes involves the retinoblastoma 
(Rb) family of proteins. E7 binds to and degrades Rb, as well as the related pocket proteins 
p105, p107 and p130, via the proteasome. Rb represses the expression of genes required 
for G1 to S transition via a variety of mechanisms, such as direct binding of Rb to the 
activation domain of E2Fs, blocking their ability to activate transcription (Flemington et 
al., 1993). An alternative mechanism exists whereby Rb binds to protein complexes that 
regulate chromatin structure, such as histone deacetylases, using a binding site distinct 
from its E2F-binding site. These proteins deacetylate histones bound to gene promoters, 
promoting the formation of nucleosomes that inhibit transcription (Luo et al., 1998). E7 
disrupts Rb-E2F interactions, allowing for constitutive activation of E2F responsive genes, 




cells prepared from HPV genome containing cultures display markers of cell cycle re-entry 
such as PCNA and were competent for host DNA replication, even after the onset of 
differentiation (Cheng et al., 1995). Furthermore, this targeting of pocket proteins is 
important for the delayed keratinocyte differentiation seen in organotypic rafts derived 
from HPV genome containing cells, indicating that the virus relies on different E7 
functions at different stages of its life cycle (Collins et al., 2005). 
This E7-induced premature cell cycle re-entry leads to induction of host defence pathways, 
including those mediated by the tumour suppressor p53. To overcome this induction of 
p53, E6 redirects the ubiquitination ability of E6-associated protein (E6-AP), a cellular E3 
ubiquitin ligase, towards p53, which is not a natural target of E6-AP, and results in its 
subsequent proteasomal degradation (Huibregtse et al., 1991; Scheffner et al., 1990, 1992, 
1993). E6-mediated degradation of p53 is thought to protect suprabasal cells from 
apoptosis as a result of E7-induced cell cycle re-entry and appears to contribute to 
replication of the viral DNA in cells (Flores et al., 2000; Park and Androphy, 2002; 
Thomas et al., 1999). In addition to causing its degradation, E6 inactivates p53 function by 
downregulating its ability to activate transcription of p53-dependent promoters (Lechner 
and Laimins, 1994; McCance et al., 1999; Zimmermann et al., 1999), which also appears 
to contribute to the maintenance and amplification of viral episomes (Kho et al., 2013; 
Lorenz et al., 2013; Wang et al., 2009).  
Other E6 functions distinct from its p53 targeting ability are also important for the viral life 
cycle, including its ability to target a subset of cellular proteins containing 
PSD95/DLG/ZO-1 (PDZ) domains. This targeting ability is mediated by a four amino acid 
class I PDZ binding motif (PBM) located in the extreme carboxyl terminus of E6 (HPV16: 




protein (reviewed in James and Roberts, 2016). Disruption of this motif in the context of 
the complete viral genome impairs cell proliferation, viral genome maintenance and 
amplification, and late viral protein expression in multiple high-risk viruses (Delury et al., 
2013; Lee and Laimins, 2004; Nicolaides et al., 2011). In addition, loss of this targeting 
ability has also been associated with an increased rate of abnormal mitoses, chromosomal 
segregation defects and genomic instability in HPV genome containing cells, suggesting it 
also plays a role in maintaining mitotic integrity of HPV genome containing cells (Marsh 
et al., 2017). E6-PDZ interactions are also important for controlling E6 protein expression 
(Kranjec et al., 2016; Nicolaides et al., 2011).  
In addition to the functions described above, the virus also depends on other host pathways 
during its life cycle, including components of the cellular DNA damage response, for viral 
genome amplification. Multiple high-risk HPV types activate the ataxia telangiectasia 
mutated (ATM) pathway, a cellular DNA repair pathway that primarily responds to DNA 
double-strand breaks, in the absence of DNA damage, with virus-induced phosphorylation 
of multiple ATM substrates throughout keratinocyte differentiation (Moody and Laimins, 
2009). This activation is mediated by E7 through the signal transducer and activator of 
transcription (STAT)-5β protein via the peroxisome proliferator-activated receptor γ; 
however, E1 can also activate ATM signalling (Hong and Laimins, 2013; Moody and 
Laimins, 2009; Sakakibara et al., 2011). Use of pharmacological inhibitors showed that the 
activity of this pathway was not required for the maintenance of the viral episome in 
undifferentiated cells but was crucial for viral genome amplification during differentiation 
(Moody and Laimins, 2009). Furthermore, E7 increases the expression of the MRN 
(MRE11, RAD50, and NBS1) complex proteins, activators of ATM following DNA 




amplification during differentiation (Anacker et al., 2014). Similarly, various other DNA 
repair factors such as Rad51 and BRCA1, which also function in repairing DNA double-
strand breaks, are required for differentiation-dependent viral genome amplification 
(Chappell et al., 2016). The virus also relies on another DNA damage response pathway 
during its life cycle – the ataxia telangiectasia and Rad3-related protein (ATR) pathway. 
This pathway protects the integrity of replicating chromosomes and appears to be required 
for viral replication, with inhibition of phosphorylation of ATR or checkpoint kinase 1 
(Chk1; a downstream target of ATR) inhibiting viral genome amplification during 
differentiation and, to a lesser extent, viral genome maintenance in undifferentiated cells 
(Hong et al., 2015).  
Another host pathway used by the virus for viral DNA replication and/or amplification 
involves members of the STAT protein family. STATs were originally discovered for their 
role in interferon-regulated gene transcription but have since been recognised as mediating 
cellular responses to a variety of cytokines and growth factors. There are seven STAT 
family members (STAT1α/β, STAT2, STAT3α/β, STAT4, STAT5A, STAT5B and 
STAT6) which, although structurally similar, have diverse biological roles and regulate 
processes ranging from embryonic development and cell differentiation to regulation of the 
immune response (Konjević et al., 2013). HPV represses STAT-1 expression primarily at 
the level of transcription, with both E6 and E7 proteins able to inhibit its expression. For 
E6, this ability depended on its binding to E6-AP. Restoration of STAT-1 in 
overexpression experiments or by treatment with gamma-interferon, which leads to 
activation of STAT-1, showed that it contributed to both episomal maintenance in 
undifferentiated cells and to viral genome amplification during keratinocyte differentiation 




Primary human foreskin keratinocytes (HFKs) maintaining HPV18 genomes displayed 
increased phosphorylation of STAT3 compared to control cells, with the expression of E6 
alone sufficient to drive this phosphorylation via a mechanism involving Janus kinases and 
the mitogen-activated protein kinase (MAPK) pathway. This occurred independently of 
E6’s ability to degrade p53, bind to E6-AP and interact with PDZ proteins. Further 
experiments showed that STAT3 was required for expression of E6 and E7 and viral 
genome maintenance in undifferentiated cells as well as viral genome amplification and 
expansion of the suprabasal compartment in organotypic raft culture (Morgan et al., 2018). 
More recent work in HPV positive cervical cancer cells showed that this E6-driven STAT3 
activation occurred via the pro-inflammatory cytokine interleukin-6 through a signalling 
axis composed of Rac1 and NFkB. Furthermore, in these cells, activation of STAT3 
contributed to cancer cell proliferation and survival (Morgan and Macdonald, 2019) 
The function of E5 during the virus life cycle remained for some years unclear however 
recent studies using E5 mutant or knockout genomes have begun to unravel a role for this 
enigmatic protein. Using normal immortalised keratinocytes maintaining HPV16 wild type 
or E5 knockout genomes, E5 was shown to be involved in suprabasal DNA synthesis 
(Genther et al., 2003). In a parallel study using primary HFKs maintaining HPV31 wild 
type or E5 knockout genomes, E5 appeared to contribute to differentiation-dependent viral 
genome amplification and expression of late viral proteins (Fehrmann et al., 2003). 
Furthermore, experiments carried out in an HPV18 life cycle model established in primary 
HFKs showed that E5 contributed to cell cycle progression and unscheduled host DNA 
synthesis in differentiating keratinocytes, which correlated with activation of the epidermal 
growth factor receptor (EGFR) in these cells. The same study showed this E5 potentiated 




on the keratinocyte growth factor receptor (KGFR), a regulator of the balance between 
epithelial proliferation and differentiation, and its effector protein kinase B (otherwise 
known as AKT) in differentiating cells (Wasson et al., 2017). Although largely examined 
in transient overexpression experiments, E5 also appears to augment other functions of the 
E6 and E7 oncoproteins (described in section 1.2.6), which may be relevant for the 
completion of the viral life cycle. 
The next stage of the viral life cycle is marked by expression of the E1^E4 protein 
(otherwise known as E4), a fusion protein derived from first five amino acids of E1 fused 
to the complete E4 ORF (Doorbar et al., 1986). It is the most abundantly expressed viral 
protein and its expression coincides with the onset of viral genome amplification in 
differentiated cells (Peh et al., 2002). Studies in life cycle models showed that its 
contributions to the viral life cycle, such as regulation of differentiation-dependent viral 
genome amplification and late gene expression, are common to the high-risk HPV16, 
HPV18 and HPV31 (Egawa et al., 2017; Wilson et al., 2005, 2007) as well as cottontail 
rabbit papillomavirus (Peh et al., 2002), although the exact mechanism by which this 
occurs is unclear. One possibility is through its ability to regulate the cell cycle. HPV16 
and 18 E4 have both been shown to induce G2 arrest by cytoplasmic sequestration of 
cyclin B/cyclin-dependent kinase (CDK)2 complexes, possibly preventing the 
phosphorylation of nuclear targets important for cell cycle progression (Davy et al., 2002; 
Knight et al., 2011; Nakahara et al., 2002). This G2 arrest likely establishes a pseudo-S 
phase state in which host DNA replication is complete but the cell remains competent for 
replication, allowing the virus access to the replicative machinery without any competition 
from host DNA synthesis. Analysis of the motifs required for this arrest, however, showed 




(Egawa et al., 2017; Knight et al., 2011), possibly reflecting important biological 
differences between these viruses.  
In the final stages of the virus life cycle, high levels of the E2 protein suppress E6 and E7 
expression, which is important for cellular differentiation, expression of the late viral 
proteins and eventual production and release of new infectious virions from the uppermost 
layers of the differentiated epithelium (Bernard et al., 1989). Studies in keratinocytes have 
suggested that these later phases occur in a multi-step process. Virion assembly begins in 
the cytoplasm where L1 is assembled into pentameric structures prior to nuclear import 
mediated by cellular karyopherin proteins, likely aided by additional proteins such as the 
heat shock protein 70 family members (Bird et al., 2008; Florin et al., 2002b; Nelson et al., 
2000). These proteins also appear to be required for incorporation of L2 into the 
developing capsid by facilitating its nuclear transport (Bordeaux et al., 2006; Florin et al., 
2004). The cellular protein nucleophosmin also appears to contribute to the correct 
assembly of the virus capsid, possibly by acting as a protein scaffold for L1 and L2, 
although this is not fully understood at present (Day et al., 2015). How the viral genome is 
then incorporated into the capsid is also unclear. While the majority of viruses contain 
packaging signals that are recognised by viral proteins to allow for encapsidation of viral 
DNA, no such sequence has been identified for HPV. In vitro experiments have suggested 
that viral DNA is instead incorporated into the capsid by a size discrimination mechanism. 
The viral capsid goes through a repeated process of assembly and disassembly, taking in 
both cellular and viral DNA, until a suitably sized DNA is encountered, leading to the 
formation of a virion that is resistant to disassembly (Cerqueira et al., 2016). This size 
discrimination mechanism is consistent with earlier observations that papillomavirus 




size of the HPV genome) (Buck et al., 2004; Stauffer et al., 1998). Once the viral DNA has 
been assembled and packaged, capsid maturation occurs in the naturally occurring redox 
environment of the uppermost layers of the epithelium, leading to the formation of 
infectious virions (Conway et al., 2009). There is evidence from an HPV18 life cycle 
model that expression of E1^E4 in these layers contributes to capsid assembly, infectivity 
and viral release through an as yet undefined mechanism (Biryukov et al., 2017). 
How exactly these infectious virions are released from the upper layers of the 
differentiated epithelium has not been fully resolved; however, it is generally thought to 
occur as the result of the sloughing off of cells containing matured virus particles. The role 
of viral proteins during this process is largely unclear but there is some evidence that E4 
may play a role in facilitating viral egress. Both HPV1 and HPV16 E4 interact with 
cytokeratin proteins and, in the case of HPV16 E4, cause their collapse (Doorbar et al., 
1991; Roberts et al., 1993). Furthermore, studies using HPV11 E4 showed that it could 
alter the morphology of differentiated keratinocytes and cornified cell envelope, leading to 
a much thinner and fragile cell envelope (Brown and Bryan, 2000; Brown et al., 2006). 
Together, these data suggest that E4 may facilitate viral release by interfering with the 
integrity of the uppermost layers of the epithelium, although further studies are required in 
primary life cycle models to confirm this mechanism. 





Figure 1.3: HPV life cycle. HPV gains entry to basal keratinocytes in the basal lamina following small microwounds or abrasions where it attaches to 
the heparin sulphate proteoglycan syndecans-1, resulting in conformational changes of L2 and L1 that results in its attachment to secondary receptors 
such as cluster of differentiation 151 (CD151) for virus internalisation. The viral genome is then trafficked through cellular vesicles until it reaches 
nuclear domain 10 (ND10) bodies. Viral DNA is replicated due to the actions of the E1 and E2 as well as various cellular proteins and is maintained as a 
low copy number episome. In the intermediate layers, E6 and E7 delay differentiation and stimulate cell division to support viral DNA replication, which 
results in amplification of the viral genome to thousands of copies per cell. In the superficial layers, the structural proteins L1 and L2 are expressed and 
this is associated with viral coating and release of progenitor virions. Viral release occurs through sloughing off of cells containing matured virus 




1.2.5 Viral transcription 
Transcription of the early viral proteins is controlled by the actions of E2 as well as a 
myriad of host transcription factors. These viral and cellular proteins bind to specific sites 
in the viral LCR and either activate or repress viral transcription. 
The viral LCR is divided into three regions known as the 5’ segment, central segment and 
the 3’ segment. The 5’ segment contains the nuclear matrix binding region and 
transcription termination signal, the central segment contains a tissue-specific enhancer 
and the 3’ segment contains the viral origin of replication and the early promoter, which 
overlaps with the start of the E6 ORF (McBride, 2009; Stünkel and Bernard, 1999). The 
promoter contains a canonical TATA box that is involved in the recruitment of the general 
transcription factor II D (TFIID) to the viral LCR, leading to ribonucleic acid (RNA) 
polymerase II-dependent transcription of viral transcripts with the potential to encode E1, 
E2, E1^E4, E5, E6, E7 and E8, which are polyadenylated at the early polyadenylation site 
(Johansson and Schwartz, 2013; Straub et al., 2015; Thierry, 2009).  
Also contained within the LCR is a number of E2 binding sites. E2 binds as a homodimer 
to specific sequences containing the consensus motif ACCGN4CGGT and recruits cellular 
factors important for regulation of viral transcription. There are multiple E2 binding sites 
in the LCR, with most alpha HPVs containing four binding sites (McBride, 2009), and E2 
binding to these sites can either activate or repress transcription. For example, at low E2 
protein levels, it only binds to E2 binding site 4, activating transcription of early viral 
genes. However, as levels of E2 protein rise, other binding sites (such as binding sites 1 





E2 binding to these repressive sites regulates the recruitment of host transcription factors 
important for viral transcription. For example, E2 binding to binding site 1, which is close 
to the TATA box, blocks the recruitment of proteins of the transcription pre-initiation 
complex, such as TFIID and TATA-binding protein and E2 binding to binding site 2 
results in the displacement of the transcription factors Sp1 and activator protein-1 (AP-1) 
from their adjacent binding sites in the LCR, repressing viral transcription. These binding 
sites are bound by E2 with low affinity and are only occupied at high E2 protein levels, 
indicating that E2 protein expression is an important regulator of viral transcription from 
the early promoter (Demeret et al., 1994; Tan et al., 1994).  
In differentiated cells, late viral transcription occurs from the late promoter within the E7 
ORF (p670 in HPV16; p811 in HPV18). The activity of this promoter is dependent on 
differentiation-specific transcription factors such as the CCAAT-enhancer binding proteins 
(Gunasekharan et al., 2012) and gives rise to HPV transcripts with the potential to encode 
E1^E4, E5, L1 and L2 that are polyadenylated at the late polyadenylation site. E1^E4 and 
E5 containing transcripts however can also be polyadenylated at the early polyadenylation 
site (Johansson and Schwartz, 2013).  
Transcription from the viral genome occurs from only one DNA strand and is 
polycistronic, giving rise to transcripts with the potential to encode for more than one viral 
protein. A complex process of alternative splicing of viral transcripts exists, yielding 
multiple messenger RNAs (mRNAs) that maximises the coding potential of the 8 kb viral 
genome (reviewed in Graham and Faizo, 2017). For example, the E6 ORF can encode up 
to four E6* proteins, depending on the exact HPV type. In HPV18, E6*I, the most well 
studied of the E6* proteins, degrades discs large 1 (Dlg1) and scribble (hScrib) in the 




There is no evidence that the HPV genome encodes viral microRNAs, small noncoding 
RNAs involved in the control of various cellular processes, but it is known that the virus 
alters expression of host microRNAs during the HPV life cycle. One well-studied example 
is miR-203a-3p, which regulates the balance of proliferation versus differentiation during 
keratinocyte differentiation. HPV E7 blocks the induction of this microRNA during 
differentiation via the MAPK/protein kinase C pathway, and this inhibition is important for 
both episomal maintenance in undifferentiated cells as well as viral genome amplification 
during keratinocyte differentiation (Melar-New and Laimins, 2010). 
1.2.6 HPV oncoproteins 
The viral oncoproteins functionally interact during infection, resulting in changes in 
cellular proliferation and apoptosis, which provide an environment conducive for viral 
DNA replication. Additional functions of the viral oncoproteins contribute to the 
immortalisation of HPV genome containing cells and, with the acquisition of oncogenic 
mutations, these infections may progress to cellular transformation and cancer (Figure 1.4; 






Figure 1.4: Functional interaction of the HPV oncoproteins. The HPV oncoproteins 
E5, E6 and E7 functionally synergise to promote the aberrant proliferation of cells 
containing HPV genomes. These interactions result in cellular hyperproliferation 
through degradation of the retinoblastoma tumour suppressor pathway by viral 
targeting of the pocket proteins, deregulation of cell polarity proteins (PDZ domain-
containing proteins) and deregulation of growth factor signalling. In response to 
aberrant cell proliferation, the host cell upregulates apoptotic pathways, including those 
mediated by p53. To ensure cell survival, E6 targets p53 for degradation through the 
ubiquitin-proteasome system, inactivating the apoptotic response. E6 can also drive 
cellular immortalisation through modulation of telomerase, leading to the emergence of 
immortal cells. Continuous expression of the viral oncoproteins through integration of 
viral DNA into the host genome leads to an unstable host environment, leading to the 
acquisition of additional oncogenic mutations that lead to cellular transformation. 























The E5 protein is a small, hydrophobic protein expressed by a subset of HPV types that, 
when overexpressed in fibroblasts appears to localise to the endoplasmic reticulum, Golgi 
apparatus and to nuclear membranes (Conrad et al., 1993). When expressed in 
keratinocytes, the natural host cell of HPV, E5 localises primarily to the endoplasmic 
reticulum (Disbrow et al., 2003).  
Unlike bovine papillomavirus type one E5 that interacts with the platelet-derived growth 
factor receptor beta (PDGFRβ) to drive cell transformation, HPV E5 proteins do not 
interact with PDGFRβ and are comparatively only weakly transforming in cell culture. 
Instead, HPV E5 appears to primarily mediate its effects via EGFR (reviewed in DiMaio 
and Petti, 2013; Müller et al., 2015). 
The first evidence of HPV E5 transforming ability came from HPV6 E5, which induced 
anchorage-independent growth in mouse fibroblasts (Chen and Mounts, 1990). Subsequent 
work using HPV16 E5 showed that it could also induce cellular transformation of murine 
fibroblasts, acting synergistically with the EGFR (Leechanachai et al., 1992; Straight et al., 
1993). In vitro studies showed that E5 can enhance phosphorylation of the EGFR in 
response to epidermal growth factor (EGF) treatment (Crusius et al., 1998; Straight et al., 
1993), induce EGF-dependent cellular proliferation of primary keratinocytes (Bouvard et 
al., 1994) and enhance the activity of EGF-dependent signalling cascades such as those 
involving ERK1/2 and protein kinase B in EGF-treated cells (Crusius et al., 1997; Gu and 
Matlashewski, 1995). Furthermore, E5 also enhances recycling of the EGFR to the plasma 
membrane and prevents its degradation by modulating membrane trafficking pathways 
(Straight et al., 1995; Thomsen et al., 2000). Consistent with a role in driving proliferation, 




frequency of epidermal hyperplasia and spontaneous tumour formation, both of which 
were dependent on EGFR activity (Genther Williams et al., 2005).  
In addition to its effects on EGF signalling, E5 potentiates the effects of other HPV 
oncoproteins. Together with E7, E5 can enhance proliferation of rodent epithelial cells 
(Leechanachai et al., 1992; Valle and Banks, 1995) and augment the ability of E6 and E7 
to immortalise primary human keratinocytes (Stöppler et al., 1996). More recently, E5 has 
been identified as a novel virus-encoded membrane channel – viroporin - and this channel 
activity seems to be important for E5-driven mitogenic signalling (Wetherill et al., 2012, 
2018). Other functions of E5 include downregulation of major histocompatibility complex 
surface complexes and reduction of antigen presentation to cytotoxic T cells, allowing for 
immune evasion of HPV infected cells (De Freitas et al., 2017), stimulation of host DNA 
synthesis (Straight et al., 1993) and increasing the motility and invasiveness of 
keratinocyte cell lines (Kivi et al., 2008).  
1.2.6.2 E6 
E6 proteins expressed by those alphavirus types associated with cancers are small 
(~15 kDa) proteins that contain two zinc fingers (ZFs) as well as a C-terminal PBM. The 
ZFs are characterised by Cys-X-X-Cys motifs and mediate its interaction with E6-AP to 
drive degradation of p53. In addition, the PBM mediates interactions with a variety of 
cellular proteins containing PDZ domains, generally resulting in degradation or 
mislocalisation of the target protein. Through these interaction domains, E6 targets a 
number of cellular pathways involved in the regulation of genome stability, apoptosis, cell 
morphology and polarity, chromatin remodelling and the immune response, among others 
(reviewed in Wallace and Galloway, 2015). Additional functions of E6 include the 




chromosome ends, which is important for the immortalisation of keratinocytes 
(Klingelhutz et al., 1996; Liu et al., 2009; Oh et al., 2001). 
E6 interactions with p53 and cellular PDZ proteins are discussed below. 
1.2.6.2.1 E6 and p53 
One of the best-studied E6 interacting partners is the p53 protein. Originally identified in 
1979, p53 has become known as the master guardian of the genome and regulates cellular 
responses to diverse genotoxic insults, such as those arising from DNA damage, hypoxia, 
oncogenic signalling and nutrient deprivation, among others, and its induction often results 
in cell cycle arrest or, in the case of irreparably damaged cells, apoptosis or senescence 
(Vousden and Prives, 2009). In addition to activation as a result of one of the above 
described stimuli, p53 is also activated upon inappropriate stimulation of DNA synthesis. 
E7-mediated premature cell cycle re-entry of suprabasal keratinocytes leads to induction of 
p53, which is targeted by E6 for degradation to prevent apoptosis of HPV genome 
containing cells. 
The mechanism by which E6 degrades p53 involves the host E3 ubiquitin ligase E6-AP. 
The p53 protein is not a natural target of E6-AP; it only binds to p53 in the presence of E6, 
leading to its degradation through the proteasome (Huibregtse et al., 1991; Scheffner et al., 
1990, 1992, 1993). This degradation effect is only towards nuclear p53, as a p53 mutant 
that localises predominantly in the cytoplasm is not degraded by E6 (Stewart et al., 2005). 
While both high and low-risk E6 proteins interact with p53, only high-risk proteins can 
induce its degradation. This is due to differences in the domains of p53 to which E6 bind; 
only high-risk E6 proteins bind to the core region of p53, which appears to be required for 




In addition to directing its degradation, E6 can also manipulate p53 function by inhibiting 
its binding to specific DNA sequences. This inhibition correlated with the relative affinity 
of E6 for p53, with E6 proteins such as those derived from HPV16 shown as a strong 
binder and potent inhibitor of p53 DNA binding (Lechner and Laimins, 1994). 
Mechanistically, E6 binding induces a conformational change in the p53 protein that 
prevents p53-DNA binding and/or disruption of already formed p53-DNA complexes 
(Thomas et al., 1995).  
A second mechanism by which E6 modulates p53 function distinct from degradation is 
through changes in its localisation. In E6-expressing cells, a subpopulation of p53 is 
retained in the cytoplasm. While not fully understood, this sequestration may arise either 
through masking of the nuclear localisation sequence located in the protein’s C-terminus or 
through enhanced nuclear export (Freedman and Levine, 1998; Stewart et al., 2005). The 
latter hypothesis is supported by findings in HPV positive cervical cancer cell lines that 
inhibition of nuclear export by the drug leptomycin B, which blocks the formation of 
several nuclear export complexes, leads to increased nuclear p53 (Freedman and Levine, 
1998).  
The ability of E6 to target p53 through multiple mechanisms is important not only during 
the virus life cycle where it contributes to replication of viral DNA and episomal 
maintenance (Flores et al., 2000; Kho et al., 2013; Lorenz et al., 2013; Park and Androphy, 
2002; Thomas et al., 1999; Wang et al., 2009), but it has important implications for cancer 
development. Loss of p53 likely contributes to the acquisition of additional oncogenic 
mutations seen during disease progression that would have otherwise been repaired, 





1.2.6.2.2 E6 and PDZ domain-containing proteins 
Other important E6 interacting partners are those that contain PDZ domains. These 
proteins often contain multiple PDZ domains as well as other interaction domains (e.g. Src 
homology 2 domains) and so often act as protein scaffolds. As a result, these proteins can 
form multiprotein complexes that are involved in diverse cellular functions, including 
neuronal synapse formation, cellular polarity and proliferation, and survival. Rather 
unsurprisingly, these proteins are often deregulated during viral infection and during 
carcinogenesis (reviewed in James and Roberts, 2016).  
In the high-risk viruses, E6 binding to PDZ domain-containing proteins occurs via a short 
peptide sequence (class I PBM) located in the protein’s carboxyl terminus. Interestingly, of 
the ~300 PDZ proteins encoded by the human genome, E6 only targets a subset of 
approximately 19 proteins (Thomas et al., 2016).  
As all high-risk E6 proteins possess a canonical PBM, the ability to target PDZ 
domain-containing proteins was therefore thought to be a marker of oncogenicity. 
However, it was recently shown that the several related, albeit non-oncogenic, virus types 
(such as HPV40) degrade PDZ domain-containing proteins. The authors suggest that, 
therefore, the ability of E6 to target PDZ domain-containing proteins represent an 
adaptation to colonise a new ecosystem in the host and this was acquired prior to the 
oncogenic phenotype (Van Doorslaer et al., 2015). 
Although all high-risk E6 proteins contain PBMs, there is variation within this region 
(HPV16 E6: ETQL; HPV18 E6: ETQV). The first hint that this difference in sequence was 
biologically relevant came from early studies on the interaction of HPV18 and HPV16 E6 
with the PDZ domain-containing proteins Dlg1 and scribble (otherwise known as hScrib). 




substrate specificity, with HPV18 E6 (PBM: ETQV) binding Dlg1 more efficiently than 
HPV16 E6, and vice versa, HPV16 E6 (PBM: ETQL) preferring hScrib over Dlg1 
(Thomas et al., 2005).  
A recent analysis compared the binding profile of the E6 PBM of various virus types, both 
oncogenic and non-oncogenic, and showed that sequences upstream of the PBM were also 
important in determining substrate specificity (Thomas et al., 2016). The results from this 
study showed that while Dlg1 was a major target of all PBMs tested, regardless of 
oncogenic potential, the interaction with hScrib correlated directly with cancer risk, with 
interactions detected for all virus types classified as Group I carcinogens by IARC 




The ability of E6 to target PDZ domain-containing proteins is important for several stages 
of the virus life cycle. Loss of this PDZ targeting ability in various experimental systems 
has shown it to play a role in cell proliferation, mitotic integrity, viral genome maintenance 
and amplification, and late viral protein expression (Lee and Laimins, 2004; Nicolaides et 
al., 2011; Delury et al., 2013; Marsh et al., 2017). Furthermore, some of these PDZ targets, 
such as hScrib, are important for regulating E6 protein expression, further highlighting the 
importance of this E6 function (Kranjec et al., 2016; Nicolaides et al., 2011). Interestingly, 
there appears to be some co-operation between E6’s p53 and PDZ targeting ability, with 
depletion of p53 improving episomal maintenance in cells lacking the PBM (Brimer and 
Vande Pol, 2014). This is intriguing as E6 mutants defective for PDZ targeting still target 
p53 as efficient as the wild type protein, which may suggest that at least one of the targets 
of the E6 PBM feeds into a cellular pathway controlled by p53 (Brimer and Vande Pol, 
2014; Nguyen et al., 2003). 
This motif likely also plays a key role in HPV-driven transformation and cancer 
development, with studies showing this targeting ability to be important for the 
transforming ability of E6 both in vivo and in vitro. Studies in immortalised keratinocytes 
showed that the E6 PBM contributed to an epithelial to mesenchymal-like phenotype with 
concomitant changes in the actin cytoskeleton and adherens junctions, all of which are 
features of the transformed phenotype in keratinocytes (Watson et al., 2003). In addition, 
this motif has been linked to anchorage-independent growth in both mouse and human 
tonsillar keratinocytes and contributes to the inhibition of apoptosis in epithelial cells 
(James et al., 2006; Spanos et al., 2008). Furthermore, studies in transgenic mice showed 




developing fewer and smaller tumours compared to those expressing a wild type E6 
protein (Shai et al., 2007).  
Little is known about which of the E6 PDZ targets are important for HPV-associated 
carcinogenesis. In normal cervical keratinocytes expressing E7, oncogenic Ras (RasG12V) 
and an E6 protein unable to degrade PDZ proteins, short hairpin RNA (shRNA)-mediated 
depletion of hScrib, MAGI1 or PAR3 increased anchorage-independent growth, with a 
combined knockdown inducing anchorage-independent growth to the same level as the 
wild type E6. Combined knockdown of hScrib, Dlg1 and Dlg4 had the same effect. 
Analysis of tumorigenicity in nude mice showed that combined knockdown of MAGI1 and 
hScrib or Dlg1, Dlg4 and hScrib enhanced tumour growth more than the individual 
shRNAs but not to the level of wild type E6. Interestingly, however, triple knockdown of 
MAGI, hScrib and PAR3 led to tumour growth at a higher rate than that of wild type E6. 
Together, these data indicate that multiple targets of the E6 PBM are relevant for HPV-
associated cervical carcinogenesis (Yoshimatsu et al., 2017) 
A description of two of the most well studied E6-PDZ interactors, Dlg1 and hScrib, is 
given below. 
 
1.2.6.2.2.1 E6 and Dlg1 
The first E6-PDZ target identified was the human homologue of the Drosophila discs 
large 1 tumour suppressor protein, Dlg1 (Kiyono et al., 1997; Gardiol et al., 1999). Dlg1 
contains three PDZ domains and is the founding member of the membrane-associated 
guanylate kinase homologs protein family (Hough et al., 1997). Much of what is known 
about Dlg function comes from a series of studies carried out in Drosophila where it was 




in neoplastic growth of imaginal discs, epithelial structures that give rise to adult body 
structure during Drosophila development. These studies showed that Dlg is required for 
the correct organisation of the cytoskeleton, for the proper localisation of membrane 
proteins and for establishing epithelial polarity in the fly (Woods et al., 1996).  
Interestingly, the human homologue of Dlg shares approximately 60% homology and has 
the same localisation as its Drosophila counterpart (Lue et al., 1994), raising the 
suggestion that it plays a similar function in human cells. Indeed, changes in Dlg1 
expression and localisation are seen in various cancer types, including cervical cancer, and 
its loss may contribute to neoplastic transformation through changes in tissue architecture 
(Mantovani et al., 2001; Sugihara et al., 2016; Watson et al., 2002).  
The E6-Dlg1 interaction results in degradation of the nuclear, phosphorylated form of the 
protein (Kiyono et al., 1997; Gardiol et al., 1999). It is much more efficiently degraded by 
HPV18 E6 than by HPV16 E6 (Thomas et al., 2005). There is some contention in the 
literature of the exact ubiquitin ligase involved in this degradation, with some studies 
stating this occurs in an E6-AP independent fashion (Pim et al., 2000; Sterlinko Grm and 
Banks, 2004), while others suggest functional E6-AP is required (Kuballa et al., 2007). 
Changes in Dlg1 localisation has been reported during cervical cancer progression, with 
loss of Dlg1 at sites of cell to cell contact associated with a concomitant increase in 
cytoplasmic Dlg1 in high-grade cancers (reviewed in Roberts et al., 2012). Total cellular 
levels of Dlg1 are also reduced in high-grade cancers. As the vast majority of cervical 
cancers contain HPV DNA, and oncogenic HPVs are known to target Dlg1 for 
degradation, it is tempting to speculate that these changes may represent an important step 
during HPV associated cervical carcinogenesis (Watson et al., 2002). However, HPV 




alternative mechanisms may also regulate Dlg1 expression in cancer (Mantovani et al., 
2001). It is plausible that the presence of oncogenic HPV genomes enhances Dlg1 
degradation but this is yet to be proven.  
 
1.2.6.2.2.2 E6 and hScrib 
hScrib is the human homologue of the Drosophila scribble protein. It is a member of the 
leucine-rich repeat and PDZ family of proteins, with 16 leucine-rich repeats and four PDZ 
domains (Murdoch et al., 2003). hScrib localises to the basolateral membrane of polarised 
epithelial cells where it colocalises with Dlg1 (Dow et al., 2003; Nakagawa et al., 2004).  
In Drosophila, loss and/or mutation of scribble results in mislocalisation of apical proteins 
and adherens junctions to the basolateral cell surface due to changes in localisation of the 
apical transmembrane protein Crumbs (Bilder and Perrimon, 2000), and results in cells that 
are overgrown and profoundly disorganised (Bilder et al., 2000). Using a Drosophila 
system containing mutant scribble combined with overexpression of the human 
homologue, hScrib was shown to functionally restore defects in differentiation, tissue 
architecture and polarity induced by the mutant fly protein (Dow et al., 2003), leading to 
the idea that both Drosophila and human proteins act as tumour suppressors. 
Analysis of hScrib during cervical cancer progression showed a dramatic loss at the protein 
level in samples derived from HPV positive invasive cancers compared to control tissue. 
Furthermore, immunohistochemical analysis was only able to detect a faint signal in the 
uppermost layers of the epithelium. This is in contrast to control tissue where it was 
localised to sites of cell to cell contact (Nakagawa et al., 2004) 
In an analogous way to HPV18 E6’s apparent preference towards Dlg1, HPV16 E6 targets 




E6 could abrogate hScrib’s inhibition of cell immortalisation in a co-operation assay using 
oncogenic Ras, suggesting that this degradation event may contribute towards cell 
immortalisation during the viral life cycle (Thomas et al., 2005).  
 
1.2.6.2.2.3 Regulation of the E6 PBM 
A canonical PKA phosphorylation motif (R/K-R/K-X-S/T) overlaps with the E6 PBM 
from several high-risk viruses, including HPV18 and HPV16, with the amino acid (serine 
or threonine) at position -3 being the phosphoacceptor (Kühne et al., 2000). In HPV18 E6, 
phosphorylation of threonine at position 156 by PKA blocks E6-PDZ interactions by steric 
hindrance (Zhang et al., 2007), preventing E6-mediated degradation of Dlg1 (Kühne et al., 
2000). In addition to regulating E6-PDZ interactions, PKA phosphorylation allows for E6 
interactions with non-PDZ proteins such as 14-3-3 family members (Boon and Banks, 
2012).  
Studies in keratinocytes maintaining HPV18 genomes in which the E6 protein cannot be 
phosphorylated by PKA showed increased growth of HPV genome containing cells and a 
more hyperproliferative phenotype on organotypic raft culture compared to cells 
maintaining wild type HPV genomes (Delury et al., 2013). In addition, this loss of kinase 
recognition has also been associated with enhanced morphological transformation of 
keratinocytes (Watson et al., 2003), suggesting that changes in E6 phosphorylation may be 
relevant for disease progression.  
In addition to the above regulation by PKA, the E6 PBM is also subject to modulation by 
oxidative stress or the DNA damage response. Experiments done in cervical cancer cells 
showed that the induction of either process resulted in phosphorylation of E6. Depending 




primarily mediated by Chk1, although checkpoint kinase 2 was involved to a lesser extent 
via activation of PKA. This was associated with an inhibition of p53 transcriptional 
activity on some p53-responsive promoters, linking the DNA damage response to control 
of the E6 PBM and its p53 targeting ability (Thatte et al., 2018).  
Recent evidence has suggested that the presence of this PKA site contributes to E6’s 
recognition of cellular PDZ proteins. Mutation of HPV18 E6 sites crucial for PKA 
phosphorylation reduced the number of PDZ proteins to which E6 could bind. In contrast, 
the generation of a PKA recognition motif in HPV66 and HPV40 E6 proteins, which have 
PBMs but not PKA recognition sites, increases PDZ recognition. While it would be 
assumed that acquisition of a PKA recognition site would limit E6-PDZ interactions 
through changes in phosphorylation, it appears instead that this contributes to the 
promiscuity of the E6 PBM (Sarabia-Vega and Banks, 2019).  
 
1.2.6.3 E7 
High-risk E7 proteins are approximately 18 kDa in size, have no known enzymatic activity 
and, like E6, target and modify the function of various cellular proteins during infection. 
E7 proteins contain at their amino-terminus sequence similarity to the conserved regions 1 
and 2 of adenovirus E1A and simian virus 40 large T, and a carboxyl zinc-binding site, 
consisting of two CXXC domains separated by 29 to 30 amino acids. Loss of E7 in an 
HPV18 life cycle model has shown it to contribute to viral DNA amplification and 
production of infectious virus during differentiation (McLaughlin-Drubin et al., 2005). 
This viral DNA amplification defect is also evident in life cycle models of HPV16 and 
HPV31 (Flores et al., 2000; Thomas et al., 1999). In all of these life cycle models, it does 
not appear to contribute to the maintenance of viral episomes (Flores et al., 2000; 




E7 appears to be the major transforming protein in standard mouse-based cell 
transformation assays, showing morphological transformation in NIH-3T3 mouse 
fibroblasts and, together with oncogenic Ras, baby rat kidney cells. For this, E7 regulates a 
myriad of host processes, including the cell cycle, transcription, cell death/survival, DNA 
damage/repair and cellular differentiation, among others (Roman and Munger, 2013; Yeo-
Teh et al., 2018).  
The best characterised E7 interaction is that of the Rb tumour suppressor and the related 
pocket proteins, p107 and p130, and is described below. 
1.2.6.3.1.1 E7 and the pocket proteins-E2F complex 
The interaction with the Rb tumour suppressor and the related pocket proteins, p107 and 
p130, is one of the best characterised E7 interactions. These interactions occur via a 
conserved LXCXE motif in the N-terminus of the protein and serve to induce host DNA 
synthesis in post-mitotic, differentiating keratinocytes (Lee et al., 1998; Münger et al., 
1989). 
This family of proteins negatively regulates cell cycle progression from G0 into G1 and 
then into S phase. The expression of these pocket proteins varies throughout the cell cycle, 
with Rb constitutively expressed throughout all stages of the cell cycle, p107 expressed 
largely in S phase and p130 in G0 (Classon and Dyson, 2001). In differentiating epithelium, 
there is also variation in expression; Rb and p107 are localised to the basal and suprabasal 
keratinocytes, with p130 confined to the uppermost differentiated layers (Roman, 2006; 
Zhang et al., 2006). 
The mechanism by which the pocket proteins control cell cycle progression involves, at 




cells but is induced as cells move through G1/S. There are eight E2F genes encoding nine 
major proteins, with three (E2F1, E2F2, and E2F3a) considered activating E2Fs based on 
experiments that showed they activate transcription when overexpressed and two (E2F4 
and E2F5) considered repressive factors. E2F6, E2F7 and E2F8 do not contain the 
sequences required for transactivation or binding to pocket proteins and therefore are 
pocket protein-independent regulators of transcription (Iaquinta and Lees, 2007).  
In normal cells, the transcriptional activity of E2Fs 1-5 is regulated largely by their 
interactions with the pocket proteins, with pocket protein binding thought to inhibit 
transcription by two mechanisms. These mechanisms include masking the key residues 
required for transcriptional activation and by recruiting repressor complexes to 
E2F-responsive promoters. In G0/1, the repressive E2Fs are complexed with p107 and p130 
proteins and associate with E2F-responsive genes to repress their transcription. Similarly, 
the activating E2Fs are bound by Rb, inhibiting their ability to activate transcription. As 
cells enter the cell cycle, there is induction of cyclin-CDK activity, which leads to 
phosphorylation of the pocket proteins, with subsequent disruption of pocket protein-E2F 
complexes (Iaquinta and Lees, 2007; Trimarchi and Lees, 2002). In the case of the 
activator E2Fs, this relief of inhibition leads to binding of E2Fs to target promoters where 
they activate transcription (Trimarchi and Lees, 2002). 
In high-risk HPV genome containing cells, E7 binds to the pocket proteins via its LXCXE 
motif and targets them for proteasomal degradation via the cullin-2 ubiquitin ligase 
complex in a manner dependent on the host protease calpain (Münger et al., 1989; Boyer et 
al., 1996; Chellappan et al., 1992; Darnell et al., 2007; Huh et al., 2007). As a result, the 
inhibitory effect of the pocket proteins on E2Fs is lost and E7-expressing cells show 




re-entry, such as PCNA and cyclins A and E in differentiating cells (Cheng et al., 1995; 
Demeter et al., 1994). This is consistent with the data from an HPV16 life cycle model that 
showed that E7-mediated induction of host suprabasal synthesis required pocket protein 
binding, although this was independent of Rb degradation (Collins et al., 2005). E7 
proteins from low-risk HPVs can associate with Rb but this interaction does not lead to 
induction of E2F-responsive genes, although they can still degrade p130 (Dyson et al., 
1989; Zhang et al., 2006). 
There is conflicting evidence whether targeting of Rb is important for cellular 
transformation, with studies in various experimental systems showing that transformation 
correlates with Rb binding (Heck et al., 1992) but others showing that it is not essential 
(Jewers et al., 1992).  
 
1.2.7 HPV and cancer  
Oncogenic HPV infection accounts for approximately 600,000 annual cases of cancer of 
the cervix, oropharynx, anus, vulva and vagina, with the vast majority (70%+) of these 
cancers being associated with HPV16 or HPV18 infection (de Martel et al., 2017; Plummer 
et al., 2016). In the cervix, HPV16 tends to be associated with the development of 
squamous cell carcinomas while HPV18 is largely associated with adenocarcinomas (Bulk 
et al., 2006). The risk factors for the development of HPV associated cancer in HPV 
infected individuals have not been fully defined but may include long term (~6+ years) use 
of the combined oral contraceptive pill and smoking (Dempsey, 2008; Vaccarella et al., 
2006). The exact mechanisms by which these factors contribute to cancer risk are unknown 
but presumably involve suppression of the immune system, leading to viral persistence, or 




The role of oncogenic HPVs in the development of cervical cancer has received much 
research attention and this multistep process is fairly well defined. This process involves 
initial infection, virus persistence, the development of a pre-cancerous lesion and cancer. 
Of note, although high-risk HPV is an incredibly common infection, with an estimated 
global prevalence of up to 25%, the vast majority of these infections are cleared by the host 
immune system within two years, with only around 10% of infected individuals at risk of 
cervical cancer (Bruni et al., 2010; Velfhuijzen et al., 2010).  
Cervical cancer features a well-defined pre-malignant phase that is amenable to clinical 
examination by cytology and/or histology based examination of cervical tissue. These 
pre-malignant changes represent a range of histological abnormalities, ranging from grade 
one cervical intraepithelial neoplasia (CIN1) whose features include mild dysplasia 
confined to the basal one-third of the epithelium to CIN3, which features severe dysplasia, 
may be present throughout the epithelium and is considered to be carcinoma in situ/pre-
cancer. Persistent infection is considered to be a key factor for the later development of 
cervical cancer, with several studies highlighting that women who harboured persistent 
oncogenic HPV were significantly more likely to go on to develop cervical neoplasia than 
those who were infected with different oncogenic type sequentially or those who cleared 
the infection (Cuschieri et al., 2005; Kjaer et al., 2002; Wallin et al., 1999). 
In those with persistent infection, a critical event in the carcinogenic process is the 
integration of the viral genome into host DNA. This integration event can occur by one of 
two mechanisms, either a single viral genome can integrate into host DNA or multiple 
copies of the viral genome integrate into host DNA, and provides HPV genome containing 
cells a growth advantage through increased expression of early viral proteins (Jeon et al., 




drives early protein expression, including disruption of the E2 ORF. Loss of E2 protein 
alleviates its repressive effect on the early promotor, which drives early oncoprotein 
expression (Nishimura et al., 2000). An alternative mechanism is one by which progressive 
methylation of E2 binding sites 1 and 2 occurs during carcinogenesis, promoting the 
binding of E2 to binding site 4 and leading to upregulation of early viral transcripts with 
the potential to encode E6 and E7 (Leung et al., 2015). Various other mechanisms may 
also be relevant during carcinogenesis, including the formation of a virus-host super-
enhancer, with the viral genome integrating adjacent to and synergising with a cellular 
enhancer, driving E6/E7 expression (Dooley et al., 2016).  
As described in section 1.2.4, expression of the E6 and E7 oncoproteins disrupt a number 
of host pathways, including those dependent on p53 and Rb, and this is important for 
multiple aspects of the viral life cycle. Although this increased expression of E6 and E7 is 
likely a driving force in progression from CIN1 to cervical cancer (Daniel et al., 1997; Liu 
et al., 2018), additional cellular insults are required for cancer progression. One key 
mechanism underlying progression is the induction of host genomic instability. For 
example, cells expressing E6 and E7 override growth arrest mediated by DNA damaging 
agents (Song et al., 2002), induce numerical and structural chromosomal abnormalities 
(Duensing and Münger, 2002) and prevent the repair of DNA lesions by impairing the 
activity of cellular DNA damage response pathways (Khanal and Galloway, 2019). It is 
thought that mechanisms such as these contribute to the acquisition of the additional 
oncogenic hits needed for cell transformation. Consistent with this, recent evidence has 
shown that mutational load correlates with the degree of cancer risk, highlighting the 
important role that these additional oncogenic events play during disease progression 




1.2.8 HPV prevention 
There are currently three licensed vaccines against HPV marketed by the pharmaceutical 
companies Merck and GlaxoSmithKline – Cervarix, Gardasil and Gardasil9. These 
vaccines contain L1 virus-like particles derived from several HPV types, produced either 
in yeast or baculovirus expression systems, and confer immunity through the generation of 
high titres of virus neutralising antibodies that appear to be stable over time (David et al., 
2009; Mariani and Venuti, 2010; Villa et al., 2006). 
Cervarix is a bivalent vaccine that offers protection against both high-risk HPV16 and 
HPV18. Gardasil is a quadrivalent vaccine that offers protection against HPV16 and 
HPV18 in addition to the low-risk HPV6 and HPV11 viruses that are associated with the 
development of genital warts and recurrent respiratory papillomatosis (Lacey et al., 2006). 
Gardasil9, which has since replaced Gardasil in vaccination programmes, confers 
protection against seven high-risk virus types as well as HPV6 and HPV11. The exact 
composition of these vaccines, including manufacturing components and adjuvants, is 
described in Harper and DeMars, 2017. All vaccines are approved from nine years of age 
with a two-dose schedule up to the age of 13 (Cervarix) or 14 (Gardasil and Gardasil9). In 
the UK, the HPV vaccination programme has been available through the NHS to girls ages 
12 and 13 since 2008, with a catch-up scheme up to the age of 25. The recommended dose 
schedule is two doses but in individuals older than 15, the recommended schedule is 3 
doses administered at months 0, 1 or 2 and 6. While the studies required for their 
regulatory approval assessed a variety of clinical endpoints, only a selection of the primary 
endpoints are described briefly here. A full description of the study endpoints can be found 




The efficacy of Cervarix was assessed in two placebo-controlled, double-blind, clinical 
studies, including a total of 19,778 women aged 15 to 25. These studies demonstrated 
significant protection against CIN1 and CIN2+ disease associated with de novo infection 
by HPV16 and HPV18, as well as protection against persistent infection by these viral 
types for up to 12 months (European Medicines Agency, 2007). Long term follow up 
studies showed that this protective effect was evident at least up to 9.4 years post-
vaccination (Naud et al., 2014). More recent data from Scotland tracking 138,392 women 
who received the bivalent vaccine at ages 12 or 13 reported a significant reduction in all 
grades of CIN disease at age 20, equating to a vaccine efficacy of >80%, as well as 
showing herd immunity against high-grade disease in unvaccinated women in the cohort 
offered vaccination (Palmer et al., 2019).  
The efficacy of Gardasil was shown in four placebo-controlled double-blind, randomised 
clinical studies, including a total of 20,541 women. These studies demonstrated that 
Gardasil provided protection against CIN1-3, adenocarcinoma in situ (AIS), vulvar 
intraepithelial neoplasia (VIN) and genital warts associated with de novo HPV6, 11, 16 
and/or 18 infections throughout the duration of the study. The efficacy of the vaccine 
against the combined incidence of persistent infection, genital warts, vulvar and vaginal 
lesions, CIN of any grade, AIS and cervical cancer related to these HPV types was 88.7%, 
with an efficacy rate of 84.7% for HPV16 or HPV18 alone. The duration of immunity 
following three doses of Gardasil has been shown for up to 14 years post-vaccination 
(European Medicines Agency, 2017a).  
Analysis of the efficacy and long term effectiveness of Gardasil9 against HPV6, 11 16 and 
18 showed that, in 16 to 26-year-old women, the vaccine was 92.2% effective in 




18 related diseases, the vaccine was 96.0% effective for CIN or AIS, 100% for VIN2/3, 
100% for vaginal intraepithelial neoplasia and 99.0% for genital warts. In women 24 to 45 
years of age, combined efficacy against HPV6, 11, 16 and 18 associated disease was 
88.7%. Finally, in men aged 16 to 26, efficacy against HPV6, 11, 16 and 18 associated 
disease was 74.9% for AIN 2/3, 100.0% for penile intraepithelial neoplasia grades 1-3 and 
89.3% for genital warts. This protection appears to be stable long term as a review of data 
from 2,084 women over 12 years showed no cases of high-grade CIN. In addition, long 
term extension studies showed no cases of high-grade intraepithelial neoplasia nor genital 
warts up to 11.5 years in both sexes (European Medicines Agency, 2017b).  
As of September 2019, the HPV vaccine will be given to boys aged 12 and 13 in England, 
Northern Ireland and Wales, and boys aged 11 and 12 in Scotland on a two-dose schedule. 
There are also calls for the vaccine to be made available to all men and boys up to the age 
of 25, matching the coverage available to girls and women on the NHS.  
1.3 The cyclic AMP (cAMP)-PKA signalling axis 
1.3.1 Cell signalling overview 
Cell signalling describes a complex network of communication events that allow cells to 
respond to changes in their environment. Signalling molecules that cannot bypass the cell 
membrane provoke their effect by binding to receptors on the cell surface. These are 
therefore known as first messenger molecules and are often peptides or peptide hormones. 
Once the signalling molecule binds to its receptor, the receptor undergoes a conformational 
change that ultimately results in the generation of a second messenger molecule that 




1.3.2 cAMP signalling overview 
Cyclic adenosine monophosphate (cAMP) was the first second messenger to be discovered 
and was identified during work to elucidate the mechanism underlying the hyperglycaemic 
actions of adrenaline and glucagon in the liver (Akileswaran et al., 2001; Sutherland et al., 
1968). Since then, cAMP has been shown to mediate the effects of numerous hormones via 
G-protein coupled signalling in mammals. In addition, cAMP is present in all kingdoms 
where it regulates diverse processes such as mammalian gene transcription and virulence 
in pathogenic bacteria and fungi (Gancedo, 2013; McDonough and Rodriguez, 2011).  
In mammalian cells, activation of the cAMP signalling pathway occurs following the 
binding of an extracellular ligand to its respective G protein-coupled receptor (GPCR) 
which, through G proteins, regulate the activity of the adenylyl cyclases (AC), a family of 
enzymes that generate cAMP from adenosine triphosphate (ATP). The effects of cAMP are 
mediated through three main effector proteins: the cAMP-dependent protein kinase A 
(PKA), exchange proteins directly activated by cAMP (EPACs) and cyclic nucleotide-
gated ion channels. The level of cAMP within cells is also regulated by another set of 
enzymes known as phosphodiesterases (PDEs), which break down cAMP into adenosine 
monophosphate (AMP), as well as through a-kinase anchoring proteins (AKAPs) that act 
as signalling hubs that compartmentalise these signalling events (Wong and Scott, 2004). 
1.3.3 Adenylyl cyclases 
There are two families of AC enzymes expressed in mammalian cells, which are either 
soluble or transmembrane-associated. Soluble AC has two heterologous catalytic domains 
in the N-terminus with several putative regulatory domains in the C-terminus, including an 




full-length protein, there is a splice variant containing just the catalytic domains (Jaiswal 
and Conti, 2001). The activity of both the full length and the splice variant soluble AC is 
stimulated by bicarbonate and calcium ions and regulates processes mediated by changes 
in these ions in diverse cells and tissues, including the testis and sperm, kidney and eye, 
among others (Litvin et al., 2003; Tresguerres et al., 2011).  
There are nine known isoforms of transmembrane ACs (I-XI), which share a common 
structure of two transmembrane and two cytoplasmic regions. Each transmembrane region 
contains six membrane-spanning domains linked to each other by cytoplasmic domains 
(Hurley, 1999). These transmembrane ACs are characterised into one of four different 
groups depending on how they are regulated; group I consists of Ca2+-stimulated ACs 1, 3 
and 8; group II of Gβγ-stimulated AC 2, 4 and 7; group III of Giα (an inhibitory Gα 
protein)/Ca2+-inhibited AC5 and 6, while group IV contains forskolin-insensitive AC9 
(Sadana and Dessauer, 2009).  
The mechanism of cAMP synthesis involves the conversion of ATP to cAMP. This is a 
cyclisation reaction of ATP with the simultaneous release of inorganic phosphate 
(otherwise known as inorganic phosphate) (Eckstein et al., 1981; Gerlt et al., 1980). 
Degradation of cAMP occurs through the actions of PDEs that catalyse the hydrolysis of 
the 3’-phosphodiester bond on the ribose sugar, converting cAMP to AMP (Ashman et al., 
1963; Skoyles and Sherry, 1992). A schematic of cAMP generation and degradation is 








Figure 1.5: cAMP metabolism. Cyclic AMP is formed by the actions of the adenylyl cyclase (AC) family of enzymes, which convert ATP 
to cAMP. Mechanistically, this is a cyclisation reaction where there is displacement of inorganic phosphate by nucleophilic attack of the 
3’-OH atom towards the inorganic phosphate, resulting in a change of configuration. Inorganic phosphate is then released (PPi). Degradation 
of cAMP to AMP is mediated by phosphodiesterase enzymes (PDEs), which catalyse the hydrolysis of phosphodiester bonds. The structural 
images were taken from the Chemical Entities of Biological Interest database where the ID numbers were ATP: 15422, cAMP: 17489 and 




1.3.4 G protein-coupled receptors and G proteins 
The first step in the cAMP signalling pathway is the activation of GPCRs and their 
associated guanine nucleotide binding proteins (i.e. G proteins). GPCRs are the largest 
family of proteins in the mammalian genome with more than 1000 human GPCRs 
identified to date. It is thought that around 80% of all known hormones and 
neurotransmitters signal through GPCRs (Lesch and Manji, 1992). Examples of GPCR-
mediated signalling include those that regulate heart contractility (β1-adrenergic receptor: 
Madamanchi 2007; McGraw & Liggett 2005) and brain function (dopamine receptor: 
Girault & Greengard 2004). Structurally, GPCRs share a common structure of seven 
hydrophobic transmembrane domains, an extracellular amino terminus and an intracellular 
carboxyl terminus. Despite this conserved structure, individual GPCRs can have unique 
combinations of cell signalling activities, with multiple G protein subtypes and G protein 
independent signalling pathways contributing to these functions (Rosenbaum et al., 2009). 
Accordingly, GPCRs have been implicated in regulating diverse physiological functions, 
such as vision, thyroid function, hormone secretion and fertility, and have also been linked 
to cancer development (Schoneberg et al., 2004). A general overview of GPCR activation 
is given below. 
When the GPCR is inactive, the guanosine diphosphate (GDP) bound alpha subunit (Gα) 
and a G protein beta and gamma heterodimeric complex (Gβγ) exist as a multi-protein 
complex bound to GDP, which may or may not be associated with the GPCR. On ligand 
binding to the GPCR, there is a conformational change in the intracellular domain of the 
GPCR that leads to the exchange of GDP for guanosine triphosphate (GTP) on Gα. This 
binding of GTP results in the dissociation of Gα from this G protein complex, activating 




conformational change in ACs, resulting in their activation and upregulation of cAMP 
synthesis (Hurley, 1999). Other effector molecules include calcium and potassium ion 
channels, phospholipase C and other kinases. Similarly, the Gβγ subunit interacts with 
various downstream effectors, including ACs, potassium channels and the β-adrenergic 
receptor kinase (Logothetis et al., 1987; Tuteja, 2009). The Gβγ subunit can also activate 
the Gα subunit (Rondard et al., 2001). Finally, inactivation of GPCR signalling occurs via 
the GTPase activity of the Gα subunit, hydrolysing GTP to GDP, leading to its 
reassociation with Gβγ, stopping the signal (Figure 1.6). 
GPCRs do not solely exist in ‘on’ or ‘off’ configurations, but instead adopt a range of 
confirmations depending on their association with other ligands and receptors, other 
signalling molecules and/or regulatory proteins (Geppetti et al., 2015). In addition to this, 
GPCRs can be spontaneously active and show ligand-independent activity, otherwise 
known as constitutive receptor activity, which contributes to the basal activity of cell 
signalling cascades (Costa et al., 1992; Schütz and Freissmuth, 1992). 
1.3.5 Phosphodiesterases  
Phosphodiesterases are a superfamily of enzymes that catalyse the hydrolysis of the cyclic 
phosphate bond in cAMP and cyclic guanosine monophosphate (cGMP) nucleotides, 
generating AMP and GMP. There are at least 11 PDE families, comprising five dual 
specific PDEs (PDEs 1-3, 10 and 11), three cAMP-specific PDEs (PDEs 4, 7 and 8) and 
three cGMP specific PDEs (PDEs 5, 6 and 9). The general structure of these proteins is a 
transmembrane helix in the N-terminus responsible for subcellular localisation, two 
regulatory domains (consisting inter alia of an autoinhibitory domain, phosphorylation 




anchoring domain (Azevedo et al., 2014). This anchoring domain is involved in targeting 






Figure 1.6. GPCR cycle. The first step in activation of G-protein coupled receptor 
signalling begins with ligand binding to its receptor (Step 1), which results in the exchange 
of GDP for GTP on the Gα subunit, with subsequent separation of the subunits to Gα or a 
Gβγ dimer (Steps 2 and 3). These activated G protein subunits then interact with their 
target proteins (Step 4). Cessation of signalling occurs when the GTP bound to the Gα is 
hydrolysed by the intrinsic GTPase activity of Gα (Step 5), leading to the reassociation of 




The PDE families are derived from 21 different genes and classified into the above groups 
based on amino acid sequence, regulatory properties and mechanisms of catalysis. PDEs 
1-4 are expressed in most cells, with PDE3 and 4 providing the bulk of the cAMP 
hydrolysis. The other PDEs are likely only expressed in select cell populations where they 
regulate critical functions therein (Francis et al., 2011). 
The activity of these enzymes is regulated by AC and guanylyl cyclases through different 
effector proteins and feedback networks, ensuring appropriate cAMP and cGMP levels for 
cell signalling networks. While the main mechanism for lowering cAMP/cGMP levels is 
through inactivation by hydrolysis of the phosphodiester bond, additional mechanisms 
such as changes in the localisation of the cyclic nucleotide into the extracellular 
environment and into adjacent cells have also been reported, although these likely only 
contribute to small changes in cAMP levels (Barber and Butcher, 1981; Cheng et al., 2010; 
Norris et al., 2009).  
1.3.6 Protein Kinase A 
Protein kinase A is a heterotetrameric protein kinase composed of two catalytic (C) 
subunits and two regulatory (R) subunits. There are two isoforms of PKA that differ in the 
identity of their R subunits (RI, RII), giving rise to either type I or type II holoenzymes 
(PKA-RI, PKA-RII) (Corbin et al., 1975; Reimann et al., 1971). There are various 
differences between the R subunits, including amino acid conservation (although they 
share 75% identity overall), molecular weight, isoelectric point and cAMP binding. 
Despite this, both regulatory subunits have the same general structure and contain a 
docking and dimerization domain in the N-terminus through which PKA can dimerise and 
interact with AKAPs (see 1.3.8). This is followed by an inhibitor site, either a 




subunit, as well as two cAMP binding domains. While there are several differences in the 
biology of these regulatory subunits, there are two important differences; firstly, the PKA-
RI holoenzyme more readily activated by cAMP than the -RII holoenzyme in both in vivo 
and in vitro experiments (Cummings et al., 1996; Dostmann et al., 1990), and RII subunits 
are autophosphorylated by the catalytic subunit, while the RI subunit is not (Langeberg and 
Scott, 2015).  
The regulatory (RIα, RIβ, RIIα, RIIβ) and catalytic (Cα, Cβ, Cγ, and PRKX) subunits exist 
as multiple isoforms, with major differences in tissue expression, biochemical and physical 
properties of these subunits (Scott, 1991; Tasken et al., 1993; Clegg et al., 1988; Jahnsen et 
al., 1986; Lee et al., 1983; Scott et al., 1987). Despite this variation, no apparent 
preferential expression with any of the catalytic subunit isoforms with RI or RII has been 
found (Beebe et al., 1990) 
The canonical mechanism for activation of PKA by cAMP was that after the generation of 
cAMP from GPCR signalling, activation of PKA occurs on cAMP binding to two sites on 
each regulatory subunit (sites A and B). When PKA is inactive, only the B site is exposed 
and available for cAMP binding. Following binding to this site, there is an intramolecular 
conformational change that allows binding of cAMP to site A. Once two molecules of 
cAMP are bound to each regulatory subunit, the catalytic subunits are liberated from the 
regulatory subunits and can phosphorylate their target proteins on serine or threonine 
residues within the PKA consensus sequence RRXS/T (Dostmann et al., 1990; Taylor et 
al., 1990). Additional analyses, however, have shown that there is more to this activation 
mechanism than first thought. Using X-ray scattering techniques under physiological 
concentrations of the holoenzymes, the addition of cAMP resulted in only partial 




well as cAMP (Vigil et al., 2004). In addition, for the RII holoenzyme, 
autophosphorylation of the catalytic inhibitor sequence was required for cAMP-induced 
PKA dissociation, with subsequent dephosphorylation by a currently unknown PDE 
required for reassociation of the subunits (Isensee et al., 2018).  
Deactivation of PKA has been less well studied but is thought to occur as a result of PDE 
binding to the cAMP binding domains of the regulatory subunits and likely involves 
allosteric communication between the two cAMP binding sites. In this model, 
PDE-mediated removal of cAMP from site A results in destabilisation of the intervening 
structure between the two cAMP sites such that the allosteric effects of site A on site B are 
lost, resulting in loss of cAMP binding at that site (Guo and Zhou, 2016). As a result, the R 
subunit, now free of cAMP, binds to the catalytic subunit, displacing the PDE and leading 
to reassociation of the holoenzyme complex and termination of the cAMP signal (Moorthy 
et al., 2011)  
1.3.7 Other effectors of cAMP signalling 
1.3.7.1 Exchange proteins directly activated by cAMP 
For over 30 years, the widely held notion was that with the exception of cyclic 
nucleotide-gated ion channels (see 1.3.7.2), the effects of cAMP were mediated 
exclusively by PKA. In 1998, however, a new family of cAMP effectors was discovered – 
the EPACs. There are two EPAC proteins in humans (EPAC1 and EPAC2) which were 
originally thought to only act as guanine nucleotide exchange factors for the Ras-like 
GTPases Rap1 and Rap2, however, additional studies showed them to act as docking 
stations for additional proteins for the co-ordination of diverse signalling events (Grandoch 
et al., 2010; Kawasaki et al., 1998; de Rooij et al., 1998). These proteins are targeted to 




membrane, and are involved in a wide array of physiological processes such as calcium 
handling, cell proliferation and differentiation and gene transcription (Grandoch et al., 
2010). 
EPACs consist of two structural domains - the N-terminal regulatory region containing two 
cAMP binding sites and the C-terminal catalytic region which confers guanine nucleotide 
exchange factor activity - connected by a central switchboard or hinge region. In the 
absence of cAMP, EPACs are kept in an autoinhibitory state whereby the N-terminal 
region folds over the C-terminal region, blocking the active site. On cAMP binding, 
however, there is an intramolecular conformational change such that this autoinhibition is 
lost and the two regions hinge away from one another, opening up the active site 
(Rehmann et al., 2008; De Rooij et al., 2000; Tsalkova et al., 2009). As a result, the 
catalytic region interacts with the target Rap protein and facilitates the exchange of GDP 
for GTP (De Rooij et al., 2000).  
As these proteins are regulated by cellular cAMP concentrations, they have been widely 
used as genetically encoded sensors to measure intracellular cAMP levels in real-time. A 
description of this, as well as other sensors used to measure cAMP and PKA activity in 
cells, is provided in section 1.3.9. 
1.3.7.2 Cyclic nucleotide-gated ion channels 
Cyclic nucleotide-gated ion channels are a family of cation channels that transduce 
signalling events important for visual and olfactory function. These channels generally 
comprise four monomers, each containing six transmembrane helices, of which the first 
four form the voltage-sensing domain of the channel and the last two forming the central 




and cGMP to the final helical structure and, as a result, lead to depolarization of the cell 
membrane through the movement of sodium and potassium ions. Mechanistically, the 
binding of the cyclic nucleotide to the channel, in its closed conformation, gives rise to an 
allosteric conformational change in the linking region between the four helices that make 
up the voltage-sensing domain, opening up the channel and allowing for movement of ions 
(Gofman et al., 2014; Goulding et al., 1994; Kaupp and Seifert, 2002; Matulef and Zagotta, 
2003).  
1.3.8 A-Kinase Anchoring Proteins  
The specificity of PKA signalling is exquisitely controlled by a combination of cellular 
factors, including interactions with a family of host proteins known as AKAPs. This family 
of proteins was first discovered as contaminants of purified PKA-RII subunits but have 
since been shown to be a structurally diverse protein family, unified by their ability to bind 
to PKA and precipitate catalytic activity (Pidoux and Taskén, 2010).  
The first AKAP to be discovered was the microtubule-associated protein-2, which was 
found to be phosphorylated by PKA in lysate derived from brain microtubule preparations 
(Vallee et al., 1981). Since then, the number of AKAPs identified has risen dramatically, 
largely due to the widespread use of the modified Far Western blot technique known as the 
RII overlay. This technique, popularised by Lohmann et al, has been used extensively to 
investigate novel RII-binding AKAPs and is possible because the vast majority of AKAPs 
retain their PKA binding activity after transfer to a nitrocellulose membrane. In this 
technique, proteins are separated in two dimensions: first by isoelectric focusing in one 
dimension and then by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) based separation in the second. The membrane is then incubated with radiolabelled 




have also been used to identify cellular AKAPs, including yeast two-hybrid approaches 
and bioinformatic screens based on algorithms designed to identify binding motifs 
(Burgers et al., 2015). To date, more than 70 AKAPs have been identified (Suryavanshi et 
al., 2018). 
The AKAP-PKA interaction is mediated through a 14 to 18 amino acid amphipathic helical 
structure that binds to the docking and dimerization domain of PKA. Both nuclear 
magnetic resonance spectroscopy and analysis of crystal structures of AKAP-PKA 
complexes have shown that the PKA regulatory subunits dimerise at the N-terminus and 
this is necessary for AKAP binding. Furthermore, the docking and dimerization domain 
consists of an antiparallel dimer that forms into a cross helix shape, providing a binding 
surface for the AKAP (Gold et al., 2006; Kinderman et al., 2006; Newlon et al., 2001; 
Pidoux and Taskén, 2010).  
In addition to this PKA binding domain, AKAPs contain additional sequences that target 
these complexes to distinct subcellular locales, including the Golgi apparatus and the 
nucleus (Wong and Scott, 2004). Accordingly, PKA activity has been detected at these 
sites (Clister et al., 2019; Li et al., 2003; Zippin et al., 2004). 
While these sequences target the AKAP-complex to the correct subcellular compartment, it 
is thought that protein-protein interactions at that site fine-tune the positioning of the 
AKAP towards it substrates (Carnegie and Scott, 2003). For example, AKAP79 localises 
to postsynaptic membranes in neurons through a targeting sequence that binds to acidic 
phospholipids and is selectively bound to glutamate receptor, calcium and potassium ion 




AKAPs further contribute to cAMP-PKA signalling by binding additional signalling 
molecules and forming multiprotein complexes important for regulation of signalling 
events. For AKAP79, in addition to binding PKA, it binds to protein kinase C and the 
calcium/calmodulin-dependent phosphatase, PP2B. These binding partners contribute to 
the functional diversity of signalling events mediated by the AKAP, where distinct 
combinations of AKAP79 binding partners dictate what signalling network the AKAP79 
complex participates in as well as regulating what substrates are targeted by the complex 
(Hoshi et al., 2003, 2005).  
Together, the data shows that AKAPs co-ordinate multiprotein signalling hubs capable of 
directing PKA to discrete subcellular sites where the kinase can act on its substrates, 
providing specificity to the cAMP-PKA signalling pathway. 
1.3.9 Imaging-based measurement of cAMP and PKA 
Up until the early 1990s, measurements of cAMP were made by conventional biochemical 
methods, including antibody-dependent competition assays, however, these experiments 
only gave information about total cAMP levels in pooled cellular populations at a single 
point in time. Although serial measurements could be taken to give an overall picture of 
cAMP changes over time, these experiments had limited spatiotemporal resolution and 
there was no information at that time of what was happening at a cellular level. As a result, 
the prevailing hypothesis at the time was that after generation by ACs, cAMP diffused 
freely into the cytoplasm where it was actioned by its effectors in the cytoplasm. Through 
the use of various genetically encoded biosensors, it is now known that cAMP signalling is 
highly organised into distinct cellular compartments, shaped by AKAPs and PDEs, to form 




The first widely used set of sensors were based on Förster resonance energy transfer 
(FRET). FRET involves the non-radiative energy transfer between a pair of donor and 
acceptor fluorophores, which is dependent on the intramolecular distance between the two 
fluorophores. All FRET sensors work in a similar fashion and generally have three 
domains: a sensor domain to which the molecule under study binds and the two 
fluorophores that make a FRET pair. The binding of the molecule under study to the sensor 
domain leads to a conformational change in the structure of the sensor, changing the 
distance between the donor and acceptor fluorophores. This change in distance is 
interpreted as a change in FRET efficiency (Paramonov et al., 2015). The first successful 
FRET sensor used to measure cAMP was based on PKA and featured the ex vivo labelling 
of catalytic subunits with fluorescein and the regulatory subunits with rhodamine, 
introduced into cells via microinjection (Adams et al., 1991). Binding of cAMP to the 
sensor resulted in dissociation of the holoenzyme such that fluorescein and rhodamine 
were no longer in close proximity, resulting in changes in FRET efficiency (Adams et al., 
1991). Microinjection techniques are however laborious and technically challenging, 
spurring on the development of a variety of other genetically encoded sensors that could be 
introduced into cells by transfection (Zaccolo et al., 2000). 
Although these PKA based sensors were instrumental in our understanding of cAMP 
dynamics, they all shared some common shortfalls, which were largely due to the 
mechanism of action of PKA. For example, as activation of PKA leads to a dissociation of 
the regulatory and catalytic subunits, one might expect the reassembled holoenzyme to 
incorporate non-FRET subunits present in the cell, which may negatively affect FRET 
efficiency in long term experiments (Paramonov et al., 2015; Rich et al., 2014). These sorts 




proteins (DiPilato et al., 2004; Nikolaev et al., 2004; Ponsioen et al., 2004). All EPAC 
sensors contain a cAMP binding domain and the two fluorophore probes. Binding of 
cAMP to its binding site in the EPAC proteins result in a change in the sensor 
confirmation, accompanied by changes in FRET efficiency. These sensors have several 
advantages over the multiprotein probes. For example, as all domains are on one molecule, 
only transfection of one plasmid construct is needed and, as compared to the multiprotein 
sensors, the activation kinetics are much more favourable and have a faster response to 
cAMP. Apart from EPAC FRET sensors, other sensors based on AKAPs have been 
developed to measure cAMP and PKA at specific subcellular sites (Paramonov et al., 
2015). 
FRET approaches are associated with several problems both due to the physical properties 
of FRET but also the technology used to measure FRET. One particular issue is that the 
fluorescent proteins used as a label are sensitive to environmental changes, such as pH, 
ionic concentrations and temperature (Leavesley and Rich, 2018). In addition, FRET 
requires an external light source for the fluorescence transfer, which can lead to 
photobleaching (Xie et al., 2011). To circumvent these problems, sensors based on 
bioluminescent resonance energy transfer (BRET) have been developed. BRET does not 
require an external light source to excite the donor fluorophore and so does not suffer from 
the problems associated with FRET, such as photobleaching, light scattering or 
autofluorescence. Other advantages to BRET-based approaches include low background 
signal and high signal to noise ratio, facilitating data analysis. This BRET approach has 
been used in this thesis to measure cAMP and PKA in keratinocytes and has been 




1.3.10 Viruses and cAMP-PKA signalling 
Several viruses have been reported to interact with the cAMP-PKA pathway, including 
HCV, HIV and respiratory syncytial virus (RSV). A brief summary of these virus 
interactions is given below. 
HCV activates cAMP response element (CRE)-dependent transcription in hepatoblastoma 
Huh-7 cells through the non-structural NS2 protein. Interestingly, levels of transcripts 
whose stability is regulated by cAMP were also decreased in a manner dependent on NS2 
expression. The data suggest that NS2 affects the stability of these mRNAs either via 
changes in intracellular cAMP or through modulation of one of the proteins involved in 
regulating the cAMP pathway (Kim et al., 2007). Furthermore, through a complex 
composed of two of the other viral structural proteins, NS3 and NS4, the virus also inhibits 
the activity of PKA and PKA-mediated phosphorylation of cAMP response element-
binding protein (CREB), a downstream PKA target that is involved in mediating cAMP-
dependent changes in gene transcription, by regulating ATP turnover (Aoubala et al., 
2001). Further evidence for a role of the cAMP-PKA pathway in the HCV life cycle came 
from studies on viral entry and infectivity. Using a mixture of Huh-7 and primary human 
hepatocytes, these studies suggested a role for the PKA-RII holoenzyme in HCV 
internalisation; inhibition of PKA activity led to a re-organisation of receptors involved in 
HCV entry. Further inhibitor studies showed that PKA was also involved in regulating 
viral infectivity, although the precise mechanism was not elucidated. Finally, HCV 
infection was shown to increase cAMP levels, with a concomitant increase in 
phosphorylation of PKA substrates (Farquhar et al., 2008). Together, these data suggest 
that HCV targets cAMP-PKA by multiple mechanisms to regulate expression of host 




The cAMP-PKA pathway is also important during the HIV-1 life cycle. Using purified 
HIV-1 virions, the catalytic subunit of PKA has been shown to be incorporated into virus 
particles where it regulates viral infectivity in permissive cells (Cartier et al., 2003). 
Furthermore, HIV-1 infection increases cAMP levels in T cells in vitro, resulting in 
activation of the PKA pathway, which appears to be mediated by the viral glycoprotein 
120 envelope protein (Hofmann et al., 1993; Nokta and Pollard, 1991; Masci et al., 2003). 
This activation of cAMP may have dual and opposite functions, however, with some 
studies showing changes in cAMP to be detrimental by decreasing anti-HIV T cell 
responses while others have shown it to be protective through limiting replication of viral 
DNA, inhibiting viral entry into cells or by decreasing viral spread. It is likely therefore 
that the functional consequence of cAMP depends on the exact stage of infection (Moreno-
Fernandez et al., 2011).  
Respiratory syncytial virus (RSV), a major cause of respiratory infection in young children 
and high-risk adults, also interacts with the cAMP-PKA pathway. RSV infection is 
associated with disruption of the airway epithelial barrier by triggering disassembly of 
tight junctions. Induction of cAMP by forskolin and/or cAMP analogues protected against 
RSV-induced disassembly of tight junctions in epithelial cells through a PKA-dependent 
mechanism. In these cells, inhibition of PKA by the kinase inhibitor H89 reversed the 
forskolin-induced stabilisation of epithelial tight junctions, confirming that PKA was 
involved in this stabilisation and not one of the other cAMP effector proteins. 
Mechanistically, this protective effect was due to stabilisation of adherens and tight 
junction structures, inhibition of RSV-induced rearrangement of the cytoskeleton and 
inhibition of viral mRNAs and viral transmission in airway epithelial monolayers (Rezaee 




Pharmacological inhibition and small interfering RNA (siRNA) knockdown experiments 
showed that EPAC2 was involved in RSV replication, production of infectious viral 
progeny and virus-induced upregulation of proinflammatory cytokines, such as monocyte 
chemoattractant protein-1 and interleukin-6 (Choi et al., 2018). 
1.3.11 HPV and PKA 
HPV interacts with multiple host signal transduction pathways during the viral life cycle to 
facilitate viral DNA replication and amplification, including PKA.  
The functions of several viral proteins are regulated by PKA phosphorylation. HPV E2 
proteins are critical regulators of viral genome maintenance and viral persistence through 
binding to host chromosomes. For HPV8, a beta HPV type associated with cutaneous 
lesions, the E2 protein requires the residues R250 and S253 for this chromosomal 
association, with the S253 residue being phosphorylated (Sekhar et al., 2010). Using an in 
vitro phosphorylation prediction software, S253 was predicted to be phosphorylated by 
PKA, and this was confirmed using activators and inhibitors of PKA activity. Treatment of 
cells with forskolin showed an increased number of cells with E2 bound to mitotic foci, 
showing that PKA activity regulated the chromosomal binding function of E2. Finally, this 
study showed that PKA phosphorylation of E2 occurred in S phase, increased the half-life 
of the E2 protein and promoted E2 binding to chromosomes from S phase through mitosis 
(Sekhar and McBride, 2012). The E4 protein from diverse HPV types (HPV1, 11 and 16) 
has also been reported to be phosphorylated by PKA (Bryan et al., 2000; Grand et al., 
1989; Wang et al., 2009b). Although the consequence of this phosphorylation event on E4 
function is unknown, it does not result in a change in localisation of the protein (Bryan et 




host keratin network so it is tempting to speculate the PKA phosphorylation may regulate 
E4 function through an as yet unidentified manner (Wang et al., 2009b).  
The virus also encodes proteins that regulate the activity of the PKA pathway. HPV16 E5 
induces the expression of cyclooxygenase-2 (COX-2), which leads to increased secretion 
of the main COX-2 product, prostaglandin E2 (PGE2). As a result, PGE2 induces the 
expression of the PGE2 receptor subtype EP4, increasing levels of cAMP. The induction of 
the EP4 receptor was shown to be due to the activity of the PKA pathway, resulting in 
increased phosphorylation of CREB and subsequent CREB binding to a variant CRE in the 
EP4 promoter, and was important for E5-induced colony formation and VEGF secretion in 
cervical cancer cells (Oh et al., 2009). In addition, the same authors showed that the 
activity of this COX-2-PGE2-induced PKA pathway was involved in E5 inhibition of 
hydrogen peroxide-induced apoptosis by regulating the expression of the pro-apoptotic 
Bax and Bak proteins (Oh et al., 2010).  
As described in section 1.2.6.2.2.3, PKA phosphorylation regulates multiple aspects of E6 
function. E6 through its C-terminal PBM targets a subset of host PDZ domain-containing 
proteins, a function which is regulated by phosphorylation at the overlapping PKA 
recognition site. Experiments in an HPV18 life cycle model showed that loss of PKA 
recognition was associated with increased cell proliferation in monolayer cells and, on 
organotypic raft culture, a more hyperproliferative phenotype (Delury et al., 2013). In 
addition, loss of PKA recognition in immortalised keratinocytes was associated with 
epithelial to mesenchymal transition (Watson et al., 2003). These data, together with that 
described in section 1.2.6.2.2.3, suggest that changes in PKA phosphorylation may be 
relevant for oncogenic progression of HPV infections. In addition, phosphorylation of the 




analysis of the consequences of this interaction is lacking but initial experiments have 
shown it to contribute to E6 protein levels (Boon and Banks, 2012). Given that 14-3-3 
family members are involved in diverse cellular processes, such as cell cycle regulation, 
apoptosis and signal transduction, and have been implicated in cancer initiation and 
progression, E6 binding may, therefore, be relevant during the oncogenic progression of 
HPV infections (Hermeking and Benzinger, 2006; Neal and Yu, 2010). 
 
1.3.12 AKAP95 
AKAP95 is an RII-specific AKAP and is one of two AKAPs found in the nucleus, the 
other being the splicing factor SFRS17A (AKAP17A). In addition to localising to the 
nucleus, AKAP95 has also been localised to the nuclear matrix (Akileswaran et al., 2001), 
nucleolus and mitotic chromatin, although the latter two are somewhat contentious with 
some studies not finding such a localisation (Collas et al., 1999; Landsverk et al., 2001; 
Marstad et al., 2016). SFRS17A binds to both RI and RII subunits, colocalises with the 
catalytic subunit in nuclear speckles in immunofluorescence experiments and is involved 
in splicing of alternative splicing of the E1A minigene in a manner dependent on its ability 
to bind to PKA (Jarnæss et al., 2009). AKAP95 is the founding member of the AKAP95 
family of proteins, characterised by the presence of two ZFs (Castello et al., 2012). Other 
members of this family include HA95, a homologue of AKAP95 that does not bind to 
PKA regulatory subunits (and therefore is not an AKAP) but binds to the catalytic subunit 
directly (Martins et al., 2000; Ørstavik et al., 2000) and ZNF326, a largely uncharacterized 




The domain structure of AKAP95 is shown in Figure 1.7 and contains a nuclear matrix 
targeting sequence (amino acids 110-1140), a bilateral nuclear localisation sequence 
(290-306), a nuclear localisation sequence (368-377), two ZFs (392 to 414; 481 to 501) 





Consistent with the scaffold function of AKAPs, AKAP95 binds to a multitude of cellular 
proteins, including heterogeneous nuclear ribonucleoproteins (hnRNPs) M, K, H, F, D and 
U proteins through the N-terminal 100 amino acids (Hu et al., 2016), the p68 RNA 
helicase via the nuclear matrix targeting sequence (Akileswaran et al., 2001) and PKA-RII 
through the PKA binding site in the C-terminus, with amino acid isoleucine (I) at position 
582 being the critical residue for this binding (Carr et al., 1992). AKAP95 participates in 
various cellular functions including cell cycle control, regulation of transcription and RNA 
metabolism, and has been implicated in human conditions such as regulation of head size 
and autism (Jarnæss et al., 2009), cleft palate (Yang et al., 2006) and cancer (Liu et al., 
2015; Zhao et al., 2015).  
Figure 1.7: AKAP95 structure. AKAP95 contains a nuclear matrix targeting sequence 
(NMTS), bilateral nuclear localisation sequences (biNLS), a nuclear localisation sequence 
(NLS) two zinc fingers (ZF1 and ZF2) and a binding site for PKA-RII subunits (PKA). 




Figure 1.8 provides an overview of several known AKAP95 functions. These include 
providing a scaffold for the minichromosome maintenance 2 (MCM2) protein loading onto 
the pre-replication complex during DNA replication (Eide et al., 2003), recruitment of 
condensin complexes onto chromosomes and regulation of chromosomal condensation 
(Collas et al., 1999; Steen et al., 2000), protein-protein interactions with cyclins D and E 
(Arsenijevic et al., 2004, 2006) and nuclear targeting of p90 ribosomal S6 kinase 1 (RSK1; 
Gao et al., 2012). Recently, AKAP95 has also been shown to regulate transcription and 
splicing (Hu et al., 2016; Jiang et al., 2013). Descriptions of some of AKAP95-dependent 






Figure 1.8: Overview of AKAP95 functions. AKAP95 regulates multiple cellular processes, including loading of MCM2 onto pre-
replication complexes (preRC), targeting of condensin complex proteins and regulation of chromatin condensation, regulation of cyclin D and 
cyclin E complexes and nuclear targeting of p90 ribosomal S6 kinase 1 (RSK1). A role for AKAP95 in transcription and splicing has recently 
been identified. A description for some of these processes is given in the text. The red circles around AKAP95 for some of these functions 




1.3.12.1 AKAP95, mitosis and cell cycle control 
AKAP95 regulates mitotic and cell cycle events through interactions with various proteins, 
including members of the condensin complex, MCM2 and cyclins D and E. 
AKAP95 is involved in multiple stages of chromosomal condensation by acting as a 
targeting molecule for condensin proteins, a group of large proteins involved in 
chromosome assembly and segregation during mitosis. At the onset of mitosis, a 
population of AKAP95 is redistributed onto chromatin following the breakdown of the 
nuclear envelope. Depletion of this chromatin-bound AKAP95 prevented chromosomal 
condensation in cervical cancer cells (HeLa), which was due to an inability to recruit 
members of the condensin complex, such as hCAP-D2/Eg7, onto chromatin (Collas et al., 
1999; Steen et al., 2000). Domain mapping experiments showed that AKAP95 binding to 
chromatin required residues 387-450 and ZF1, although ZF2 rescued chromatin binding in 
a mutant AKAP95 protein with a compromised ZF1. The residues required for 
chromosomal condensation were within 387-569, including both ZFs, and this region was 
sufficient for recruitment of condensin proteins to chromatin. Interestingly, the PKA 
binding domain of AKAP95 was not involved in the onset of chromosomal condensation 
but PKA activity was required for maintenance of condensed chromosomes (Eide et al., 
2002). The fact this PKA activity is required may suggest that the kinase phosphorylates 
subunits of the condensin complex or other structural proteins involved in the maintenance 
of condensed chromatin during mitosis (Landsverk et al., 2001). 
The AKAP95-MCM2 interaction was found by a yeast two-hybrid approach aiming to 
identify novel AKAP95 interacting partners and was confirmed using both glutathione 
S-transferase (GST) pull-down and co-immunoprecipitation experiments from chromatin. 




interaction through incubation of HeLa cell nuclei with a 1-195 AKAP95 peptide 
dramatically inhibited both the initiation and elongation phases of DNA replication in 
vitro. This occurred via changes in MCM2, with depletion of AKAP95 resulting in a loss 
of nuclear MCM2 protein. Accordingly, rescue experiments using a recombinant AKAP95 
protein restored nuclear MCM2 levels. Disruption of the AKAP95-PKA interaction did not 
impair either stage of DNA replication but inhibition of PKA activity negatively affected 
the initiation of DNA replication. Together, the data suggest that AKAP95 regulates DNA 
replication by anchoring MCM2 in the nucleus and that PKA activity is important for 
initiation but not elongation stages of DNA replication. How this might occur is not yet 
clear but as activation of PKA is required for S phase progression by phosphorylation of 
Cdc6, AKAP95 may target PKA to the nucleus to facilitate this phosphorylation event. 
Alternatively, there may be a nuclear pool of PKA catalytic subunits that are involved in 
phosphorylating nuclear substrates for progression of mitosis (Eide et al., 2003).  
Another set of proteins under the control of AKAP95 is the D and E type cyclins, cyclins 
D1, D2, D3 and E1 (Arsenijevic et al., 2004, 2006). These proteins are important 
regulators of cell cycle progression that, when bound to their respective cyclin-dependent 
kinases, drive the phosphorylation of various downstream substrates important for cell 
cycle progression, including other cyclins, condensins and lamin proteins (which are 
involved in nuclear envelope breakdown at mitosis) (Lodish et al., 2007). Co-
immunoprecipitation experiments using both endogenous and overexpressed proteins 
showed that AKAP95 bound all D-type cyclins and the association was specific, with 
AKAP95 not binding known binding partners of cyclin D proteins, CDK4 or p27kip1. 
Surprisingly, these protein complexes were regulated by CDK4 levels, with overexpression 




Later experiments showed that AKAP95 mediates the binding of the PKA-RII holoenzyme 
to cyclin D3, although this interaction was not regulated by levels of cAMP (Arsenijevic et 
al., 2006). In the same study, AKAP95 was shown to also interact with cyclin E1 and was 
displaced by its catalytic partner CDK2. Similar to the cyclin D3 experiments, AKAP95 
also mediated PKA-RII binding to cyclin E1 and was unaffected by changes in cAMP 
(Arsenijevic et al., 2006).  
1.3.12.2 AKAP95, transcription and splicing 
AKAP95 was first assumed to be involved in transcriptional regulation by virtue of its 
binding to the nuclear matrix and the p68 RNA helicase, a DEAD-box protein implicated 
in cellular processes such as initiation of transcription and assembly of the spliceosome 
(Akileswaran et al., 2001). More recent experiments showed that AKAP95 was a novel 
binding partner of DPY30, a common subunit of the mixed-lineage leukaemia (MLL) 
family of histone-3 methyltransferases, which are responsible for histone H3 lysine 4 
(H3K4)-mediated chromatin modifications and transcriptional activation. AKAP95 
binding to MLL-DPY30 complexes directly enhances the methyltransferase activity of the 
MLL complex and drives expression of a chromosomal reporter gene, occurring 
concomitantly with increased levels of di- and tri-methylation of H3K4, epigenetic marks 
generally associated with transcriptional activation (Sims and Reinberg, 2006). This 
transcriptional stimulation requires the N-terminal 100 amino acids and AKAP95 binding 
to DPY30. Functional analysis of this interaction in mouse embryonic stem cells showed 
that AKAP95 regulated a common set of genes as DPY30, such as those involved in early 
development, in retinoic acid-treated cells (Jiang et al., 2013).  
In addition to its role in retinoic acid-mediated gene transcription in mouse ES cells, 




hnRNPs (Hu et al., 2016). These proteins control the maturation of newly formed RNAs 
(pre-mRNAs) into mRNAs through processes such as alternative splicing, stabilisation of 
the mRNA during cellular transport and control of translation (Geuens et al., 2016; 
Martinez-Contreras et al., 2007). Through mass spectroscopy-based analysis and 
subsequent validation by co-immunoprecipitation experiments, AKAP95 was found to 
interact with several RNA processing factors through its N-terminus, including multiple 
hnRNP proteins (hnRNP M, K, H, F, D and U). Use of various AKAP95 mutant proteins 
combined with AKAP95 knockdown or overexpression experiments showed that the N-
terminal 100 residues and ZFs are involved in splicing in a minigene splicing system. The 
ability of AKAP95 to regulate splicing was further demonstrated using an endogenous 
target of hnRNP F, one of the novel AKAP95-interacting hnRNPs; exon 11 of the 
FAM126A transcript. Treatment of cells with either shRNA or siRNA against AKAP95 
resulted in skipping (reduced inclusion) of exon 11 of the transcript, which depended on 
the integrity of the ZFs. Finally, this analysis showed that AKAP95 binds to the introns 
immediately upstream of the exons that it regulates and loss of AKAP95 functionally 
mimics the loss of hnRNP F, U and H proteins, suggesting that AKAP95 selectively co-





1.4 Hypothesis and Aims 
In order for the virus to successfully replicate in squamous epithelia, HPV alters the milieu 
of the infected keratinocyte to one that supports the viral replication process. This involves 
interaction with the host’s kinome to modify viral protein function and/or host protein 
function. HPV proteins are phosphorylated by a variety of kinases but they can also 
modulate the activity of signal transduction pathways, as is the case with E5 and EGF 
signalling (Straight et al., 1995; Watson et al., 2003), or E4 and SRPK1 activity (Prescott 
et al., 2014). Another signalling pathway that is intimately involved in the infectious cycle 
is PKA, and whilst several HPV proteins are known PKA substrates (E2, E4, E6), it is not 
clear if or how the virus modulates PKA signalling activity during infection. Moreover, 
when the effects of PKA signalling on the function of the E6 PBM are considered, reduced 
PKA activity might promote morphological transformation (Watson et al., 2003) whereas 
increased activity may lead to increased viral DNA integration (Delury et al., 2013). 
Deregulation of this host pathway could, therefore, be an independent risk factor for 
progression of high-risk HPV infections.  
Therefore, it was hypothesised that high-risk HPV modulates the activity of the PKA 
pathway to support the infectious cycle and that this virus-host interaction has a 
consequence on HPV protein function.  
Therefore, the aims of this thesis are: 
1. Determine if HPV18 modulates the activity of the PKA pathway using a 
bioluminescent resonance energy transfer approach to study PKA activation in a 
physiologically relevant system composed of the natural host cells of the virus – the 




2. To identify and characterize the association between HPV proteins and host factors 
involved in the regulation and control of PKA signalling – AKAP95-HPV18 E6 
(Chapter 4).  
3. Investigate the functional importance of the HPV18 E6-AKAP95 interaction in 





CHAPTER 2 MATERIALS AND METHODS 
2.1 Cell culture 
2.1.1 General information 
All cell culture work was carried out in a HEPA-filtered laminar flow hood. Surfaces were 
wiped with 70% industrial methylated spirit. Work with HPV genome containing 
keratinocytes was approved by the Health and Safety Executive (reference number 
GM67/05.1).  
 
2.1.2 Cell growth conditions 
NIH-3T3 J2 cells (hereafter called J2 cells) were maintained in Dulbecco’s modified Eagle 
medium (DMEM), HEPES modification (Sigma-Aldrich, Gillingham, UK), supplemented 
with 4 mM L-glutamine (Sigma-Aldrich) and 10% (vol/vol) Gibco adult bovine serum 
(ThermoFisher Scientific, Paisley, UK) HeLa, HEK293T (hereafter 293T) and C33A cells 
were grown in DMEM, HEPES modification, supplemented with 4 mM L-glutamine and 
10% (vol/vol) foetal calf serum (FCS) (All Sigma-Aldrich). Primary HFKs were 
maintained in Gibco Keratinocyte-Serum Free Media supplemented with 20 µg/ml bovine 
pituitary extract and 0.1 ng/ml human recombinant EGF (ThermoFisher Scientific). 
Establishment of HPV18 genome containing cell lines (HFK-18) by transfection of the 
HPV18 genome into HFKs was carried out by previous members of Dr Roberts’ laboratory 





























8 – 12 Weeks 
Figure 2.1. Generation of primary human foreskin keratinocytes maintaining HPV18 genomes. Low passage human foreskin 
keratinocytes were co-transfected with plasmids encoding the HPV18 genome and neomycin (neo) resistance. One day after transfection, 
transfected cells were seeded onto a layer of γ-irradiated J2-3T3 cells and grown for 8 days in the presence of G418 antibiotic in 




2.1.3 Maintenance of HPV18 genome containing lines  
Growth and maintenance of HPV genome containing lines are described fully in Wilson et 
al., 2005. Untransfected normal immortalised keratinocytes (NIKS) were a kind gift of 
Professor Paul Lambert, University of Wisconsin-Madison, USA, and NIKS containing 
HPV18 genomes (NIKS-18) were established by Dr S Roberts and Dr G Knight 
(unpublished). NIKS cells were maintained in F media, composed of 3:1 DMEM: Ham's 
F12 media, 5% foetal bovine serum (FBS), 24 μg/ml adenine, 8.4 ng/ml cholera toxin, 
10 ng/ml EGF, 2.4 µg/ml hydrocortisone and supplemented with 5 µg/ml insulin before 
use. HPV18 genome containing HFKs were maintained in E media (see 2.1.4).  
These cell lines were grown on a layer of -irradiated J2 cells. For this, J2 cells were 
grown to 80% confluency, harvested by trypsinisation and resuspended at 2x106 cells/ml, 
before irradiation with 30 Gray using a Caesium-137 radiation source (Biomedical 
Services Unit, University of Birmingham, UK). Irradiated J2 cells were plated out in the 
required media at a concentration of 2x106 per 10 cm tissue culture plate (Falcon, 
ThermoFisher Scientific) and allowed to settle for at least two hours or overnight before 
the addition of HPV18 genome containing cells. Plates were shaken gently to allow for 
even distribution of cells and maintained in E media containing 10% (vol/vol) foetal calf 
serum (Sigma-Aldrich; Wilson et al., 2007; see 2.1.4 ). Irradiated J2 cells were stored at 
4°C for a period not exceeding one week. 
 
2.1.4 Preparation of E media 
To prepare two litres of E media, the following components were mixed: 1200 ml DMEM 
HEPES modification, 640 ml Ham’s F12 nutrient mixture (ThermoFisher Scientific), 




(ThermoFischer Scientific), 100 ml FBS (Sigma-Aldrich), 2 ml 1000X Cholera toxin (ICN 
Biomedical, California, USA) and 2 ml 1000X hydrocortisone (Sigma-Aldrich). Following 
mixing, the media was filter sterilised through a 0.22 µm vacuum filter system (Corning, 
ThermoFisher Scientific) and was supplemented with 5 ng/ml EGF before use. HyClone™ 
FBS (ThermoFisher Scientific) was used for E media and batch tested to ensure adequate 
growth of HPV18 genome containing cells.  
 
2.1.5 Preparation of 100X cocktail  
Preparation of 200 ml of 100X cocktail was by mixing the following components: 20 ml of 
0.18 M adenine, 20 ml of 5 mg/ml insulin, 20 ml of 5 mg/ml transferrin and 20 ml of 
2x10-8 triiodo-L-thyronine in phosphate-buffered saline (PBS; 137 mM sodium chloride, 
2.7 mM potassium chloride, 10 mM disodium phosphate and 1.8 mM monopotassium 
phosphate). All chemicals were purchased from Sigma-Aldrich. The cocktail was filter 
sterilised and frozen at -20°C prior to use.  
 
2.1.6 Cell passage 
Cells were passaged once they reached 80-85% confluency. For this, the media was 
removed and plates washed with PBS. Cells were detached by use of TrypLE solution 
(ThermoFisher Scientific) with incubation at 37°C. Trypsin was neutralised with 
serum-containing media or soybean trypsin inhibitor (0.25 mg/ml soybean trypsin inhibitor 
(Invitrogen, ThermoFisher Scientific) in PBS). This solution was then transferred to a 
centrifuge tube and the dish washed with additional media or PBS to gather any remaining 




haemocytometer if desired. After centrifugation at 201 x g for five minutes in an 
Eppendorf 5810 centrifuge, cells were resuspended and plated at the desired density.  
 
2.1.7 Organotypic raft cultures 
Organotypic raft cultures were prepared by Dr Sally Roberts (Wilson and Laimins, 2005). 
Briefly, 2x106 keratinocytes were grown on a collagen plug containing 2x106 
non-irradiated J2 fibroblasts. After 96 hours, or sooner if the media on the plug turned 
yellow one day after media change, the plug was lifted onto a wire mesh and the 
underneath flooded with E media lacking EGF to create a liquid-air interface. Media was 
changed every two days and the rafts were harvested after 13 days. Harvesting was by 
flooding the dish with 3% formaldehyde in culture media prior to embedding in paraffin 
and sectioning by Propath UK Ltd, Hereford, UK.  
 
2.1.8 Cell freezing 
Cells were frozen down routinely to maintain stocks. For this, cells were processed as 
above for cell passage and after centrifugation, resuspended to 1-2x106 cells/ml in freezing 
media (9:1 ratio media: dimethyl sulfoxide (DMSO)). Primary keratinocytes were frozen 
in cell media with 10% FCS containing 20% (vol/vol) glycerol or 10% (vol/vol) DMSO. 
One millilitre of cell solution was placed in cryovials (Greiner Bio-One, Stroudwater, UK) 
and stored at -80°C in a Nalgene Mr Frosty system. Long-term storage was in the vapour 





2.1.9 Cell thawing 
Cells were removed from liquid nitrogen and allowed to thaw briefly in a water bath set to 
37°C. The cell solution was transferred dropwise to a universal tube containing 10 ml 
media, before centrifugation at 201 x g for five minutes. Cells were then resuspended in 
fresh media and plated out at the required density. Alternatively, thawed cells were added 
directly to a cell culture dish containing media.  
2.2 Cell Biology 
2.2.1 Cell fixation and permeabilization for immunofluorescence staining 
Cells were plated directly onto coverslips and allowed to adhere. Coverslips were washed 
twice in PBS before fixation. For methanol fixation, coverslips were treated with cold 
methanol (-20°C) for ten minutes before permeabilization in cold acetone for one minute. 
For paraformaldehyde fixation, coverslips with treated with 4% paraformaldehyde for ten 
minutes before permeabilization in 0.1% Triton X-100 in PBS for ten minutes. After 
fixation, coverslips were washed in PBS and left either in PBS at 4°C for short-term 
storage or left to air dry and stored at -20°C. 
 
2.2.2 Agitated low-temperature epitope retrieval  
For immunofluorescence staining of sections from organotypic raft culture, formalin-fixed 
and paraffin-embedded slides were deparaffinised and rehydrated by sequential 
immersions in xylene, absolute ethanol and then water, followed by agitated 
low-temperature epitope retrieval (Watson et al., 2002). For this, raft sections were 




0.01% Tween 20, pH 8.0) at 65°C overnight with stirring. Once cooled, slides were 
processed as described in section 2.2.3 for immunostaining.  
 
2.2.3 Indirect immunofluorescence (IF) staining 
Fixed cells were blocked in IF blocking buffer (20% heat-inactivated normal goat serum 
and 0.1% (wt/vol) bovine serum albumin (BSA) fraction V (Sigma-Aldrich) in PBS) for at 
least one hour before incubation with the primary antibody in blocking solution overnight 
at 4°C. All staining procedures were carried out in a humidified chamber to prevent 
evaporation of the antibody. Cells were washed three times in PBS under agitation before 
incubation with the appropriate Alexa Fluor species-specific secondary antibody for one 
hour at 37°C. Cells were washed a further three times before incubation in PBS containing 
the DNA stain 4’6-Diamidino-2-phenylindole (DAPI) for five minutes before being 
mounted onto microscope slides using Fluoroshield (Sigma-Aldrich). Slides were stored at 
-20°C. Images were captured using a Nikon Eclipse E600 microscope and associated 
software.  
 
2.2.4 Plasmid DNA transfection 
For transfection into 10 cm plates, cells were seeded at 3x106 and, the following day, 
transfected using 5-10 µg plasmid DNA using X-tremeGene DNA transfection reagent 
(Roche, Sussex, UK) or linear polyethyleneimine (Sigma-Aldrich) at a ratio of 1:3 DNA to 






2.2.5 Plasmid DNA transfection for Bioluminescence Resonance Energy 
Transfer 
One day prior to transfection, established cell lines (i.e. all cells bar parental primary 
keratinocytes) were plated at a density of 2x104 cells/well in a Nunc™ white bottomed 
96 well plate (ThermoFisher Scientific) and transfected using X-tremeGene DNA 
transfection reagent at a ratio of 1:3 DNA to reagent. Cells were transfected with 200 ng of 
plasmid DNA encoding PKA isoform I (PKA-I: Renilla luciferase (Rluc)-RIα and green 
fluorescent protein (GFP)-Cα), PKA isoform II (PKA-RII: Rluc-RIIα and GFP-Cα) or 100 
ng encoding the cAMP target EPAC. Control cells expressing only Renilla luciferase (100 
ng) were included to determine background as well as non-transfected cells.  
For the oncoprotein identification experiments, cells were also transfected with constructs 
expressing HPV18 E5 (kindly provided by Dr Andrew Macdonald, University of Leeds), 
E6 and E7, alongside the BRET sensors. 
For transfection into parental primary keratinocytes, cells were seeded at 3-4x105 in a 
six-well plate and transfected with 2 µg PKA-I/II or 1 µg EPAC using 
TransIT-Keratinocyte Transfection Reagent at a ratio of 1:1.5 DNA to reagent (Mirus Bio 
LLC, Madison, USA). After 24 hours, these cells were harvested by trypsin and plated out 
at 2x104 cells/well in 96 well plates. BRET was performed 48 hours after transfection. In 
all transfections, total DNA was kept equivalent by transfecting empty vector. 
 
2.2.6 Bioluminescence Resonance Energy Transfer  
Bioluminescence resonance energy transfer was carried out as described elsewhere (Prinz 
et al., 2006). Briefly, 48 hours post-transfection, media was removed, and the cells rinsed 




(Coelenterazine 400a, Biotium, UK) either in the presence or absence of the 
cAMP-elevating agent forskolin (final concentration: 10 µM). To quantify BRET, light 
emission was measured at 410 nm wavelength ± 80 nm bandpass for the donor luciferase 
and a 515 nm wavelength ± 30 nm bandpass for the GFP acceptor using a PheraStar high 
throughput plate reader (BMG LabTech, Ortenberg, Germany). The emission from 
non-transfected (NT) cells was subtracted and the BRET signal calculated as (emission 
(515 nm–NT 515 nm)/(emission (410 nm–NT 410 nm)). All reagents were a generous gift 
of Dr Mandy Diskar, University of Birmingham, or purchased commercially. Graphs and 
statistical analysis were carried out on GraphPad Prism 5 (San Diego, USA).  
Unless otherwise stated in the figure legends, statistical analyses (Student’s t-tests) were 
conducted to compare control cells with those expressing either HPV18 oncoproteins or 
the complete viral genome. Statistical significance was denoted by inclusion of the 
following in the figures: ns demonstrates non-significance at the level of p=0.05, * denotes 
p<0.05, ** denotes p<0.01 and *** denotes p<0.001.  
 
2.2.7 CRE-luciferase assays 
C33A cells were seeded into a six-well plate as described in section 2.25 and, after 
24 hours, were transfected with 100 ng of  CRE-luciferase reporter alongside 100 ng each 
of the expression vectors indicated in the figure legends using X-tremeGene DNA 
transfection reagent at a ratio of 1:3 DNA to reagent. Total DNA was kept equivalent by 
transfecting empty vector plasmid. After 48 hours, cells were harvested in 200 μl of 
passive lysis buffer and quantification of relative light units was determined using the Stop 
& Glo reagent system (Promega, Wisconsin, USA). Statistical analyses were carried out as 





2.2.8 Preparation of lentiviral particles 
Lentiviral particles were prepared by transfecting second-generation TRIPZ shRNA 
constructs, along with packaging and envelope constructs, into 70-80% confluent 293T 
cells. Constructs were obtained from Dharmacon as a set of three shRNA sequences 
targeted against AKAP95. Transfection was performed using 9 µg shRNA construct, 
4.5 µg pMDG.2 (encoding the vesicular stomatitis virus envelope protein) and 6.75 µg 
psPAX2 (encoding the packaging proteins Gag, Pol, Rev and Tat from HIV-1) using a 3:1 
ratio of linear polyethyleneimine to DNA. After incubation for 30 minutes at room 
temperature, the transfection complex was added to the cells. At 48 and 72 hours 
post-transfection, cell media was harvested, filtered through a 0.45 µm filter and stored 
at -80°C before use. Typically, one ml of filtered media was used to infect one well of a 
six-well plate.  
ShRNA AKAP95 sequences were: ShAKAP95 1: 5’-TTCATAACCTTGCCAGCTG-3’, 
ShAKAP95 2: 5’-AAATTGTCATCTCCTTCCA-3’ or ShAKAP95 3: 
5’-TAGATTACAGCATATTCTG-3’. The TRIPZ control non-targeting construct was 
provided by Dr Clare Davies, University of Birmingham, and contains the shRNA 
sequence 5’-CTTACTCTCGCCCAAGCGAGAG-3’.  
 
2.2.9 Lentivirus infection 
Cells were seeded in a six-well dish such that they were 70% confluent at the time of 
infection. Cell media was removed and replaced with fresh media containing 8 µg/ml 
hexadimethrine bromide (otherwise known as polybrene), before the addition of media 




wrap and cells were then centrifuged at room temperature at 804 x g for 90 minutes in a 
fixed bucket centrifuge (Eppendorf 5810). Lentivirus particle-containing media was then 
removed, the cells washed with PBS, and then complete media added to cells. After 
48 hours, cells were re-plated in 10 cm dishes and underwent drug selection by addition of 
puromycin until the uninfected cells had died, typically 0.5-1 µg/ml puromycin over a 
period of four to five days. A kill curve was established for each cell line used such that all 
uninfected cells are dead by day four or five. The plasmid pHIV-szGreen was used a 
positive control for infection (kindly provided by Dr Clare Davies, University of 
Birmingham). Induction of the shRNA was triggered by the addition of doxycycline into 
the cell media. Cells were maintained in normal growth media containing tetracycline free 
serum. 
 
2.2.10 Crude subcellular fractionation 
Crude fractionation of cells was done using the REAP method, as previously described 
(Suzuki et al., 2010). Cells were washed in ice-cold PBS and scraped from the tissue 
culture dish into a 1.5 ml microcentrifuge tubes in 1 ml PBS. After a brief centrifugation at 
top speed in a tabletop microfuge (21,130 x g) for 10 seconds to collect the cells, the 
supernatant was removed and the cells triturated five times in 900 µl ice-cold 0.1% NP-40. 
Three hundred µl of this lysate was removed for the whole cell sample to which 100 µl 4X 
Laemmli sample buffer containing 5% (vol/vol) β-mercaptoethanol was added. The 
remaining 600 µl was centrifuged for 10 seconds as above and 300 µl removed for the 
cytoplasmic fraction, to which 100 µl of Laemmli sample buffer was added. The pellet was 
then resuspended in 1 ml ice-cold 0.1% NP-40 and centrifuged as above, and the 




buffer (nuclear fraction). Nuclear and whole-cell fractions were sonicated once at 30% 
amplitude for 10 seconds using a Microson ultrasonic cell disrupter (Misonix, New York, 
USA). All samples were then heated at 95°C for five to 10 minutes prior to SDS-PAGE.  
 
2.2.11 Subcellular fractionation 
Subcellular fractionation was carried out using the ProteoExtract Subcellular Proteome 
Extraction Kit (Merck, Watford, UK) as per manufacturer’s instructions. All solutions 
were supplemented with protease and phosphatase inhibitors and buffer III was also 
supplemented with benzonase. All buffers were used cold except for buffer IV, which was 
used at room temperature as it contains SDS. Briefly, monolayer cells were washed twice 
with Tris-buffered saline (TBS; 50 mM Tris-HCl and 150 mM sodium chloride in PBS) 
before incubation with 1 ml buffer I for 10 minutes at 4°C, which was then transferred to a 
pre-cooled Eppendorf tube (fraction one: cytosol). Next, 1 ml buffer II was added to the 
monolayer cells and incubated at 4°C for 30 minutes before being transferred to an 
Eppendorf tube (fraction two: membrane/organelle associated). Five hundred µl buffer III 
containing benzonase was then added to cells and incubated at 4°C for 10 minutes before 
the supernatant was transferred to a pre-cooled Eppendorf tube (fraction three: nuclear). 
Finally, 500 µl room temperature buffer IV was added to the cell monolayer and the dish 
swirled to collect any residual material, before collecting in a Eppendorf (fraction four: 
cytoskeletal). For Western blot analysis of these fractions, 15 µl of each was added to 15 µl 
Laemmli buffer containing 5% (vol/vol) β-mercaptoethanol, boiled at 95-100°C for five to 




2.3 Southern blotting 
2.3.1 Isolation of DNA 
Cells were washed in PBS and resuspended in lysis buffer (400 mM sodium chloride, 10 
mM Tris (pH 7.4), 10 mM EDTA) and RNase A added to a final concentration of 
400 µg/ml. Lysates were mixed and incubated at 37°C for 60 minutes before the addition 
of 50 µg/ml proteinase K and 0.2% (vol/vol) SDS, and incubated at 37C for 2-3 hours or 
overnight. Cellular DNA was then sheared by passing the cell lysate through a blunted 
20-gauge needle.  
DNA isolation was by phenol-chloroform extraction. This was performed by the addition 
of 6 ml phenol/chloroform/isoamyl alcohol in a ratio of 25:24:1 before repeated inversion 
of the tube and centrifugation at 537 x g for five minutes. The upper aqueous layer was 
retained and the extraction was repeated. Finally, the aqueous layer was extracted with 
6 ml chloroform/isoamyl alcohol in a ratio of 24:1. DNA was precipitated by the addition 
of two volumes of ethanol and one-tenth volume of 3 M sodium acetate (pH 5.2), and 
incubated overnight at -20°C. The following day, samples were centrifugated at 537 x g for 
30 minutes and the DNA pellet was washed twice with 70% ethanol, before centrifugation 
as above. After removal of the supernatant, the DNA was left to air dry at room 
temperature and resuspended in sterile Tris-EDTA buffer (TE buffer; 10 mM Tris-HCl and 
0.1 mM EDTA, pH 8.0). DNA concentration was determined by the nucleic acid setting on 





2.3.2 Digestion of DNA 
Five micrograms of purified DNA were digested with restriction enzymes overnight at 
37°C in a total volume of 20 µl. For HPV18, EcoRI will linearize the HPV18 genome 
while BglII will not cut the HPV18 genome. Reactions were set up with DpnI to digest any 
residual bacterial DNA from the HPV18 plasmid before overnight incubation at 37°C. 
DNA was resolved on a 0.8% (wt/vol) agarose gel prepared in Tris-Borate-EDTA buffer 
(TBE; 45 mM Tris-HCl, 45 mM boric acid and 1 mM EDTA) containing 0.2 µg/ml 
ethidium bromide overnight at 50 V. To enable quantification of viral genome copy 
number, purified HPV18 DNA was used to prepare copy number standards equivalent to 5, 
50 and 500 genome copies per cell. 
 
2.3.3 Transfer of DNA to a nylon membrane 
Once electrophoresis had finished, loading and digestion quality of the DNA was checked 
by viewing the gel under ultraviolet (UV) light (Gene Flash UV lightbox, Syngene, UK). 
The gel was then washed twice in 250 mM HCl for 30 minutes each at room temperature, 
before two washes in 400 mM sodium hydroxide (NaOH) under gentle agitation. 
For transfer of the DNA to the nylon membrane, a tray was prepared using 1 L of 400 mM 
NaOH with a glass plate placed on the tray. A 24 x 33 cm sheet of Whatman™ paper was 
soaked in NaOH and placed on the glass plate, both ends submerged in NaOH. Bubbles 
were removed by rolling a pipette over the paper, and then three more layers of 
Whatman™ paper added. The agarose gel was flipped and placed on top of the paper, with 
the loading wells facing downwards. Bubbles were removed as above. A 20 x 22.5 cm 




followed by four layers of the Whatman™ paper. Finally, paper towels were placed on top, 
covering the paper, to ensure there were no gaps between stacks. Another glass plate was 
placed on top alongside a weight. Saran wrap was then used to ensure the top and bottom 
layers of Whatman™ papers did not touch. This was left overnight. 
The following day, the positions of the wells were marked onto the nylon membrane. The 
DNA was cross-linked to the membrane using a Stratalinker UV crosslinker in crosslink 
mode. The membrane was then soaked in 2X saline-sodium citrate (SSC) buffer (30 mM 
trisodium citrate and 300 mM sodium chloride, pH 7.0) and sorted at -20°C in saran wrap.  
2.3.4 Preparation of the radiolabelled DNA probe 
To make the radiolabelled HPV18 probe, the pGEMII-HPV18 plasmid (a kind gift of 
Frank Stubenrauch, University of Tubingen) was digested with EcoRI to release the 
HPV18 complete genome and the digest resolved on a 1% (wt/vol) agarose gel. The 
released viral genome of ~8000 bps was cut out of the gel with a clean scalpel and the 
DNA extracted using a QIAquick gel extraction kit (see section 2.4.3). Fifty nanograms of 
purified DNA was then diluted with TE buffer to a final volume of 14 µl and denatured by 
boiling at 95°C for five minutes before incubation on ice for a further five minutes. To this, 
5 µl oligonucleotide labelling buffer (1 mg/ml random deoxynucleotide primers, 1 M 
HEPES, pH 6.6), 1.5 µl nuclear grade BSA and 1.5 µl Klenow polymerase was added, 
followed by 30 µC of radiolabelled deoxynucleotide (32P-dCTP, EasyTides, PerkinElmer). 
The reaction was incubated for several hours in a lead container at room temperature. 
Unincorporated deoxynucleotide was removed by purification on an Illustra Probe Quant 





2.3.5 Hybridisation of radiolabelled probe to DNA 
To prepare the hybridisation buffer, 2X hybridisation solution (5X SSC: 750 mM sodium 
chloride and 75 mM M trisodium citrate (pH 7.0)), 10X Denhardt’s solution (0.2% 
(wt/vol) Ficoll 400, 0.2% (wt/vol) polyvinylpyrrolidone), 0.2% (wt/vol) BSA fraction V 
and 20% (wt/vol) dextran sulphate) were mixed. The hybridisation solution was mixed 1:1 
with deionized formamide and SDS added to a final concentration of 0.1% (wt/vol). Two 
hundred µl of a 10 mg/ml solution of salmon sperm was prepared by boiling at 100°C 
before incubation on an ice/water slurry for two minutes. This was then added to 10 ml 
hybridisation buffer (pre-hybridisation buffer).  
The membrane was rolled tight in a nylon gauze and placed in a hybridisation canister and 
rotated such that the membrane unrolled inside the canister, DNA facing outwards. Ten 
millilitres pre-hybridisation buffer (containing the salmon sperm) was then added to the 
canister and this was rotated for one hour at 42°C. This was then removed and replaced by 
10 ml hybridisation buffer containing the radiolabelled DNA probe and boiled salmon 
sperm, before being incubated at 42°C overnight with rotation.  
 
2.3.6 Stringency washes 
The membrane was rinsed in buffer one (600 mM sodium citrate, 300 mM sodium chloride 
and 0.1% (wt/vol) SDS, pH 7.0) before two 15 minutes washes in the same buffer. Then, 
the membrane was washed twice in buffer two (150 mM sodium citrate, 75 mM sodium 
chloride and 0.1% (wt/vol) SDS pH 7.0) followed by a further two washes in buffer three 
(30 mM sodium citrate, 15 mM sodium chloride and 0.1% (wt/vol) SDS, pH 7.0). All 




four (30 mM sodium citrate, 15 mM sodium chloride and 0.1% (wt/vol) SDS, pH 7.0). The 
membrane was then wrapped in saran wrap and exposed to x-ray film with an intensifying 
screen at -80°C. 
2.4 Molecular methods 
2.4.1 Polymerase Chain Reaction (PCR) 
For the preparation of the GST-HPV18 E6 fusion protein, pGEMII-HPV18 was used to 
amplify the complete HPV18 E6 ORF. This plasmid contains the complete HPV18 
genome cloned into the pGEMII vector at the EcoRI site at residue 2440. DNA was 
amplified using Phusion® High-Fidelity DNA Polymerase (New England Biolabs (NEB), 
Hitchin, UK) in a 20 µl reaction containing 200 µM dNTPs, 0.5 µM forward and reverse 
primers, 20 ng plasmid DNA and 1 U of DNA polymerase. Amplification was performed 
on an Applied Biosciences thermal cycler using a 10-minute hot start at 98°C followed by 
35 cycles of 30 seconds at 75°C, 30 seconds at 70°C and two minutes at 72°C. The final 
extension step was 10 minutes at 72°C before hold at 4°C.  
The primers used to amplify the E6 ORF were forward 5’-G TAA TGA ATT CTG GCG 
CGC TTT GAG GAT CCA ACA-3’ and reverse 5’-GTATTGAATTC TTA TAC TTG 
TGT TTC TCT GCG-3’. These primers were designed to introduce an EcoRI digestion 
site, shown underlined, and were synthesised by AltaBioscience, Birmingham, UK.  
 
2.4.2 Agarose gel electrophoresis 
DNA was resolved by 1-1.5% (wt/vol) agarose gel electrophoresis in a horizontal 




buffer in a microwave and allowed to cool at approximately 50-60°C before casting. DNA 
was mixed with Midori Green Nucleic Acid Stain (Geneflow, Lichfield, UK) prior to 
loading alongside a 1 kb DNA ladder for size determination (Invitrogen). Alternatively, 
ethidium bromide was added to the gel at a final concentration of 0.2 μg/ml and gels run at 
80-110 volts until finished. DNA bands were visualised under UV light per section 2.3.3. 
 
2.4.3 Gel Purification of DNA  
After resolution of DNA fragments by agarose gel electrophoresis, bands were excised and 
purified using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s 
instructions. Briefly, the band was cut out of the gel using a clean scalpel and placed in 
solubilisation buffer for 10 minutes at 50°C to melt the agarose, following which one 
volume of isopropanol was added. This was then applied to a QIAquick DNA binding 
column and centrifuged for one minute at 16, 000 x g in a tabletop centrifuge. The column 
was washed by adding 750 µl wash buffer, centrifuged as above, and DNA eluted by 
applying 30-50 µl TE buffer and collected by a further centrifugation step. Eluted DNA 
was stored at -20°C.  
 
2.4.4 Restriction enzyme digestion 
For the preparation of the pGEX-2T plasmid, restriction enzyme digestion of vector DNA 
was carried out using 5-10 µg DNA with 10-20 units of EcoRI in a total volume of 20-
50 µl, as per manufacturer’s instructions. Digestion was carried out at 37°C for at least two 
hours or overnight. To verify digestion, an aliquot was analysed using agarose gel 





2.4.5 Alkaline Phosphatase treatment of DNA 
For sticky end cloning, the 5’ terminal phosphate groups were removed from DNA using 
alkaline phosphatase (NEB) as per manufacturer’s instructions. Briefly, digested DNA was 
incubated with a one-tenth volume of reaction buffer and then one to five units of alkaline 
phosphatase as per manufacturer’s instructions. The solution was incubated at 37°C for one 
hour before inactivation at 65°C for 15 minutes.  
 
2.4.6 DNA ligation  
Following restriction enzyme digestion, samples were heat inactivated prior to ligation by 
a ten-minute incubation at 65°C before being placed on ice. Ligation of HPV18 E6 and 
pGEX-2T plasmids were carried out using a vector to insert ratio of 1:3, 1:5 and 1:10 with 
T4 DNA ligase as described by the manufacturer overnight at 16°C (NEB). DNA was then 
transformed into bacteria, as described in section 2.5.2.  
2.5 Bacterial methods 
2.5.1 General information 
The Escherichia coli (E. coli) DH5α strain was used as a host for the growth of all 
plasmids for bacterial transformation and preparation of plasmid DNA. BL21 or Rosetta 2 
DE3 pLysS strains were used for expression of GST fusion proteins. Agar plates were 
made using Luria-Bertani (LB) medium (1% (wt/vol) bacto-tryptone, 0.5% (wt/vol) bacto-
yeast extract and 1% (wt/vol) sodium chloride) supplemented with agar. After autoclaving, 
the agar solution was boiled in a microwave and allowed to cool to approximately 50-60°C 
before the addition of antibiotics. Typical concentrations were ampicillin 100 µg/ml, 




20-30 ml agar was added to 10 cm bacterial dishes and allowed to set and dry in a 
microbiological safety hood under aseptic conditions. Plates were stored at 4°C for a 
maximum of six weeks.  
 
2.5.2 Bacterial transformation  
E. coli cells were thawed on ice and 30-50 µl added to a pre-cooled Eppendorf tube. 
Plasmid DNA was then added to the tube and incubated on ice for 30 minutes, heat 
shocked at 42°C for 45 seconds then placed back on ice for two minutes. Five hundred µl 
LB was then added per tube and placed on a shaker set to 200 revolutions per minute for 
one hour. Two hundred µl cell solution was then streaked out onto the relevant agar plate 
with the appropriate antibiotic. The remainder of the cell solution was stored at 4°C for 
further plating, as needed. After overnight incubation at 37°C, single colonies of bacteria 
were picked and used to inoculate 10 ml LB media with antibiotic for generation of small 
cultures. These small cultures were then diluted into a larger 200-300 ml culture if desired. 
Both were incubated overnight at 37°C with shaking before use.  
 
2.5.3 Long-term storage of transformed bacteria 
One ml transformed bacteria from an overnight culture was added to 500 µl sterile 50% 
(vol/vol) glycerol solution in a cryovial, mixed thoroughly, and stored at -80°C.  
 
2.5.4 Preparation of plasmid DNA 
Preparation of plasmid DNA for transfection was as per manufacturer’s instructions using 
the PureLink® HiPure Plasmid Maxiprep Kit (Invitrogen), except the final ethanol 




buffer. DNA concentration was determined by the nucleic acid setting on a Nanodrop 
spectrophotometer with TE buffer as a blank. 
 
2.5.5 Expression of recombinant proteins 
Purified DNA was used to transform BL21 or Rosetta 2 competent cells (Stratagene, 
California, USA), as above. After overnight incubation of a 10-20 ml culture with 
antibiotics, this was transferred to 0.5-2 litre LB culture containing 2% glucose and 
incubated at 37°C to an optical density measured at 600 nm (OD600) of 0.6-0.8. Induction 
was by addition of 0.4 mM isopropyl-β-d-thiogalactopyranoside (IPTG) and incubated 
with shaking at 37°C for three to four hours, or overnight at 15-20°C with 0.1 mM IPTG. 
Cells were pelleted by centrifugation (5000 x g, 4°C, 15 minutes) and froze at -80°C prior 
to processing. GST-AKAP95 was a kind gift of Professor Kjetil Tasken, University of 
Oslo. GST-HPV11E6 and GST-HPV16E6 were kind gifts of Dr Miranda Thomas and 
Professor Lawrence Banks, International Centre for Genetic Engineering and 
Biotechnology, Trieste. 
 
2.5.6 Purification of recombinant GST proteins 
Bacteria were thawed gently on ice and resuspended in bacteria lysis buffer (50 mM 
HEPES (pH 7.5), 2% Triton X-100 in PBS) supplemented with 5 mg/ml lysozyme. 
Bacteria were then sonicated on ice. For purification of GST-AKAP95, sonication was one 
period of 15 seconds on at 20% amplitude. For GST-HPV18 E6, sonication was for three 
periods of 10-20 seconds on and 40 seconds off at 20% amplitude. Lysates were then 
cleared by high-speed centrifugation at 10,000 x g for 15 minutes. Soluble recombinant 




overnight prior to extensive washing in lysis buffer. Soluble GST proteins were prepared 
by subsequently eluting the GST protein into lysis buffer containing 50 mM reduced 
glutathione at pH 8. Soluble proteins were then dialysed overnight in storage buffer 
(25 mM HEPES (pH 7.5), 200 mM sodium chloride, 20% (vol/vol) glycerol). 
Alternatively, beads were resuspended in an equal volume of PBS containing 50% glycerol 
and 1% Triton X-100. Recombinant proteins were stored at -20°C. 
 
2.5.7 GST pull-down from cell lysates 
Cells were lysed in E1A buffer (50 mM HEPES (pH 7.5), 250 mM sodium chloride and 
0.1% NP-40) before end-over-end incubation with GST fusion proteins overnight at 4°C. 
After overnight incubation, pre-washed GST beads were added where appropriate for at 
least two hours at 4°C. For GST fusion proteins already bound to the beads, the fusion 
proteins were added directly to the cell lysate. After extensive washing (5+) in lysis buffer, 
the beads were resuspended in an equal volume of 2X Laemmli buffer supplemented with 
5% (vol/vol) β-mercaptoethanol, boiled at 95°C for 10 minutes and loaded onto 
SDS-PAGE gels for Western blotting, as described in section 2.6.2.  
 
2.5.8 Plasmid DNA constructs for interaction mapping 
To map the HPV18 E6-interacting domains on AKAP95, a series of AKAP95 mutants in 
the pcDNA3 background were used, encoding FLAG/HA (FH-) tagged proteins at the 
amino terminus. These mutants were FH-AKAP95(1-692), FH-AKAP95(101-692), 
FH-AKAP95(1-210), FH-AKAP95(211-692), FH-AKAP95(1-340), 




gifts of Professor Hao Jiang (Hu et al., 2016). FH-AKAP95(I582P) contains a mutation 
that renders it unable to bind to PKA and the ZF C>S mutant cannot bind to DNA.  
Similarly, mutant HPV18 E6 constructs were used to map the AKAP95 binding site on E6. 
These mutants were wild-type HPV18 E6, Arg153Leu or Thr156Glu mutants, and have 
been described elsewhere (Watson et al, 2003). Replacement of arginine at amino acid 153 
with leucine destroys the PKA recognition sequence (RRXS/T) and this mutant E6 no 
longer responds to PKA signalling and can degrade PDZ substances in a PKA independent 
manner (LeuE6; Kühne et al., 2000). The threonine residue at residue 156 lies within the 
PBM of HPV18 E6 and the hydroxyl oxygen of this residue is involved in E6-PDZ 
interactions. Substitution by glutamic acid inhibits binding to the PDZ substrate Dlg1 and 
inhibits its degradation in vitro (GluE6; Gardiol et al., 1999). An additional mutant was 
used in which the last four amino acids that make up the E6 PBM have been deleted by 
insertion of two translation termination codons at positions 155 and 156 (ΔPDZE6; Delury 
et al., 2013).  
2.6 Protein biochemistry 
2.6.1 Bradford assay 
Protein concentrations were determined by the Bradford method. A standard curve was 
first established using a Bio-Photometer (Eppendorf, Stevenage, UK) using serial dilutions 
of BSA (Sigma-Aldrich) ranging from 2 mg/ml to 0.125 mg/ml, diluted with Bio-Rad 
Protein Assay Reagent (Hemel Hempstead, UK), as per manufacturer’s instructions. 






Cells were harvested directly in E1A lysis buffer and co-immunoprecipitations performed 
as described in Parish et al., 2006. Briefly, the cell lysate was sonicated for 10 seconds at 
30% amplitude. After centrifugation to remove insoluble material, lysates were incubated 
overnight at 4°C with 4-5 µg of the indicated antibody before incubation with Protein A/G 
Sepharose beads (Sigma-Aldrich) for at least two hours at 4°C. The beads were washed 
extensively in wash buffer (100 mM Tris-HCl (pH 8.0), 150 mM sodium chloride, 0.5% 




Samples were lysed in urea lysis buffer (8 M urea, 150 mM sodium chloride, 2 mM Tris-
HCl (pH 7.2), protease and phosphatase inhibitors) unless otherwise indicated, sonicated 
once at 30% amplitude for 10 seconds, and cleared by high-speed centrifugation, 
16,000 x g for 15 minutes at 4°C. A total of 20-30 µg total protein was prepared for 
electrophoresis by addition of 2X Laemmli buffer supplemented with 5% (vol/vol) 
β-mercaptoethanol and boiled at 95-100°C for five to 10 minutes on a hot plate. Protein 
samples were resolved on a polyacrylamide separating gel (350 mM Tris-HCl buffer (pH 
7.8), 10-15% (wt/vol) polyacrylamide (37.5:1, acrylamide: bis-acrylamide), 1% (wt/vol) 
SDS, 0.5% (wt/vol) ammonium persulphate (APS) and 0.08% (vol/vol) N,N,N',N'-
Tetramethylethylenediamine (TEMED)). A layer of 100% isopropanol was added to the 
gel once poured to ensure a smooth surface. Once set, the isopropanol was removed, the 
gel washed with water and a stacking gel (120 mM Tris-HCl buffer (pH 6.8), 4.5% 




TEMED) poured and an appropriate comb added to the gel and allowed to set. Once set, 
the electrophoretic apparatus was flooded with cold running buffer (25 mM Tris-HCl, 
192 mM glycine, 0.1% (wt/vol) SDS, pH 8.3) and the comb removed. Wells were then 
washed with running buffer before samples were added to wells. Electrophoresis was 
performed using the Bio-Rad Mini-Protean® system at 20-30 mA for 1-2 hours or until the 
protein marker had reached the end of the gel. 
 
2.6.4 Western blotting 
Following protein separation by SDS-PAGE, proteins were transferred to nitrocellulose 
membranes (Pall Corporation, Portsmouth, UK) in a Trans-Blot transfer tank (Bio-Rad) 
flooded with transfer buffer (25 mM Tris-HCl, 192 mM glycine, 20% (vol/vol) methanol, 
pH 8.3) set at 15-25 mA for overnight transfer or 350 mA for three hours. To assess 
transfer, membranes were stained with the reversible protein stain Ponceau S 
(0.1% (wt/vol) Ponceau S stain in 5% (vol/vol) acetic acid) to visualise protein bands, 
before subsequent de-staining by washing in several changes of TBS containing 0.1% 
Tween-20 (TBS-T: 50 mM Tris-HCl and 150 mM sodium chloride, 0.1% Tween-20, pH 
7.6). Membranes were then incubated on a rocking platform with blocking buffer (5% 
(wt/vol) dried skimmed milk powder in TBS-T or 5% (wt/vol) BSA in TBS-T for 
phosphor-antibodies) for at least 60 minutes before incubation with primary antibody 
(Table 2.1) in blocking buffer overnight on a rocking platform. Protein loading was 
assessed by blotting for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Following 
incubation with the primary antibody, membranes were washed four times for 10-15 
minutes each in TBS-T before incubation with the appropriate species-specific secondary 




four additional washes, the membrane was developed by enhanced chemiluminescence and 
signals captured on X-ray film (GE Healthcare, Amersham, UK) or using the Fusion FX 





Table 2.1: Table of antibodies 
Antibody Clone/ID Manufacturer Species WB 
dilution 
IF dilution  
DLG1  NAG (Roberts et al., 2007) Rabbit 1/200 - 
hScrib C20 Santa Cruz  Goat 1/2000 - 
p53 DO-1 (Stephen et al., 1995) Mouse 1/100 1/50 
GAPDH 6C5 Santa Cruz Mouse  1/5000 - 
Cytokeratin 
18 
CK5 Sigma Mouse 1/1000 - 
E-Cadherin 610182 BD Biosciences Mouse  1/1000 - 
GRB2 C7 Santa Cruz Mouse 1/200 - 
HPV18 E6 G7 Santa Cruz Mouse 1/100 - 
HPV18 E7 8E2 Abcam Mouse 1/1000 - 
PKA-RI 18/PKA(RI) BD Biosciences Mouse 1/1000 - 
PKA-RII 40/PKA(RII) BD Biosciences Mouse 1/1000 - 




4781S Cell Signalling 
Technology 




9621 Cell Signalling 
Technology 
Rabbit 1/1000 - 
AKAP95 A301-062A Bethyl Laboratories 
Inc. 
Rabbit 1/2000 1/200 
Cyclin D1 H295 Santa Cruz Rabbit 1/1000 - 
Flag M2 Sigma Mouse 1/1000 - 





CHAPTER 3 INVESTIGATING THE EFFECT OF HPV18 
ON THE ACTIVITY OF THE PROTEIN KINASE A 
SIGNALLING PATHWAY 
3.1 Introduction 
Human oncogenic viruses, including HPV, interact with and remodel host signalling 
pathways to facilitate viral DNA replication and drive host cell transformation, and these 
interactions are important for the oncogenic progression of viral infections. The HPV E6 
and E7 oncoproteins have been reported to interact with as many as 243 cellular proteins, 
regulating up to 153 different signal transduction pathways, including the host 
cAMP-dependent PKA pathway (Zhao et al., 2011). This pathway is important for several 
aspects of the HPV life cycle, including regulation of viral protein function, and changes in 
PKA signalling may be relevant during disease progression, as discussed in section 1.3.11 
of the introduction to this thesis.  
Given that PKA is important for multiple aspects of the HPV life cycle and changes in the 
activity of the pathway may be relevant for oncogenic progression of HPV infections, we 
were interested in understanding whether the virus is able to manipulate cAMP and/or 
PKA signalling in squamous epithelium keratinocytes, the natural target of the virus. For 
this, an assay based on BRET was used to investigate both cAMP and PKA signalling in 
living cells. This assay allows for real-time evaluation of cAMP and PKA dynamics based 
on changes in protein subunit interactions (described in detail in section 3.2.1). Using this 
assay, there was increased activity of the kinase in NIKS harbouring HPV18 episomes 




pathway (unpublished data from the Roberts and McKeating laboratories). NIKS have 
been used to model life cycle events of various oncogenic HPVs (Flores et al., 1999; 
Nakahara and Lambert, 2007) but they are a spontaneously immortalised human 
keratinocyte line. As primary squamous keratinocytes are the natural target cell of the 
virus, it was, therefore, important to investigate the HPV-PKA axis in physiologically 
relevant cells.  
3.2 Results  
3.2.1 Bioluminescence Resonance Energy Transfer sensors to study PKA 
activity 
To understand whether HPV18 can manipulate PKA activity, BRET-based biosensors 
were used to examine PKA dynamics in intact cells. This assay uses Renilla luciferase 
(Rluc)-tagged regulatory subunits (i.e. Rluc-PKA-RI or -RII) and a GFP-tagged catalytic 
subunit (GFP-Cα) as the energy donor and acceptor respectively. Co-transfection of these 
sensors allows for recombinant expression of the PKA holoenzyme in cells with known 
subunit concentration (Prinz et al., 2006). 
When the regulatory and catalytic subunits are assembled as a holoenzyme (i.e. PKA is 
inactive), there is energy transfer from Rluc-PKA-R subunit to GFP-Cα (410 to 515 nm). 
On PKA activation by cAMP, the holoenzyme dissociates and this leads to an increase in 
intra-molecular distance between the donor and acceptor components of the biosensor, 
resulting in a loss of energy transfer to GFP-Cα. As such, changes in energy transfer to 
GFP-Cα can be used to study PKA activation.  
Changes in cAMP levels can also be examined using this technique by using the known 




both the luciferase donor and GFP acceptor at opposing termini and, following an increase 
in cAMP, the intra-molecular distance between the sensors increases, leading to a change 
in energy transfer to the GFP moiety.  
A diagram of these biosensors is shown in Figure 3.1, with Figure 3.2 describing the 
changes in energy transfer under low and high cAMP levels. Note that lower BRET ratios 

















Figure 3.1: Genetically encoded bioluminescent sensors to examine PKA and cAMP signalling in living cells. The Renilla luciferase 
bioluminescent donor (Rluc) and green fluorescent protein (GFP) are fused to the regulatory and catalytic subunits of PKA (A), or 
different domains of EPAC (B), respectively. Energy transfer occurs when these sensors are in close proximity (1-10 nm). PKA or EPAC 














Figure 3.2: Intra-molecular distance dictates energy transfer to GFP acceptor molecules during BRET. When PKA/EPAC is inactive 
(low cAMP levels), the Rluc-tagged donor (D) is in close proximity (1-10 nm) to the GFP-acceptor (A) and there is energy transfer between 
the donor and acceptor, resulting in light emission measurable at both 410 nm and 515 nm. When cAMP levels are high, there is an increase 
in intra-molecular distance such that there is no longer energy transfer from the donor to the acceptor moiety. This results in the light emission 





3.2.2 HPV18 replication in normal immortalised keratinocytes is associated 
with changes in PKA activity 
It was first confirmed whether HPV18 replication in NIKS cells affected the activation of 
the PKA sensors in the absence of any exogenous stimulation. As shown in Figure 3.3A, 
HPV18 replication did not significantly affect the activity of the PKA-RI sensor (NIKS 
0.187 ± 0.0188 and NIKS-18 0.167 ± 0.0157, p=0.07); however, there was increased 
activity of the PKA-RII sensor (NIKS 0.202 ± 0.007 and NIKS-18 0.108 ± 0.006, 
p=<0.01). To correlate this PKA-RII activation with cAMP, the activity of the EPAC 
cAMP sensor was then determined. Interestingly, HPV18 replication also increased the 
activity of cAMP sensor EPAC (NIKS 0.206 ± 0.021 and NIKS-18 0.116 ± 0.009, p=0.03), 
which may suggest that the increased PKA-RII activity seen in HPV18 genome containing 
cells is driven by changes in cAMP. Visualising these data as a fold change showed that 
NIKS maintaining HPV18 genomes showed an approximate 1.2-fold, 1.9-fold and 1.8-fold 
increase in activity of the PKA-RI, -RII and cAMP sensors, respectively, compared to 
control NIKS (data not shown). 
Next, whether HPV18 affected the activity of the PKA pathway upon chemical induction 
of cAMP levels was examined. For this, forskolin was used to increase the activity of 
adenylate cyclases, leading to an increase in cellular cAMP (Figure 3.3 B). Here, viral 
replication was associated with increased activity of both PKA sensors: PKA-RI (NIKS 
0.149 ± 0.024 and NIKS-18 0.087 ± 0.004, p=<0.01) and PKA-RII (NIKS 0.148 ± 0.003 
and NIKS-18 0.045 ± 0.004, p=<0.001). Furthermore, replication of the virus was also 
associated with increased activity of the cAMP sensor (NIKS 0.147 ± 0.017 and NIKS-18 




was associated with a 1.6-fold, 3.3-fold and 1.8-fold increase in activity of the 
PKA-RI, -RII and cAMP sensors (data not shown). 
These data suggest that HPV18 replication is associated with increased activity of PKA-RI, 
-RII and cAMP biosensors. Under both unstimulated and stimulated conditions, this 
increased activity is greatest for the -RII subunit, which may suggest that HPV 
preferentially activates the RII isoform during viral replication in NIKS cells.  
 
3.2.3 Identification of a transfection reagent for primary human foreskin 
keratinocytes 
While a variety of keratinocyte lines, including NIKS, have been used to study HPV in the 
laboratory, they are not a truly physiological model system to study HPV life cycle events. 
For example, NIKS are near diploid, containing 47 chromosomes due to additional long 
arm of chromosome 8, and express wild type p53 (Allen-Hoffmann et al., 2000). In 
addition, there are various differences in how the virus interacts with NIKS compared with 
primary HFKs. For example, infection by HPV16 pseudovirions in NIKS was 
approximately 400-fold more efficient than in HFKs (Griffin et al., 2013), which is 
consistent with earlier studies that showed NIKS cells to be more permissible for HPV31b 
infection than HFKs (Ozbun, 2002). Furthermore, NIKS are a spontaneously immortalised 
cell line so one must be aware of the underlying genetic changes in these cells, which may 
not be present in primary HFKs. These examples clearly illustrate the importance of using 
an appropriate culture system to study HPV. It was, therefore, important to examine 
whether HPV18 regulates PKA in a physiologically relevant system established in primary 





Figure 3.3: Normal immortalised keratinocytes maintaining HPV18 genomes show altered PKA activation. NIKS or NIKS cells 
containing HPV18 genomes (NIKS-18) cells were transfected with PKA or cAMP biosensors. The activity of these biosensors was 
determined 48 hours later by bioluminescent resonance energy transfer in the absence (unstimulated) or presence (stimulated) of the cAMP 
elevating agent forskolin. Data ±SEM taken from three independent experiments. Statistical significance was determined by Student’s t-test 




For this, it was first important to find a transfection reagent for primary HFKs suitable for 
high-level expression of the PKA/cAMP biosensors as HFKs are traditionally quite 
difficult to transfect. HFKs grown in monolayer culture were transfected with a GFP 
encoding plasmid (pMAX-GFP) using a variety of commercially available transfection 
reagents and assayed by fluorescence microscopy for GFP expression 48 hours later to 
determine transfection efficiency. Rate of transfection was judged by determining the 
percentage of cells that were GFP positive. As shown in Figure 3.4, Mirus Keratinocyte 
provided the highest transfection efficiency of the reagents tested with minimal effects on 
cell morphology and viability. Several of the other reagents, including Viromer Red and 
Mirus 20:20, resulted in very poor transfection efficiencies and cell viability. Additionally, 
these reagents disturbed the ability of these cells to form the traditional cobblestone 
appearance of primary keratinocytes. Further optimisation of the Mirus Keratinocyte 
reagent provided a DNA to reagent ratio for maximum transgene expression but with low 





















Figure 3.4: Identification of a transfection reagent suitable for primary human 
foreskin keratinocytes. Primary HFKs were plated out in a six-well plate and transfected 
with a GFP expression vector using the indicated reagents as per manufacturer’s 
instructions. GFP expression was assayed by fluorescence microscopy and morphology 
examined under phase contrast. NT: not transfected. Scale bar: 10 μm. Percentages 
represent transfection efficiency as determined by the ‘Find Maxima’ method on ImageJ to 




3.2.4 HPV18 replication in a primary human foreskin keratinocyte grown to 
low passage also associated with changes in PKA activity 
Having identified a suitable transfection reagent, the BRET experiments were then carried 
out in donor matched HFK and HFK cells maintaining HPV18 genomes (Wilson et al., 
2007). It has been reported that oncogenic HPV episomes, including HPV18, in primary 
keratinocyte donors are sometimes reduced upon cell passage concomitant with the 
integration of viral DNA into the host DNA (Delury et al., 2013; Lace et al., 2011), an 
event that is linked to malignant progression of infections (Burk et al., 2017). Therefore, 
changes to PKA activity by HPV might contribute to this progression. To examine this, the 
BRET assay was carried out in HPV18 genome containing cells grown to both low (HFK-
18 LP) and high cell passages (HFK-18 HP).  
In Figure 3.5 A, for foreskin donor one (top row), HPV18 replication in cells cultured to 
low cell passages displayed slightly increased activity of the PKA-RI sensor compared to 
control cells (HFK 0.157 ± 0.024 and HFK-18 LP 0.110 ± 0.022), although this did not 
reach significance (p=0.06). For PKA-RII, there was increased activity of the biosensor in 
HFK-18 LP cells (HFK 0.164 ± 0.014 and HFK-18 LP 0.046 ± 0.021, p=<0.01), which 
occurred concomitantly with a significant increase in cAMP sensor activity (HFK 0.311 ± 
0.031 and HFK-18 LP 0.200 ± 0.026, p=<0.01). In cells stimulated with forskolin (Figure 
3.5 B), there was a significant decrease in PKA-RI sensor activity with HPV18 replication 
(HFK 0.134 ± 0.024 and HFK-18 LP 0.193 ± 0.012, p=0.02); however, significant 
increases in PKA-RII (HFK 0.148 ± 0.014 and HFK-18 LP 0.060 ± 0.012, p=0.01) and 
cAMP sensor (HFK 0.285 ± 0.031 and HFK-18 LP 0.166 ± 0.015, p=<0.01) activity were 




In the second foreskin donor (bottom row, Figure 3.5), replication of the HPV18 genome 
in unstimulated cells (panel C) was associated with increased activity of all biosensors; 
PKA-RI (HFK 0.198 ± 0.012, HFK-18 LP 0.136 ± 0.006, p=<0.05), PKA-RII 
(HFK 0.168 ± 0.014 and HFK-18 LP 0.095 ± 0.001, p=<0.01) and cAMP (HFK 0.304 ± 
0.014, HFK-18 LP 0.173 ± 0.011, p=<0.01). After stimulation with forskolin (panel D), 
there was no significant effect of HPV18 replication on PKA-RI activity (HFK 0.129 ± 
0.021 and HFK-18 LP 0.104 ± 0.036 (p=>0.05). However, viral replication was associated 
with significant increases in PKA-RII (HFK 0.087 ± 0.016 and HFK-18 LP 0.041 ± 0.012, 
p=<0.01) and cAMP sensor activity (HFK 0.171 ± 0.017 and HFK-18 LP 0.130 ± 0.01, 
p=<0.05).  
The data obtained in unstimulated LP cells showed that HPV18 replication was associated 
with small changes in PKA-RI activity but a more marked increase in PKA-RII and cAMP 
activity, which was statistically significant in both donor backgrounds. On stimulation with 
forskolin, there was a small increase in PKA-RI activity in one foreskin donor but no 
change in the other donor, possibly suggesting a donor-specific effect of HPV18 on 
PKA-RI activity. Consistent with the unstimulated data, there is a significant activation of 
both PKA-RII and cAMP activity in cells treated with forskolin. Thus, the data show a 
consistent activation of PKA-RII and cAMP in LP cells maintaining HPV genomes.  
 
3.2.5 HPV18 replication in primary human foreskin keratinocytes grown to 
high passage also display alterations in PKA and cAMP activity  
In unstimulated HFKs derived from donor one grown to high passage (Figure 3.6 A), 
replication of the HPV18 genome had no effect on the PKA-RI (HFK 0.157 ± 0.024 and 




HP 0.135 ± 0.017, p=0.09). HPV18 replication was associated with increased activity of 
the cAMP sensor (HFK 0.311 ± 0.031 and HFK-18 HP 0.194 ± 0.011, p=<0.01).  
After stimulation of the cells with forskolin (Figure 3.6 B), there was no significant 
activation of the PKA-RI sensor in cells maintaining HPV18 genomes (HFK 0.147 ± 0.014 
and HFK-18 HP 0.102 ± 0.022, p=0.1). However, the activity of the PKA-RII (HFK 0.166 
± 0.018 and HFK-18 HP 0.079 ± 0.014, p=0.04) and cAMP (HFK 0.285 ± 0.031 and 
HFK-18 HP 0.128 ± 0.0135, p=<0.01) sensors was significantly increased in cells 
maintaining viral genomes.  
In the second foreskin donor, in unstimulated cells (Figure 3.6 C), the presence of the 
HPV18 genome did not significantly affect the activity of the PKA-RI sensor (HFK 0.198 
± 0.01 and HFK-18 HP 0.144 ± 0.01, p=0.07). In contrast, viral replication significantly 
increased the activity of both PKA-RII (HFK 0.168 ± 0.03 and HFK-18 HP 0.103 ± 0.02, 
p=<0.01) and cAMP sensors (HFK 0.304 ± 0.02 and HFK-18 HP 0.163 ± 0.03, p=<0.001).  
In cells treated with forskolin (Figure 3.6 D), replication of HPV18 DNA did not affect the 
activity of the PKA-RI sensor (HFK 0.129 ± 0.03 and HFK-18 HP 0.086 ± 0.02, p=0.08), 
however significant activation of both the PKA-RII (HFK 0.087 ± 0.02 and HFK-18 HP 
0.046 ± 0.01, p=0.01) and cAMP (HFK 0.171 ± 0.01 and HFK-18 HP 0.106 ± 0.03, 
p=0.01) sensors were detected in these cells.  
In unstimulated HP cells, there is no activation of PKA-RI in cells containing HPV18 
genomes but small changes in PKA-RII activity in one foreskin donor. In both donors, 
replication of HPV18 DNA was associated with significant increases in cAMP sensor 
activity. In cells stimulated with forskolin, there is no activation of PKA-RI but significant 
activation of PKA-RII in both donor backgrounds, occurring concomitantly with 




Taken together, the data from LP and HP cells showed marked activation of PKA-RII, 
albeit less so in the HP cells, and a variable response to HPV18 DNA replication for 
PKA-RI activity. In all foreskin donors, under both unstimulated and stimulation 




Figure 3.5: HPV18 replication in low passage primary human foreskin keratinocytes regulates PKA activity. HFK or HFK-18 cells 
from two foreskin donors were transfected with PKA or cAMP biosensors. The activity of these biosensors was determined 48 hours later by 
bioluminescent resonance energy transfer in the absence (unstimulated; A, C) or presence (stimulated; B, D) of the cAMP elevating agent 
forskolin. Data ±SEM taken from three independent experiments. Statistical significance was determined by Student’s t-test comparing HFK 





Figure 3.6: HPV18 replication in high passage primary human foreskin keratinocytes regulates PKA and cAMP activity. HFK or 
HFK-18 cells from two foreskin donors were transfected with PKA or cAMP biosensors. The activity of these biosensors was determined 48 
hours later by bioluminescent resonance energy transfer in the absence (unstimulated; A, C) or presence (stimulated; B, D) of the cAMP 
elevating agent forskolin. Data ±SEM taken from three independent experiments. Statistical significance was determined by Student’s t-test 





3.2.6 Both episomal and integrated HPV18 genomes regulate PKA activity  
The data in HFKs presented thus far showed that viral replication was associated with 
changes in PKA and cAMP sensor activity in cells maintaining HPV18 genomes grown to 
both low and high cell passage. The main difference between these cells is that the 
increased activity of PKA-RII was less marked in HP cells, which may reflect changes in 
the physical state of viral DNA in these cells. The HPV18 genome containing cells used 
for the low passage BRET analysis were all below passage 10 (p<10) and high passage 
were beyond passage 15 (p>15). To examine the physical status of the viral genome, DNA 
was extracted from cells from the two different foreskin donors by phenol-chloroform 
extraction and digested with either EcoRI, which linearizes the HPV18 genome, or BglIII, 
which does not cut the HPV18 genome but will cut host DNA, prior to Southern blot 
analysis. Residual input DNA was digested with DpnI. The Southern blot for data from 
donor one (top row, Figures 3.5 and 3.6) is shown in Figure 3.7 and donor two (bottom 
row, Figures 3.5 and 3.6) shown in Figure 3.8.  
In Figure 3.7, episomal forms of the HPV18 DNA migrate as supercoiled (SC) and open 
circle (OC) forms in the presence of the non-cutter BglII, and as a linear 8 kilobase (kb) 
band upon digestion with the single cutter EcoRI. The intensity of the bands begin to 
diminish around passage 10 and continues to do so until passage 13 where they are no 
longer visible. This suggests that in these cells the viral genome is maintained as an 
episome to passage 10 but then these episomes are gradually lost upon extended cell 
passage (>p13). In addition, there are faint bands at approximately 6 kb at p13 and p15 
cells cut with EcoRI that may represent a virus-host junction in these cells (see black 




detected up to passage 9 before a gradual loss of episomes up to passage 13. No viral 
episomes were detected from passage 16 to 21. In addition, there are higher molecular 
bands, evident in cells grown to passage 8-10, that may represent concatemeric forms of 
the HPV genome (indicated by black arrowhead). The SC band is very faint in these cells, 
indicating that the major proportion of episomes are in the form of open/relaxed circles.  
Taken together, the Southern blot data shows that, in both foreskin donors, cells grown to 
low passage (p<10) contain episomal HPV18 genomes and these episomes are lost with 
extended cell culture and the viral DNA has become integrated into the host. Thus, in the 
BRET analyses, the LP cells contain episomes and HP cells contain lack or have reduced 





Figure 3.7: Detection of HPV18 genome status by Southern blotting in donor one BRET series. DNA was extracted from 
HPV18 genome containing HFKs grown to the indicated passages, prior to digestion with either EcoRI or BglII to analyse the 
physical status of the HPV genome. OC: open circle. L: linear. SC: supercoiled. Southern blotting was performed by Mr Dhananjay 





Figure 3.8: Detection of HPV18 genome status by Southern blotting in donor two BRET series. DNA was extracted from 
HPV18 genome containing HFKs grown to the indicated passages, prior to digestion with either EcoRI or BglII to analyse the 
physical status of the HPV genome. OC: open circle. L: linear. SC: supercoiled. Southern blotting was carried out by Mr 




3.2.7 HPV18 genome containing cells display increased phosphorylation of 
PKA substrates 
To correlate the increased activity of the PKA-RII and cAMP sensors with activation of 
the PKA pathway, lysates derived from HFK or HFK-18 cells were examined for 
expression of phosphorylated PKA substrates. This antibody detects proteins that contain a 
phosphorylated serine or threonine with arginine residues at positions -3 and -2 within the 
PKA recognition motif RRXS*/T*. Figure 3.9 demonstrates that replication of HPV18 
DNA is associated with increased phosphorylation of PKA substrates, with the black 
arrowheads in the figure representing substrates that are increased in expression in the 
HFK-18 cells. Interestingly, the increased expression of some of these substrates (for 
example, the bands at approximately 80, 46 and 25 kDa) were seen in lysates derived from 
both donors. Similar results were obtained using an independent antibody that detects 
proteins a phosphorylated serine or threonine residue with arginine at the -3 position (data 
not shown). Together, these data suggest that the virus induces phosphorylation of a 
common set of PKA substrates during viral replication, although the exact identity of these 







Figure 3.9: Increased expression of phosphorylated PKA substrates in HFK cells 
maintaining HPV18 genome. Lysates from donor matched HFK or HFK-18 cells were 
probed for expression of phosphorylated PKA substrates using an antibody that detects 
phosphorylated serine or threonine residues within the consensus PKA recognition 
sequence. Note that WT(1) and WT(2) represent independently prepared HFK-18 




3.2.8 PKA-RI and -RII subunit expression in HFK-18 cells 
As discussed in section 1.3.6 in the introduction to this thesis, the main function of the 
PKA regulatory subunits is to inhibit the activation of the catalytic subunits. This has been 
best exemplified by patients with Carney Complex, a multiple neuroendocrine tumour 
disease state featuring inactivating mutations in the gene encoding PKA-RI (PRKAR1A), 
giving rise to upregulated PKA catalytic activity. Furthermore, loss of PKA-RI leads to 
upregulation of cyclin D1 expression, which is thought to contribute to tumour 
development (Nadella and Kirschner, 2005; Porter et al., 2001). On the other hand, PKA-
RI expression is increased in various cancer cell lines and primary tumours where it is 
associated with poor prognosis, and knockdown of PKA-RI induces growth arrest, 
apoptosis and changes in cell morphology in cancer cell lines (Neary et al., 2004), 
suggesting dual roles for this regulatory subunit. 
To understand whether the changes in PKA activity seen in the BRET experiments were 
due to changes in expression of the regulatory subunits, lysates were prepared directly 
from the 96 well plates used for BRET experiments and assayed for regulatory subunit 
protein expression. Figure 3.10 shows that there is no change in expression of the PKA-RI 
subunit in the presence of the viral genome in either low or high passage cells, either 
unstimulated or stimulated with the cAMP elevating agent forskolin (indicated by +), 
compared to HFK cells. Expression of PKA-RII appeared to be increased in cells 
maintaining HPV18 genomes in cells grown both to low and high cell passages, compared 
to donor matched HFK cells; however, this was not reproducible in subsequent 
experiments. These data indicate that the presence of the HPV18 genome does not affect 





Figure 3.10: PKA-RI and -RII expression under both unstimulated and 
forskolin-stimulated conditions in cells grown to low or high cell passage. Lysates 
derived from foreskin donor one were examined for expression of PKA-RI and PKA-
RII subunits under both unstimulated and forskolin-stimulated (indicated by +) 




Next, to examine whether changes in localisation underpinned the observed changes in 
PKA sensor activity, the subcellular distribution of PKA-RI and -RII subunits was 
examined by immunofluorescence in HFK and HFK-18 cells. The data in Figure 3.11 
show that in HFK cells, localisation of PKA-RI is diffusely cytoplasmic with some areas of 
intense staining at the nuclear membrane (white arrowheads). In cells maintaining HPV18 
genomes, there are no major differences in subcellular localisation of PKA-RI; staining is 
still diffusely cytoplasmic with an area of intense staining surrounding the nucleus (white 
arrowheads). For PKA-RII, staining is also diffusely cytoplasmic in HFK cells; however, 
some cells show increased signal adjacent to the nucleus that may represent association 
with the Golgi apparatus (red arrowheads; Dohrman et al., 1996). In addition, several cells 
(indicated by white arrowheads) contain bright nuclear PKA-RI foci. In HFK-18 cells, 
there is no gross redistribution of PKA-RII; there are still bright PKA-RII nuclear foci and 
a bright signal adjacent to the nucleus, albeit this is less apparent in these cells. Although 
not quantified, the HFK-18 cells appear to contain more PKA-RII foci per nucleus. 
These data revealed no gross redistribution of PKA regulatory subunits in cells 
maintaining HPV18 genomes compared to control HFK cells. There may be an increased 
number of PKA-RII foci per nucleus in cells containing HPV18 genomes, although this 
requires further investigation. It would be also prudent to examine using antibodies against 
the E1 and E2 proteins whether these increased nuclear foci represent viral replication 








Figure 3.11: PKA-RI and -RII subcellular localisation in HFK and HFK-18 cells. 
HFK and HFK-18 cells were fixed as described in 4% paraformaldehyde and processed 
for indirect immunofluorescence using antibodies specific for PKA-RI or PKA-RII 




3.2.9 HPV18 E5 regulates PKA-RI activity 
To determine how HPV18 manipulates PKA activity, it was important to identify which of 
the HPV proteins were involved. Since other viruses have shown that manipulation of this 
pathway is often via the virus oncoproteins, the BRET assay was repeated in HPV negative 
C33A cervical cancer cells transfected with, either alone or in combination, E5, E6 or E7 
expression vectors.  
First, whether E6 or E7, alone or together, contributed to changes in PKA activity was 
examined. As illustrated in Figure 3.12 A, in the absence of cAMP stimulation, there were 
no significant changes in PKA or cAMP activity in cells expressing E6, E7 or E6E7, 
compared to empty vector control. Similarly, in Figure 3.12 B, in cells pre-treated with 
forskolin, there were no significant alterations in PKA or cAMP sensor activity in cells 
expressing E6, E7 or E6E7 compared to control cells.  
Next, whether E5 contributed to PKA and/or cAMP activity was tested using a 
GFP-tagged E5 protein kindly provided by Dr Andrew Macdonald, University of Leeds. In 
Figure 3.13 A, there were no significant alterations in PKA or cAMP sensor activity in 
vehicle-treated cells expressing GFP-E5 compared to control cells expressing a GFP 
plasmid. Interestingly, however, when cells were pre-treated with forskolin (Figure 3.13 
B), there was significant activation of the cAMP sensor (Control 0.12 ± 0.021 and E5 0.07 
± 0.01, p=0.01). In addition, the activity of PKA-RI was also significantly increased 
(Control 0.08 ± 0.01 and E5 0.05 ± 0.01, p=0.04) but without any concomitant change in 
PKA-RII sensor activity. These data suggest that E5 is able to selectively modulate 





Figure 3.12: HPV18 E6 and E7 do not regulate PKA activity. C33A cells were transfected with empty vector (control), E6, E7 
or E6E7 expression plasmids, as indicated, as well as BRET biosensors. The activity of these biosensors was determined 48 hours 
later by bioluminescent resonance energy transfer in the absence (unstimulated) or presence (stimulated) of the cAMP elevating 
agent forskolin. Data ±SEM taken from three independent experiments. Statistical significance was determined using the Student’s 






Figure 3.13: HPV18 E5 regulates cAMP concentration and PKA-RI activity. C33A cells were transfected with GFP or  
GFP-E5 expression vectors, as indicated, as well as BRET biosensors. The activity of these biosensors was determined 48 hours 
later by bioluminescent resonance energy transfer in the absence (unstimulated) or presence (stimulated) of the cAMP elevating 
agent forskolin. Data ±SEM taken from three independent experiments. Statistical significance was determined by Student’s t-test 
comparing E5-expressing cells to control cells where ns indicates a non-significant result at the cut off of p=0.05, * denotes p<0.05 




3.2.10 HPV18 E5 regulates PKA-RI-induced cAMP response element-luciferase 
activity  
It was next of interest to determine whether the E5 associated increases in cAMP and 
PKA-RI sensor activity seen in the BRET assay were functionally relevant. For this, the 
activity of a CRE-luciferase reporter was measured in C33A cells expressing GFP or 
GFP-E5 alongside the different PKA subunits (RI, RII, Cα) under both vehicle and 
forskolin-treated conditions. This reporter contains the firefly luciferase gene under the 
control of a multimerised CRE located upstream of a minimal promoter. Elevation of 
intracellular cAMP results in CREB binding CRE, leading to luciferase expression 
(Lazzeroni et al., 2013).  
First, the induction of the CRE-reporter was examined in C33A cells treated either with 
vehicle or forskolin to ensure that the sensor responds to changes in cAMP. These data 
(Figure 3.14) show that addition of forskolin was associated with an approximate 140-fold 
increase in CRE-luciferase sensor activity relative to unstimulated cells, indicating that the 
sensor responds to forskolin-stimulated induction of cAMP. The large error bars under 
stimulated conditions likely represent the wide variation in CRE-luciferase activity 






Figure 3.14: Stimulation of CRE-luciferase activity in forskolin-stimulated C33A 
cells. C33A cells were transfected with a CRE-luciferase expression plasmid and, after 48 
hours, were treated with vehicle (unstimulated) or forskolin (stimulated) and assayed for 
CRE-luciferase activity by luciferase assay. Data normalised to corresponding 




In Figure 3.15 A, in vehicle-treated cultures, transfection of the RI regulatory unit did not 
strongly induce luciferase expression (~19-fold over untransfected (UT) cells), but 
co-transfection of the complete PKA-RI holoenzyme (PKA-RI and Cα) resulted in an 
approximate 800-fold increase in luciferase expression compared to UT cells. Transfection 
of the catalytic subunit alone (Cα) resulted in an ~250-fold increase in luciferase 
expression. Transfection of the RII regulatory unit alone or the complete PKA-RII 
holoenzyme (PKA-RII and Cα) did not strongly induce luciferase expression (all <30-fold 
compared to UT cells). Similarly, expression of E5 alone did not result in significant 
activation of the CRE-luciferase sensor (~10-fold compared to UT). Interestingly, 
co-expression of E5 with either the complete PKA-RI holoenzyme or Cα alone resulted in 
a significant decrease of luciferase expression to 150-fold and 52-fold over UT, 
respectively, which equates to about an 80% repression (PKA-RI and Cα 791-fold over 
UT, E5, PKA-RI, Cα 150-fold over UT; Cα 251-fold over UT and E5, Cα 52-fold over 
UT). There was no effect on the activity of the CRE reporter in the presence of the other 
PKA subunits, suggesting a specific impact of E5 on the PKA-RI holoenzyme. 
Similar results were obtained in cells pre-treated with forskolin, albeit the magnitude of 
luciferase expression was much greater in these cells, as expected (Figure 3.15 B). In these 
experiments, co-transfection of the complete PKA-RI holoenzyme resulted in an 
approximate 4600-fold induction of luciferase expression over UT cells, which was 
heavily repressed to ~1300-fold over UT in cells expressing E5 (~70% repression). In 
addition, expression of Cα alone resulted in ~1700-fold induction of luciferase expression, 
which decreased to ~250-fold when expressed with E5 (~85% repression). All other 




Together, these data show that E5 negatively regulates the ability of PKA-RI and Cα to 





Figure 3.15: HPV18 E5 regulates PKA-RI and Cα dependent CRE-luciferase transcription. C33A cells transfected with the 
indicated expression vectors alongside CRE-luciferase DNA were assayed for luminescence 48 hours post-transfection in the absence 
(panel A: unstimulated) or presence (panel B: stimulated) of the cAMP elevating agent forskolin. Data ±SEM taken from three 
independent experiments. UT: untransfected. RI: PKA-RI. RII: PKA-RII. Cα: PKA-Cα. CRE-Luc: CRE-luciferase. Statistical 
significance was determined using the Student’s t-test between the indicated conditions where * denotes p<0.05, ** denotes p<0.01 and 





The ability of HPV to modulate host signalling pathways during infection is critical for the 
viral life cycle as it provides an environment conducive to viral DNA replication. The host 
pathway mediated by the cAMP-dependent PKA is an important regulator of multiple 
aspects of the virus life cycle, including regulation of oncoprotein function (see section 
1.3.11). For example, PKA phosphorylation of the E6 PBM negatively regulates its 
interactions with cellular PDZ domain-containing proteins, whilst allowing for interactions 
with proteins that only recognise the phosphorylated form of the E6 PDZ, such as 14-3-3 
family members. In addition, changes in PKA signalling may also be important for the 
oncogenic progression of HPV infections; loss of PKA recognition of E6 in an HPV18 life 
cycle model is associated with increased growth of HPV genome containing cells and a 
more hyperproliferative phenotype on raft culture. In addition, loss of kinase recognition is 
associated with enhanced morphological transformation of keratinocytes.  
Details of whether the virus can manipulate the activity of this pathway directly during its 
infectious cycle, which may be of relevance for viral replication, are lacking. In this 
chapter, cAMP and PKA signalling dynamics were investigated in HPV18 life cycle 
models established in immortalised (NIKS) and primary epidermal keratinocytes 
harbouring complete HPV genomes. 
Using genetically encoded cAMP and PKA biosensors in immortalised and primary cells 
harbouring HPV18 genomes, the presence of the viral genome as an episome 
(unintegrated) was consistently associated with increased levels of cAMP, as measured by 
increased activity of the EPAC biosensor, as well as increases in PKA-RII activity. 




different primary keratinocyte donors, suggesting a physiologically relevant effect. 
Changes were also observed for PKA-RI but these were far less marked and not always 
consistent between the models or between foreskin donors. In accordance with the BRET 
results, we also detected an increased number of phosphorylated PKA substrates in HFK 
cells maintaining HPV18 genomes in two donor backgrounds, suggesting that the BRET 
assay results are indicative of in vivo phosphorylation events. This is the first 
demonstration to our knowledge of changes in PKA signalling activity in a physiological 
model of the HPV18 infectious cycle.  
Furthermore, in the HPV18 model based in primary keratinocytes, grown to a higher cell 
passage, viral episomes were severely reduced and most likely the viral DNA had 
integrated. Experience from the Roberts laboratory and others have shown that upon 
extended cell culture wild type HPV18 genomes can eventually integrate, mimicking a 
viral mechanism in oncogenic progression. Integration leads to increased levels of E6 and 
E7 and often the loss of expression of other viral factors, such as E2. In these cells, BRET 
assays showed retention of increased cAMP signalling and PKA-RII activity, although the 
magnitude of these changes was not as great as the low passage cells.  
Microarray profiling in cells overexpressing PKA-RI or -RII subunits showed that these 
regulatory units dictated the balance between cellular proliferation and differentiation, with 
PKA-RI overexpression upregulating the expression of genes associated with cell growth 
and -RII with differentiation (Cheadle et al., 2008). It would, therefore, be interesting to 
examine PKA and cAMP signalling dynamics upon activation of the productive cycle of 
the virus by keratinocyte differentiation. 
The functional consequence of this increased PKA activity is not yet clear so future 




PKA substrates in HFK versus HFK-18 cells. For example, using antibodies directed 
against phosphorylated PKA substrates to co-immunoprecipitate PKA phosphoproteins 
from cell lysates, mass spectrometry approaches such as liquid chromatography-tandem 
mass spectrometry combined with titanium dioxide enrichment of phosphoproteins will 
likely provide a starting point to unravel the HPV phosphoproteome (Hamaguchi et al., 
2015; Imamura et al., 2017). As HPV is known to induce the phosphorylation of various 
cellular proteins, such as those involved in DNA damage response signalling and cell 
communication networks (e.g. STATs), during its life cycle, these experiments will be 
important for the further identification of host proteins required for the HPV infectious 
cycle.  
Unpublished data from the Roberts’ laboratory has shown that there is selective 
downregulation of PKA-RI, but not PKA-RII, subunits in HeLa cervical cancer cells, 
(McCormack, Roberts, unpublished data). Changes in PKA-RI subunit expression are seen 
in individuals with the neuroendocrine tumour condition, the Carney Complex, which 
features inactivating mutations in PKA-RI, leading to dysregulated PKA signalling and 
tumour development. In addition, RI null mouse embryonic fibroblasts show constitutive 
PKA activity and become immortalised in a manner that appears to be dependent on 
upregulation of D-type cyclins (Kirschner et al., 2000; Nadella and Kirschner, 2005). Thus, 
changes in PKA-RI expression may be relevant for the progression of HPV infections or 
maintenance of the transformed phenotype. Consistent with the constitutive upregulation 
of PKA activity in cells lacking PKA-RI, BRET data in HeLa cells showed a dramatic 
increase in PKA and cAMP sensor activity compared to both primary HFKs and those 




the virus differentially interacts with the PKA pathway at certain stages of the virus life 
cycle. 
To understand whether HPV oncoproteins were contributing to the changes in PKA and 
cAMP activity, the BRET assay was repeated in cells expressing the viral oncoproteins E5, 
E6 or E7, either alone or in combination. Although overexpression of one or two viral 
oncoproteins is unlikely to faithfully recapitulate the situation in cells containing the 
complete viral genome, it was interesting to note that E5 expression increased the activity 
of both cAMP and PKA-RI biosensors, without any noticeable change in PKA-RII 
activity. There were no noticeable changes in cells expressing E6 or E7, either alone or in 
combination. While the effect of transfecting all of the viral oncoproteins, alone or in 
combination, into cells was not examined due to time constraints, it may be that the full 
repertoire of viral oncoproteins (or at least alternative combinations than those examined 
here) is required to phenocopy the results observed in cells maintaining the whole viral 
genome. The fact we did not observe the same PKA activation pattern during these 
overexpression experiments may suggest that this is the case.  
An alternative explanation is that these overexpression experiments do not recapitulate the 
proper timing of oncoprotein expression during in vivo viral replication or the functional 
interactions that occur between viral proteins. For example, there is evidence that E5 
interacts with E6 and E7 functions by enhancing cell proliferation and immortalisation of 
keratinocytes, raising the possibility that functional interactions between the viral 
oncoproteins are relevant for how the virus interacts with host cells (reviewed in Müller et 
al., 2015). Furthermore, these experiments were done in HPV negative cancer cells that 
were already transformed and may therefore not respond to changes in PKA signalling in 




primary human keratinocytes, therefore, would likely determine the identity of the viral 
protein responsible for the alterations in PKA signalling seen in this chapter.  
Although the results presented here are in contrast to previously published reports of 
higher basal cAMP levels in cells expressing HPV16 E5 (Oh et al., 2009), the BRET 
results following forskolin stimulation are consistent with the ability of E5 to increase 
cAMP levels compared to control cells. At present, there is no literature comparing cAMP 
production in cells expressing HPV16 and HPV18 E5, so we cannot exclude that these 
results represent an important difference in HPV biology or may have arisen due to 
differences in experimental methods. Nevertheless, the finding that E5 leads to increased 
cAMP concentrations and PKA-RI activity in forskolin-stimulated cells indicates that the 
virus is able to modulate cAMP signalling with a bearing on PKA activation in C33A cells.  
PKA is the main downstream mediator of cAMP gene regulation responses in mammalian 
cells. In this process, the binding of cAMP to PKA results in kinase activation, with 
subsequent liberation of PKA catalytic subunits. These subunits then translocate to the 
nucleus and phosphorylate target proteins such as the transcription factor CREB at 
serine-133. Phospho-CREB recruits the transcriptional coactivator CREB-binding 
protein/p300 to cyclic response elements on target genes, which modify gene expression 
by regulating chromatin and interacting with various proteins of the general transcriptional 
machinery (Chrivia et al., 1993; Della Fazia et al., 1997; Gonzalez and Montminy, 1989).  
To understand whether E5 can regulate this process by modulating cAMP and PKA-RI 
activity, the activity of a CRE-luciferase reporter was assessed in cells expressing E5 
together with the various PKA subunits. These experiments showed that in both vehicle 
and forskolin-treated C33A cells, the complete PKA-RI holoenzyme, and to a lesser extent 




Furthermore, this luciferase signal was heavily repressed in cells expressing HPV18 E5, 
suggesting that E5 negatively regulates PKA-RI-dependent activation of CRE-luciferase 
transcription. The fact that this result occurred under both vehicle and forskolin treatment 
conditions was unexpected given that no significant changes in cAMP or PKA-RI activity 
were seen in vehicle-treated E5-expressing cells in the BRET assay, although this may 
reflect differences in sensitivity between the two assays. 
Intriguingly, these data do not agree with a previous report that suggested E5 drives 
CRE-luciferase expression in C33A cells in a PKA and CREB dependent manner, although 
that study used a variant CRE sequence (CGTCA) derived from the EP4 promoter (Oh et 
al., 2009). In fact, using a CRE-luciferase construct that contains the canonical CRE 
sequence (TGACGTCA), the data described in this thesis showed that E5 clearly has the 
opposite effect and can suppress PKA-dependent CRE-luciferase transcription. How this 
occurs is unclear. One would imagine that if E5 increases cAMP and in doing so activates 
PKA then the downstream effect would be further activation of CRE-luciferase expression 
in E5-expressing cells compared to control, rather than a significant repression of 
luminescent signal.  
The data in this chapter add to the growing knowledge of HPV18 E5 biology. As described 
in section 1.2.4, data from an HPV18 life cycle model established in primary HFKs 
showed that loss of E5 had no detectable effect in basal keratinocytes; however, there was 
a significant impact in suprabasal cells. In these cells, E5 contributed to cell cycle 
progression and unscheduled host DNA synthesis in suprabasal cells, correlating with 
activation of EGFR in these cells. There was no impact of loss of E5 on viral genome 
amplification nor late protein expression with keratinocyte differentiation. The same study 




modulation of KGFR signalling. Accordingly, blockade of KGFR rescued the 
differentiation phenotype associated with loss of E5 expression (Wasson et al., 2017).  
To establish the functional consequence of E5-mediated regulation of PKA-RI activity, 
future experiments using cAMP antagonists to selectively inhibit PKA-RI signalling (e.g. 
Rp-8-Br-cAMPS) in HFKs containing wild type and E5 knockout viral genomes would 
provide insight into the importance of this novel E5-host interaction. These experiments 
could include analysis of the impact of PKA-RI signalling on known E5 cellular functions 
(such as examination of suprabasal cell cycle re-entry and host DNA synthesis) as well as 
gene expression profiling to identify genes downstream of E5 and PKA-RI that may act as 
novel regulators of the HPV18 life cycle. 
Overall, the data presented in this chapter showed that HPV18 replication in model 
systems established in primary and immortalised keratinocytes demonstrated marked 
changes in PKA-RII and cAMP signalling, which was associated with increased 
phosphorylation of PKA substrates. These changes were not due to overt changes in 
changes in expression or localisation of the PKA regulatory subunits. Furthermore, 
overexpression experiments in HPV negative cervical cancer cells (C33A cells) showed 
that HPV18 E5 induced PKA-RI and cAMP sensor activity. Initial functional analysis of 
this interaction using a CRE-luciferase reporter showed that E5 negatively regulated the 
ability of the complete PKA-RI holoenzyme to activate CRE-luciferase transcription. 
Future experiments using specific PKA-RI inhibitors in HFK cells maintaining wild type 
and E5 knockout genomes will likely provide information as to the functional consequence 





CHAPTER 4 INTERACTION OF HPV18 E6 AND 
A-KINASE ANCHORING PROTEIN 95  
4.1 Introduction 
The data presented in the previous chapter demonstrated that PKA activity was modulated 
in human keratinocytes that both maintain HPV18 genomes and support the productive 
virus life cycle upon differentiation. In addition, PKA activity is also altered in HPV18 
positive HeLa cervical cancer cells, which harbour integrated forms of the viral genome. 
Notably, the changes in PKA activity occurred concomitantly with changes in cellular 
cAMP concentration.  
The downstream effects of cAMP signalling are finely tuned by the actions of AKAPs, 
cellular proteins that assemble PKA and other effector proteins to discrete cellular 
microdomains, forming multiprotein scaffolds that action cAMP signalling. The first 
indication that cAMP signalling undergoes such organisation came from Hayes and 
colleagues who showed that a number of GPCR activators elevated cAMP to similar levels 
but produced distinct cellular responses (Hayes et al., 1980). This was underscored by 
work where FRET-based sensors targeted to different subcellular locales displayed 
different responses to cAMP elevating agents, suggesting that cAMP responses were 
spatiotemporally regulated in cells (Di Benedetto et al., 2008; Zaccolo et al., 2000). In 
these cellular compartments, cAMP is actioned upon by either PKA-RI or -RII 
holoenzymes where each PKA isoform phosphorylates a discrete set of substrates (Wong 




preferentially bind to RII subunits, there is a growing list of AKAPs that bind to RI, and 
some that are dual specific (reviewed in Torres-Quesada et al., 2017). 
In addition to PKA, the macromolecular scaffold structures organised by AKAPs contain a 
variety of other proteins, including other protein kinases, PDEs that degrade the cAMP 
signal, and protein phosphatases that remove phosphate groups from phospho-substrates. 
Taken together, the AKAP based scaffolds direct PKA to its substrates and convey tight 
spatiotemporal control to cAMP signalling (Langeberg and Scott, 2015). 
In order to successfully propagate in squamous epithelium, HPV interacts with and 
modulates many signalling pathways to create an environment conducive for viral 
replication. Modulation of the signal transduction pathway is often through an association 
between an HPV protein and a factor in the pathway and can involve either inhibition of a 
pathway (e.g. STAT-1; Hong et al., 2011), or activation (e.g. ATM; Moody and Laimins, 
2009). Therefore, one approach taken to investigate further the interaction between HPV 
and PKA signalling was to determine whether the virus interacted with any of the 
components of the signal transduction pathway. This investigation identified a novel 
interaction between HPV18 E6 and the nuclear PKA-anchoring protein AKAP95. 
4.2 Results 
4.2.1 AKAP95 may be a conserved E6 target 
Given that HPV18 modulates PKA activity and this is concomitant with changes in cAMP 
levels, we were interested to see if the virus interacted with other components of the PKA 
pathway. To examine this possibility, published mass spectroscopy databases of HPV 
protein-interacting partners were scrutinised for PKA pathway components. These 




al., 2012; Rozenblatt-Rosen et al., 2012; White et al., 2012a) and E7 proteins (White et al., 
2012b), as well as the online VirHostNet and virusMINT databases (Cesareni et al., 2002; 
Navratil et al., 2009). 
While the regulatory or catalytic subunits of PKA were not represented in this mass 
spectroscopy analysis, a potential interaction between E6 and the nuclear PKA-anchoring 
protein AKAP95 was found for alpha-HPV types 18, 45 and 52 – all defined as group 1 
carcinogens by IARC (Table 4.1). Interestingly, these data did not suggest a potential 
interaction of E6 and AKAP95 between other high-risk alpha-types tested (HPV16 and 
HPV33), even when complexes were analysed in the presence of the proteasome inhibitor 
MG132. A separate mass spectroscopic screen suggested that HPV16 E7 may bind to 
AKAP95, which may indicate that there are type-specific differences in AKAP95 binding 
(Table 4.1). AKAP95 was not found in complexes containing the low-risk alpha type 
HPV6. However, several E6 proteins from beta-HPV types were included in the mass 
spectroscopic analysis and the E6 proteins of HPV17a and HPV38, both types linked to 
causing non-melanoma cutaneous malignancies, were complexed with AKAP95. Together, 
the mass spectroscopic analyses suggest that E6 from diverse HPV types may bind to 
AKAP95, including HPV18. 
4.2.2 Optimisation of GST-AKAP95 purification 
To investigate whether AKAP95 was a novel interacting partner of HPV18 E6, it was first 
expressed recombinantly as a GST fusion protein. Full-length human AKAP95 cloned into 
pGEX-KG was a kind gift of Professor Kjetil Tasken, University of Oslo, and transformed 
into BL21 competent E. coli cells. A small-scale (~10 ml) pilot experiment was first 
carried out to test induction of GST-AKAP95 upon addition of IPTG. After induction at 




GST-AKAP95 (131 kDa) can be seen on a Coomassie-stained gel, indicating successful 




Table 4.1: AKAP95 may be a common binding partner of E6 proteins from diverse HPV types. Scrutiny of published E6-mass 
spectroscopic databases identifies AKAP95 as a potential binding partner. AKAP95 binders are shown. Non-AKAP95 binders include E6 




Genus Species HPV 
type(s) 
Detected in vehicle 




Reference Clinical manifestations 
E6 
Alpha  7 18 
45 
Y Y White et al., 
2012 
High risk—malignant mucosal 
lesions 
Alpha 9 52 Y Y White et al., 
2012 
High risk—malignant mucosal 
lesions 
Beta  2 17a 
38 
Y Y White et al., 
2012 
Most frequently causing 
cutaneous lesions. Associated 
with EV. 
E7 
Alpha 9 17 NA NA Gulbache et 
al., 2012 



















Figure 4.1: Induction of GST-AKAP95 by IPTG. Coomassie-stained SDS-PAGE gel of 
equal densities of E.coli transformed with a GST-AKAP95 plasmid before IPTG induction 
(-IPTG) and after IPTG induction for 3 hours (+IPTG). The position of GST-AKAP95 is 






Having shown that GST-AKAP95 is expressed in E. coli, it was then necessary to define 
the purification conditions. Using a larger ~50 ml culture of E. coli, cells were lysed in 
PBS containing 2% Triton-X100 and insoluble material removed by high-speed 
centrifugation. Insoluble material was then solubilised directly in an equal volume of 
Laemmli buffer containing β-mercaptoethanol. The soluble fraction was incubated 
overnight with glutathione beads, washed, and then the fusion protein was eluted from the 
beads by sequential incubations in reduced glutathione. Equal volumes of all samples were 
examined for the presence of GST-AKAP95 by Coomassie staining. As shown in 
Figure 4.2 A, the addition of IPTG results in the production of a ~131 kDa band 
corresponding to the expected molecular weight of GST-AKAP95 and this is absent in the 
uninduced lane. After separation of soluble and insoluble fractions, GST-AKAP95 
appeared in both fractions. Equal amounts of the reduced glutathione eluate were analysed 
for GST-AKAP95; however, no appreciable GST-AKAP95 could be seen on the 
Coomassie-stained gel.  
Given the robust induction of GST-AKAP95 by IPTG, purification was then tested in a 
much larger one-litre culture of E. coli (Figure 4.2 B). Again, GST-AKAP95 was found in 
both soluble and insoluble fractions after lysis in PBS buffer containing 2% Triton-X100. 
This attempt resulted in appreciable levels of GST-AKAP95 on the Coomassie-stained gel, 
indicating that a larger bacterial culture was sufficient to purify recombinant AKAP95. 
Various other attempts were made to improve the yield of purified GST-AKAP95, such as 
varying incubation temperature and IPTG concentration; however, there were no marked 
increases in GST-AKAP95 yield. Different E. coli strains were also tested as AKAP95 
contains codons not commonly used in E. coli (Rosano and Ceccarelli, 2009), however, 




For this reason, subsequent purifications were done using at least one-litre cultures of 
E. coli. Sonication times were also varied to improve the release of GST-AKAP95 from 
insoluble inclusion bodies but this often resulted in a lack of binding of GST-AKAP95 to 





Figure 4.2: Optimisation of GST-AKAP95 purification from E. coli. Coomassie 
stained gel of lysates of BL21 E. coli expressing GST-AKAP95 induced with IPTG for 
three hours at 37 C and glutathione-purified eluates. Panel A represents 50 ml culture and 
B represents 1 L culture. GST-AKAP95 is marked by arrows. U: uninduced, I: induced; S: 




4.2.3 Optimisation of GST-HPV18 E6 purification 
In order to perform GST-E6 pull-down assays, HPV18 E6 was expressed recombinantly as 
a GST fusion protein (GST-HPV18 E6). The complete coding sequence of HPV18 E6 was 
PCR amplified from the plasmid pGEM2-HPV18, which contains the whole HPV18 
genome, and ligated into an appropriately prepared pGEX-2T vector to form 
pGST-HPV18 E6. BL21 E. coli cells were transformed with this plasmid and used to 
express the fusion protein. 
When overexpressed in E. coli, recombinant E6 can be found in bacterial inclusion bodies, 
even when fused to GST or MBP tags, which often provide solubility to the fusion protein 
(Nominé et al., 2001, 2006; Verma et al., 2013). Indeed, GST-HPV18 E6 is insoluble in 
1-2% Triton-X100, concentrations commonly used in GST protein purification (Figure 
4.3). Initial attempts to solubilise GST-HPV18 E6 in 2% Triton-X100 involved lowering 
IPTG concentration and induction temperatures, heat shock prior to induction (Thomas and 
Baneyx, 1996), as well as the addition of ethanol to the broth, both of which mimic the 
heat shock response (Chhetri et al., 2015). However, these methods failed to significantly 
enhance the purification of soluble GST-HPV18 E6. 
Recombinant HPV18 E6 in E. coli associates with bacterial membranes and/or inclusion 
bodies, which makes purification using traditional methods technically challenging 
(Miranda Thomas, personal communication). As an alternative method to improve protein 
extraction, cells were subjected to a sonication trial. Cells expressing GST-HPV18 E6 
were lysed in 2% Triton-X100, sonicated at a fixed amplitude for various periods of time 
and then soluble extracts examined for GST-HPV18 E6. As shown in Figure 4.4 A, 
several short rounds of sonication were required to extract GST-HPV18 E6 (~46 kDa) 




fusion protein to bind to the glutathione beads (data not shown). Therefore, several short 








Figure 4.3: GST-HPV18 E6 is insoluble in PBS containing 2% Triton-X100. BL21 E. 
coli expressing GST-HPV18 E6 were grown in liquid culture before induction with IPTG 
for three hours at 37̊C. Cells were harvested in PBS and Triton-X100 added to the 
indicated concentrations. After removal of insoluble material by centrifugation, equal 
volumes of soluble extracts were electrophoresed, and total protein stained by Coomassie. 
The position of GST-HPV18 E6 is shown by an arrowhead. Note this gel is a cropped 




The ability of the detergent n-lauryl sarcosine (otherwise known as sarkosyl) to solubilise 
GST-HPV18 E6 was also investigated. Sarkosyl has been used to solubilise cysteine-rich 
ZF domain-containing proteins, such as E6, and is known to disrupt aggregates that are 
insoluble in NP-40 and Triton-X100 based buffers (Park et al., 2011; Tao et al., 2010). 
GST-HPV18 E6 was expressed in E. coli and lysed in PBS, before the addition of sarkosyl 
or Triton-X100 as indicated in Figure 4.4 B. The addition of up to 2% sarkosyl resulted in 
a greater amount of total solubilised protein, including GST-HPV18 E6, compared to 
Triton-X100, suggesting that this detergent could be used in purification. However, 
large-scale purification from a one-litre culture using sarkosyl was technically challenging 
due to the high viscosity of the lysate, likely due to the efficient release of E. coli DNA. As 
substantial amounts of DNase and lengthy sonication times were required to reduce this 
viscosity to workable levels, it was preferable to extract GST-HPV18 E6 by sonication in a 
2% Triton-X100 based buffer as this provided sufficient recombinant protein for GST pull-
down assays. Taken together, these experiments have refined the purification protocol for 





Figure 4.4: Optimisation of sonication and detergent extraction of GST-HPV18 E6. 
BL21 E. coli expressing GST-HPV18 E6 were grown in liquid culture before induction 
with IPTG for three hours at 37̊C. Panel A: Cells were harvested in PBS buffer containing 
2% Triton-X100, before sonication as indicated. Soluble extracts were examined for 
GST-HPV18 E6. B: Cells were harvested in PBS and the indicated detergent was added to 
the final concentrations shown. After removal of insoluble material, equal volumes of 
soluble extracts were electrophoresed and total protein stained by Coomassie. The position 




4.2.4 Expression of GST-AKAP95 and GST-HPV18 E6 
To verify the binding of HPV18 E6 to AKAP95, both proteins were expressed as GST-
fusion proteins and purified on glutathione Sepharose beads using the optimised 
protocols outlined in sections 4.2.2 and 4.2.3. Both GST-AKAP95 and GST-HPV18 E6 
migrated at their expected molecular weight by SDS-PAGE: GST-AKAP95 131 kDa and 
GST-HPV18 E6 46 kDa and were recognised by antibodies specific to the individual 
proteins (Figure 4.5).  
Although it is generally thought that soluble recombinant proteins are functional as 
misfolded proteins tend to precipitate, numerous reports have suggested that soluble fusion 
proteins may, in fact, show very little biological activity compared to native protein 
(reviewed in Nominé et al., 2001). To verify that the recombinant AKAP95 and E6 
proteins were folded correctly, they were examined for binding to known interacting 
partners from cell lysates. GST-AKAP95 and GST-HPV18 E6 were incubated separately 
with cell lysate derived from C33A cells. GST-AKAP95 was examined for its ability to 
bind to cyclin D1 and p53 was used as a known GST-HPV18 E6 target, alongside GST as 
a negative control (Lechner and Laimins, 1994; Arsenijevic et al., 2004). Western blotting 
of the washed precipitate showed that the recombinant proteins were able to bind their 
known endogenous targets (Figure 4.6). Together, these data suggest that both 
GST-AKAP95 and GST-HPV18 E6 were likely to be folded correctly and able to interact 







Figure 4.5: Recombinant GST-AKAP95 and GST-HPV18 E6 proteins are recognised 
by specific antibodies. The indicated GST or GST-fusion proteins were electrophoresed 
and immunoblotted with antibodies specific to AKAP95 (panel A; polyclonal) and HPV18 



















Figure 4.6: Recombinant GST-AKAP95 and GST-HPV18E6 proteins bind to endogenous targets from cell lysate. 
Purified GST or the indicated GST-fusion protein was incubated with lysate derived from C33A cells. Panel A represents an 
immunoblot using an anti-cyclin D antibody. Panel B represents an immunoblot for p53. The lower portion of each panel 





4.2.5 AKAP95 and HPV18 E6 interact in vitro 
Having shown that the GST-fusion proteins bound known protein targets, they were then 
assayed for their ability to bind to endogenous E6 or AKAP95 protein from cell lysates in 
a GST pull-down assay. Crude nuclear fractions were prepared from HeLa and C33A 
cervical cancer cell lines. Purified GST-AKAP95 bound to glutathione Sepharose beads, 
was incubated with nuclear lysate from HeLa cervical cancer cells, which expresses E6 
from integrated HPV18 DNA, alongside GST as a negative control. Similarly, purified 
GST-HPV18 E6 was incubated with nuclear lysate from C33A (HPV negative) cells as a 
source of endogenous AKAP95 protein. (Nuclear extract was used to enrich for 
endogenous AKAP95 as it is thought to be expressed at a relatively low level.). After 
thorough washing of the beads, interacting proteins were detected by Western blotting and 
the results are shown in Figure 4.7. GST-AKAP95 pulled down HPV18 E6 from HeLa 
cell lysate (Figure 4.7 A) and GST-HPV18 E6 precipitated endogenous AKAP95 from 
C33A lysate (Figure 4.7 B). In both cases, the interactions were specific as GST 
pulldowns were negative or contained a very low level of the proteins.  
Next, whether GST-AKAP95 can precipitate E6 from primary HFKs maintaining episomes 
of HPV18 genomes was examined. In Figure 4.8, a lysate was prepared from HFKs 
harbouring HPV18 episomes and this was incubated with purified GST or GST-AKAP95 
proteins. While a small amount of E6 was isolated by the control GST protein, there was a 
significant enrichment of E6 complexed with GST-AKAP95, suggesting that in a 
physiologically relevant primary keratinocyte model of HPV18 infected cells 
GST-AKAP95 interacts with HPV18 E6 expressed from intact HPV18 genomes. Taken 









Figure 4.7: HPV18 E6 and AKAP95 interact in vitro by GST pull down assay. A: Purified GST-AKAP95 was incubated with HeLa nuclear 
lysate and Western blotted for HPV18 E6. Top panel represents Western blot for AKAP95 and bottom panel the corresponding Ponceau S 
stained membrane to demonstrate loading of GST proteins. B: Purified GST-HPV18 E6 was incubated with C33A nuclear cell lysate and 
Western blotted for AKAP95. Top panel represents Western blot for AKAP95 and bottom the corresponding Coomassie gel to demonstrate 

















Figure 4.8: GST-AKAP95 interacts with endogenous E6 from primary human foreskin 
keratinocytes maintaining HPV18 genomes. Purified GST or GST-AKAP95 fusion proteins 
were incubated in lysate derived from primary human foreskin keratinocytes maintaining 
HPV18 genomes. Co-purifying proteins were detected by immunoblotting using an antibody 
specific for HPV18 E6. The lower Coomassie stained gel demonstrates loading of 







4.2.6 AKAP95 binds to HPV18 E6 and not HPV16 or HPV11 E6. 
While the E6-interaction mass spectroscopy data indicated that several high-risk alpha- and 
beta-HPV types could bind to AKAP95, neither HPV16 E6 nor the low-risk HPV6 E6 
appeared in this analysis, even under conditions that inhibited the proteasome. These data 
could indicate that E6 binding to AKAP95 is type-specific. To determine whether HPV16 
E6 could bind to AKAP95, GST-E6 fusion proteins were prepared from HPV16 (Figure 
4.9 A), as well as a low-risk type HPV11 (Figure 4.9 B) and examined alongside HPV18 
for their ability to bind to endogenous AKAP95 from C33A cell lysate.  
The data shown in Figure 4.9A demonstrates that AKAP95 binding is restricted to HPV18 
E6, as there is no appreciable binding of AKAP95 to GST-HPV16 E6 under these 
conditions. To understand whether there are differences in AKAP95 binding between low 
and high-risk E6 proteins, this experiment was then repeated using GST-HPV11 E6. While 
purification of GST-HPV11 E6 from E. coli was much more technically challenging and 
resulted in a lower yield of purified protein, the interaction data presented in Figure 4.9B  
shows that there is no appreciable binding of AKAP95 to GST-HPV11 E6 fusion protein. 






Figure 4.9: GSTE6 fusion proteins of HPV16 and HPV11 do not interact with AKAP95. Purified GST or GST E6 proteins as 
indicated were incubated with C33A lysate overnight, and after thorough washing of the beads, co-purifying AKAP95 was examined by 
Western blotting using an AKAP95-specific antibody. Panel A represents incubation of GST, GST-HPV16E6 or -HPV18E6. Panel B 
represents incubation with GST or GST-HPV11E6. The lower Ponceau S stained membrane demonstrates loading of GST proteins 
(indicated by *). Input represents 2% of cell lysate used in pull down reactions. Arrows represent full length proteins. Note that all blots 









4.2.7 HPV18 E6 and AKAP95 interact in vivo 
Having shown that HPV18 E6 and AKAP95 interact in vitro by GST pull-down assays, it 
was important to show that this interaction occurs in intact cells by 
co-immunoprecipitation. This was done using antibodies specific to AKAP95 and HPV18 
E6 to co-immunoprecipitate endogenous proteins from cell lysates. Endogenous 
co-immunoprecipitations were used to avoid the potential pitfalls of protein 
overexpression, including mislocalisation of overexpressed protein in a different cellular 
compartment to endogenous protein and to avoid the potential interference of epitope tags. 
In the first instance, HeLa cells were used as GST-AKAP95 was able to bind to E6 
expressed from the integrated HPV18 genome. As shown in Figure 4.10, incubation of 
HeLa nuclear lysate with a monoclonal antibody directed against HPV18 E6 (left panel) 
co-immunoprecipitated endogenous AKAP95. The reverse co-immunoprecipitation was 
also possible; incubation of HeLa lysate with an AKAP95 specific polyclonal antibody 
co-immunoprecipitated endogenous E6 (right panel). Neither protein was 
co-immunoprecipitated by a species matched IgG control. Short exposure of the film is 
shown in Figure 4.10 A, while a longer exposure is shown in Figure 4.10 B. Interestingly, 
there are additional lower molecular weight bands detected by the HPV18 E6 antibody in 
both E6- and AKAP95-immunoprecipitates (indicated by arrowheads). Some of these may 
be breakdown products, but some might be spliced products of the E6 ORF (HPV18 E6*I, 
E6*II). Taken together, these data show that the E6-AKAP95 complex exists in vivo in 
HPV18-positive HeLa cervical cancer cells.  
It was then important to determine whether this interaction occurs in a physiologically 
relevant model of the HPV life cycle. For this, a lysate was prepared from HFK-18 cells 




shows that in this physiological model endogenous AKAP95 and E6 are present in a 








Figure 4.10: Reciprocal co-immunoprecipitation of HPV18 E6 and AKAP95 in HeLa cells HeLa nuclear lysate was 
immunoprecipitated with the indicated antibodies and the interacting proteins determined by immunoblotting. Panel A 
represents a short exposure while panel B is a long exposure. Smaller E6-specific products may represent a spliced product 






Figure 4.11: Interaction of HPV18 E6 and AKAP95 in primary HPV18 genome containing cells. Lysate derived from HFK-18 cells was 
immunoprecipitated using either specific anti-AKAP95 (A) or anti-HPV18E6 (B) antibodies, or control IgG. Co-immunoprecipitating proteins 
were resolved and detected by Western blotting using the indicated antibodies. Input is 5% of total lysate used for co-immunoprecipitation. 




4.2.8 Mapping the AKAP95 interacting domains of E6  
To map the HPV18 E6 residues involved in the interaction with AKAP95, a series of E6 
mutants were used. In the first instance, since the Roberts group studied E6–PDZ 
interactions (Watson et al., 2003; Delury et al., 2013; Marsh et al., 2017) and several E6 
mutants were available that contained mutation of the E6 PBM and the overlapping PKA 
recognition sequence, these were investigated for AKAP95 binding. A class I PBM exists 
at the extreme C-terminus of E6 (155ETQV158). The threonine residue at 156 is critical for 
binding PDZ substrates, including Dlg1. PKA phosphorylation of the threonine residue in 
the E6 PBM disrupts binding with PDZ targets but the phospho-sequence forms a platform 
for binding 14-3-3 proteins (Boon and Banks, 2012; Kühne et al., 2000). The replacement 
of the threonine with glutamic acid acts as a phospho-mimic (T156E; GluE6) and disrupts 
binding to Dlg1. Thus, this mutant is impaired for targeting of PDZ domain-containing 
proteins (Gardiol et al., 1999). Whether this GluE6 mutant is functional in binding to 
14-3-3 proteins is unknown. Mutation of a key arginine in the PKA recognition motif 
(Arg153-X-X-Thr156; R153L, LeuE6) abrogates phosphorylation of the E6 PBM (i.e. it is no 
longer a substrate for PKA) and therefore E6 binds to and degrades PDZ domain-
containing proteins in a PKA independent manner (Kühne et al., 2000).  








Figure 4.12: HPV18 E6 mutant proteins used in this study. The wild type HPV18 E6 
protein contains at its extreme carboxyl terminus a class I PDZ binding motif (PBM) 
through which it binds cellular PDZ domain-containing proteins. Phosphorylation of the 
overlapping PKA consensus recognition motif negatively regulates E6-PDZ interactions 
while allowing for phospho-E6-dependent interactions with 14-3-3 proteins. The LeuE6 
mutant contains a R153L substitution that destroys the PKA recognition motif, allowing 
for constitutive (PKA-independent) binding of E6 to cellular PDZ proteins. The GluE6 
mutant contains a T156E substitution that impairs E6 recognition of PDZ proteins and the 
ΔPDZ protein contains two translational termination codons at positions 155 and 156, 
removing the entire E6 PBM; these two mutant proteins cannot bind to cellular PDZ 




To determine whether the ability of E6 to recognise PDZ proteins or to be phosphorylated 
by PKA was important for the E6-AKAP95 interaction, these E6 mutants were expressed 
in 293T cells and examined for their ability to bind to GST-AKAP95 in GST pull-down 
experiments. 293T cells were chosen for these experiments as they are easily transfectable 
by inexpensive transfection reagents and have been used to profile HPVE6-PDZ 
interactions (Belotti et al., 2013). The data shown in Figure 4.13 highlights several 
important pieces of data. First, HPV18 E6 interacts with GST-AKAP95 in this cell 
background. Second, the substitution of the threonine residue for glutamic acid in the E6 
PBM, which abrogates E6-PDZ interactions, compromises AKAP95 binding. Finally, the 
destruction of the PKA phosphorylation site does not affect E6-AKAP95 binding. These 
results suggest that the ability of E6 to bind to AKAP95 does not depend on the integrity of 
the PKA phosphorylation site that overlaps with the E6 PBM but rather the ability of E6 to 
target cellular PDZ domain-containing proteins. 
To confirm that the E6-AKAP95 interaction depended on the ability of E6 to target cellular 
PDZ proteins, a second mutant E6 mutant defective for PDZ targeting was tested. This 
mutant (ΔPDZE6) contains two translation termination codons at positions 155 and 156, 
deleting the four residues that make up the E6 PBM (Delury et al., 2013).  
Similar to the GluE6 mutant, the ΔPDZE6 mutant shown in Figure 4.14 does not bind to 
GST-AKAP95.  







Figure 4.13: The E6 PDZ binding motif mediates the E6-AKAP95 interaction. 
Purified GST or GST-AKAP95 were incubated with cellular lysate derived from 
293T cells expressing the indicated E6 mutants. Co-purifying proteins were 
separated by electrophoresis and residual E6 examined by Western blotting with a 
specific antibody. The top panel represents the HPV18 E6 immunoblot, while the 
lower panel demonstrates loading of the GST fusion proteins. Representative of 





Figure 4.14: Loss of E6-PDZ targeting compromises the E6-AKAP95 
interaction. Purified GST or GST-AKAP95 was incubated with cellular lysate 
derived from 293T cells expressing the indicated E6 mutants. Co-purifying proteins 
were separated by electrophoresis and GST-AKAP95 bound E6 examined by 
Western blotting with a specific antibody. The top panel represents the HPV18 E6 
immunoblot, while the lower panel demonstrates loading of the GST fusion 





4.2.9 AKAP95 binds to the cellular PDZ domain-containing protein hScrib 
The finding that the E6-AKAP95 interaction was dependent on the integrity of the E6 
PBM was surprising since the AKAP95 sequence does not contain any appreciable PDZ 
domain structure when analysed by the MoDPepInt Server, an online resource that 
analyses protein sequence for the presence of SH2, SH3 and PDZ domains (Kundu et al., 
2014). Given that E6 has been shown to bind to at least 20 cellular PDZ domain-containing 
proteins through this binding motif (reviewed in James and Roberts, 2016), it is possible 
that the E6-AKAP95 interaction is mediated by interaction(s) with cellular PDZ proteins. 
With this in mind, a published mass spectroscopy database of AKAP95-binding partners 
was scrutinised for PDZ domain-containing proteins that are known targets of the E6 PBM 
(López-Soop et al., 2017; Table 4.2). 
Analysis of the database highlighted potential interactors of AKAP95 with three PDZ 
domain-containing proteins: hScrib, ZO-1, and ZO-2. Of note, ZO-2 has been previously 
shown to interact with hScrib in polarised epithelial cells and ZO-1 is a known binding 
partner of ZO-2 (Bauer et al., 2010; Itoh et al., 1999; Métais et al., 2005). Given the 
considerable number of unique peptides (10) detected for hScrib in the AKAP95-mass 
spectroscopy data, it was important to first determine whether or not hScrib was a true 
binding partner of AKAP95. hScrib and two other PDZ proteins known to be E6 targets, 
Dlg1 and MAGI-1 but were not represented in the AKAP95-mass spectroscopy data, were 
expressed as HA- or Flag-tagged proteins in 293T cells and binding to GST-AKAP95 
determined by GST pull-downs. As shown in Figure 4.15, GST-AKAP95 interacted 
specifically with HA-hScrib and not HA-Dlg1 or FLAG-MAGI, suggesting that hScrib 
was a novel AKAP95 interacting partner. Therefore, these data suggest the interaction 










Protein Unique peptides Observable peptides 
Scribble (hScrib) 10 127 
Tight junction protein ZO-1 2 141 
Tight junction protein ZO-2 2 97 
Table 4.2: AKAP95-PDZ potential interactors. Scrutiny of published AKAP95 mass spectroscopic databases identifies a variety of cellular 




















Figure 4.15: hScrib is a novel AKAP95 binding partner. Purified GST or 
GST-AKAP95 was incubated with cellular lysate derived from 293T cells 
expressing the indicated expression vectors. Co-purifying proteins were separated 
by electrophoresis and detected by Western blotting using the indicated antibodies. 
The top panels represent the immunoblots, while the lower panel demonstrates 





4.2.10 The HPV18 E6 PBM is required for AKAP95 binding in vivo 
To further verify that there was an E6 complex containing AKAP95 in vivo and this was 
dependent on the integrity of the E6 PBM, E6 was immunoprecipitated from primary 
HFKs maintaining either the wild type HPV18 genome or a mutant genome carrying a 
deletion of the E6 PBM (ΔPDZE6; Delury et al., 2013) and immunoblotted for AKAP95 
and hScrib. As shown in Figure 4.16, only in wild type E6 containing HPV18 genomes 
was AKAP95 detected in the E6 immunoprecipitates and this was absent in 
immunoprecipitates isolated from the ∆PDZ cells, suggesting that the E6 PBM is crucial 
for the in vivo association of this protein complex. Supporting this is the finding that only 
wild type E6-immunoprecipitates also contain hScrib, consistent with our model that 
suggests E6 targeting of hScrib is required for assembly of the E6-AKAP95 protein 














Figure 4.16: The interaction of HPV18 E6, AKAP95 and hScrib depends on an 
intact E6 PBM in vivo. E6 was immunoprecipitated from primary human foreskin 
keratinocytes maintaining either wild type (WTE6) or ΔPDZ genomes and 
examined for binding to AKAP95 and hScrib by Western blotting. Representative 





4.2.11 Mapping the interacting domains of AKAP95 on E6 
Next, to map the interacting regions on AKAP95 responsible for binding to HPV18 E6, a 
GST pull-down based approach using various FLAG-HA-tagged AKAP95 mutants was 
used. The AKAP95 mutants were expressed in 293T cells and their ability to interact with 
GST-HPV18 E6 examined by GST pull-downs and Western blotting.  
In the first instance, two mutants were used to define whether the E6-interacting site was 
on the N-terminal (residues 1-340) or C-terminal (residues 341-692) domains of AKAP95. 
The results shown in Figure 4.17 indicate that both amino and carboxyl termini of 
AKAP95 bind to GST-HPV18 E6, suggesting that multiple regions of AKAP95 are 
required for interaction. Therefore, to better define the E6-interacting region(s), various 






Figure 4.17: Both amino and carboxyl termini of AKAP95 are required for E6 
interaction. Panel A: schematic of the AKAP95 mutants used in the GST pull down. 
Panel B: purified GST or GST-HPV18E6 was incubated with cellular lysate derived from 
293T cells expressing the indicated FH-AKAP95 mutants, alongside GST as a negative 
control. Co-purifying proteins were separated by electrophoresis and detected by Western 
blotting using the indicated antibody. The top panels represent the immunoblots, while the 
lower panel demonstrates loading of the GST and GST fusion proteins (also indicated by 




4.2.11.1 E6 binds to amino acids 1-100 in the amino terminus of AKAP95 
The GST pull-down experiments were repeated using expression vectors encoding 
fragments within amino acids (aa) 1-340. Fragments covering aa 1-210, 211-692 and 
101-692 were expressed in 293T cells and their binding to GST-HPV18 E6 examined in 
pull-down experiments. As shown in Figure 4.18, GST-HPV18 E6 binds strongly to aa 
1-210 while a lesser interaction is seen with a fragment covering amino acids 211-692. 
There is no appreciable interaction with 101-692. These data suggest that the amino acids 









Figure 4.18: The amino terminal 100 amino acids primarily bind to GST-E6. 
Panel A: schematic of the full length and AKAP95 mutants used in the GST pull 
down. Panel B : purified GST or GST-HPV18E6 were incubated with lysate 
derived from 293T cells expressing the indicated FH-AKAP95 fragments. Co-
purifying proteins were separated by electrophoresis and detected by Western 
blotting using an antibody against the HA tag. The top panel represents the 
immunoblots, while the lower panel demonstrates loading of the GST fusion 




4.2.11.2 The PKA binding site on AKAP95 is required for the E6-AKAP95 
interaction  
Embedded within the carboxyl terminus of AKAP95 is a binding site for PKA-RII and 
point mutation at this site at position 582 (I582P) disrupts the AKAP95-RII interaction 
(Carr et al., 1992). To understand whether AKAP95 binding to PKA is important in 
mediating the E6-AKAP95 interaction, GST-E6 pull-down experiments were carried out 
using both wild type and I582P expression vectors. The data presented in Figure 4.19 
shows that GST-HPV18 E6 binds to wild type AKAP95 but binding is abrogated in the 
presence of the I582P point mutation, suggesting that the ability of AKAP95 to bind to 







Figure 4.19: The PKA-binding ability of AKAP95 is important for its 
interaction with E6. Purified GST or GST-HPV18E6 were incubated with lysate 
derived from 293T cells expressing either the FH-wild type or FH-I582P AKAP95 
mutant. Co-purifying proteins were separated by electrophoresis and detected by 
Western blotting using an antibody against the HA tag. The top panel represents the 
immunoblots, while the lower panel demonstrates loading of the GST fusion 




4.2.11.3 AKAP95 zinc fingers are not important for its interaction with E6 
Also within the carboxyl terminus of AKAP95 are two ZFs that are important for its 
interaction with DNA. To determine whether the ZFs were necessary for AKAP95 binding 
to E6, the GST-HPV18 E6 pull-downs were repeated with either the wild type protein or a 
mutant containing Cys to Ser mutations (ZF C-S) in both ZF domains to abrogate its DNA 
binding ability. The data shown in Figure 4.20 indicates that disruption of the ZFs does 
not impair the ability of AKAP95 to bind to E6, with the mutant protein actually binding 
E6 more efficiently than wild type AKAP95.  







Figure 4.20: Disruption of both AKAP95 zinc fingers does not impair the 
AKAP95-E6 interaction. Purified GST or GST-HPV18E6 were incubated with 
lysate derived from 293T cells expressing either the FH-wild type or FH-ZFC-S 
AKAP95 mutant. Co-purifying proteins were separated by electrophoresis and 
detected by Western blotting using an antibody against the HA tag. The top panel 
represents the immunoblots while the lower panel demonstrates loading of the GST 







Figure 4.21: Schematic of the AKAP95 domains required for its interaction 
with E6. The various full length FLAG/HA-tagged AKAP95 mutants are shown 
with all known domains marked. The column labelled ‘E6 binding’ highlights 
binding to GST-HPV18E6 in GST pull down assays where ‘+’ indicates binding 
and ‘-‘ indicates no binding. NMTS: nuclear matrix targeting sequence. BiNLS: 
bilateral nuclear localisation signal. NLS: nuclear localisation signal. ZF: zinc 





The replication of the HPV18 genome in primary HFKs was associated with increased 
activity of the PKA holoenzyme. Bearing in mind that many viruses modulate signal 
transduction pathways by targeting individual components of the pathway, it was 
important to determine if HPV interacts with factors associated with PKA signalling, 
including pathway regulators. Scrutiny of publicly available databases for HPV protein 
(E2, E6 and E7)-protein interactions highlighted a potential interaction between diverse E6 
proteins, including HPV18, and the nuclear PKA-anchoring protein AKAP95. 
After first expressing and ensuring that the GST fusions of AKAP95 and HPV18 E6 were 
functional, this novel virus-host interaction was then confirmed through both in vitro and 
in vivo approaches. Using lysates derived from immortalised cervical cancer cells as well 
as primary HFK cells maintaining HPV18 genomes, GST pull-downs and 
co-immunoprecipitation experiments confirmed the presence of an AKAP95-HPV18 E6 
complex in cells.  
While this is, at least to our knowledge, the first description of an HPV oncoprotein 
interacting with a cellular AKAP, viruses such as HIV and adenovirus, also interact with 
AKAPs.  
For HIV-1, viral reverse transcriptase, the protein responsible for converting viral RNA to 
DNA, directly interacts with AKAP194 (Lemay et al., 2008), a cellular AKAP that binds 
to both PKA-RI and-RII holoenzymes and targets them to various subcellular locales, 
including the outer mitochondrial membrane, endoplasmic reticulum and nuclear 
membrane (Herberg et al., 2000; Huang et al., 1999). Functional analysis using siRNA 
knockdown experiments showed that the AKAP was involved in HIV-1 infection of HeLa 




replicative cycle; siAKAP194-transfected cells had 40-50% of early and late reverse 
transcriptase products, resulting in lower levels of viral protein expression. A mutant 
reverse transcriptase protein that could not bind to AKAP149 showed major defects in 
early and late stages of reverse transcription, further confirming a role for the AKAP in 
HIV-1 transcriptional control (Lemay et al., 2008). How the AKAP regulates these 
functions is unclear however it can bind to various proteins that may influence viral 
transcription (Warren et al., 2009). For example, AKAP149 anchors both PKA and PDE4 
to mitochondria, both of which have been implicated in viral replication (Rabbi et al., 
1998; Sun et al., 2000). In addition, PKA is thought to be involved in viral reactivation 
from latently infected cells (Rabbi et al., 1998) and is also incorporated into the HIV-1 
capsid, which may be important for viral infectivity (Cartier et al., 2003). Therefore, PKA 
signalling, at least in part mediated by AKAPs, is likely to be a key regulator of the HIV-1 
life cycle.  
In addition, the adenovirus (Ad) type 12 E1A12S oncoprotein acts as a viral AKAP and 
redistributes PKA-RII holoenzymes to the nuclei of infected cells where it activates the 
viral E2 promoter, whose products are essential for viral replication (Fax et al., 2001). The 
Ad type 5 E1A protein was later shown to bind to both PKA-RI and -RII subunits through 
an AKAP-like domain in the protein’s amino terminus (King et al., 2016). In contrast to 
Ad12, Ad5, despite binding both regulatory subunits, only redistributed PKA-RI subunits 
during infection. Knockdown of the individual PKA subunits (RI, RII, Cα) only affected 
expression of viral proteins from the E3 and E4 transcriptional units, which are early 
transcribed regions whose products regulate the immune response of infected cells (E3) 
metabolism of viral mRNAs, viral DNA replication and modulation of host protein 




data suggest that the E1A-PKA axis was involved in regulating viral transcription, protein 
expression and production of viral progeny (King et al., 2016). Further work from the same 
group showed that this PKA targeting ability was shared between other E1A proteins from 
diverse Ad species (Ads 3, 9, 12 and 40), all of which contain the AKAP-like motif in the 
proteins’ amino terminus previously identified for Ad5. Despite this conserved motif, the 
E1A proteins displayed type-specific interactions with the PKA regulatory subunits, with 
Ad9 relocalising RI and Ad3 relocalising RII from the cytoplasm to the nucleus. 
Interestingly, however, these apparent preferences can be modulated by changes in 
expression of the regulatory subunits; loss of PKA-RI in cells expressing Ad5 E1A 
resulted in its interaction with PKA-RII instead. Finally, knockdown of the PKA subunits, 
similar to Ad5, resulted in reductions in viral genome replication and viral titre, indicating 
that the viral AKAP played an important role in the viral life cycle (King et al., 2018). 
Together, these data highlight the important role that AKAPs play in the life cycle of 
different viruses, which indicate a precedent for the E6-AKAP95 interaction playing a 
functional role in the life cycle of HPV. 
Following on from the confirmation that AKAP95 bound HPV18 E6 in vitro and in vivo, 
whether AKAP95 was a common binder of diverse E6 proteins was then examined. The 
mass spectrometry analysis described in Table 4.1 highlighted a potential interaction with 
E6 proteins from a number of high-risk types in the alpha genera, but not HPV16 which is 
the most prevalent HPV type in cancers. In fact, a GST-HPV16 E6 protein, when assayed 
for its ability to bind to AKAP95, only showed a very faint interaction with AKAP95, 
suggesting that HPV16 E6 was not a major binder of the protein. Interestingly, E6 proteins 
of several HPV types of the beta genera were identified as AKAP95 binders in the mass 




carcinogenesis. Furthermore, the mass spectrometry analysis did not report an interaction 
between the E6 protein of HPV6b, a low-risk alphavirus and AKAP95, and the data 
presented here did not show any apparent binding of the low-risk HPV11 E6 to AKAP95 
in GST pull-downs. The fact that the E6-AKAP95 interaction appears to be restricted to 
those virus types linked to cancer development may suggest that it plays an important role 
in HPV associated carcinogenesis. Furthermore, the E6-AKAP95 interaction is maintained 
in HeLa cervical cancer cells, which may again suggest it is relevant for HPV associated 
cancer. Recently, AKAP95 has been shown to be required for cellular transformation in 
primary mouse embryonic fibroblasts, whereby its loss impedes cellular transformation by 
the oncogenes H-RASG12V and c-MYC in oncogene co-operation assays in tissue culture 
and in vivo tumorigenicity assays in nude mice. These data suggest that AKAP95 is 
required for the oncogene-induced transformation of normal cells to cancer cells (Wei et 
al., 2019), giving further weight to the possibility that the E6-AKAP95 interaction is 
relevant for HPV carcinogenesis. 
A surprising result was the requirement for an intact E6 PBM for AKAP95 binding and 
this was shown to occur in vitro by GST-AKAP95 pull-down of E6 mutants with a 
disrupted PBM, but also in vivo in HFKs harbouring intact HPV18 genomes that express a 
mutant ∆PDZE6 protein. Supporting a role for an active E6 PBM in AKAP95 binding was 
the finding that E6-AKAP95 binding was unaffected by a mutation in the PKA recognition 
sequence that overlaps with the PBM, suggesting that E6-PDZ targeting and not PKA 
regulation of the PBM was important for the interaction.  
AKAP95 does not contain any appreciable PDZ domain structure so, given that AKAPs 
often form multiprotein signalling hubs, we next questioned whether the 




PBM. Scrutiny of AKAP95 protein-protein interaction databases highlighted potential 
interactions with the host PDZ proteins hScrib, ZO-1 and ZO-2. This was interesting given 
that hScrib binds to ZO-2 via its PDZ domains and ZO-2 interacts with ZO-1, suggesting 
that AKAP95 may be interacting with a multiprotein complex composed of these proteins 
(Bauer et al., 2010; Itoh et al., 1999; Métais et al., 2005).  
In vitro GST pull-down experiments confirmed that GST-AKAP95 interacted with hScrib 
in the absence of HPV18 E6. The function of this novel protein-protein interaction is 
unclear, especially as AKAP95 is mainly nuclear and cytoskeletal in localisation and 
hScrib has been reported to largely localise to sites of cell to cell contact, although 
subcellular fractionation experiments have revealed a significant proportion of the protein 
in keratinocyte nuclear fractions (Kranjec et al., 2016). Nuclear hScrib is also seen in 
hepatocellular carcinoma, albeit the functional relevance is unclear (Kapil et al., 2017). 
This raises the possibility that AKAP95 binds to a subpopulation of hScrib protein for an 
as yet unidentified nuclear function. To confirm the exact subcellular fraction of hScrib 
that interacts with AKAP95, proximity ligation assay could be carried out using antibodies 
against both proteins; this technique allows for visualisation of protein interactions in fixed 
cell and/or tissue samples (Klaesson et al., 2018). 
This is not the first report of a PDZ protein associating with a cellular AKAP. Trafficking 
of the β1-adrenergic receptor (β1-AR) back to the cell membrane after agonist-promoted 
internalisation is important for re-sensitisation of β1-AR signalling. This recycling 
mechanism requires the binding of AKAP79 to the carboxyl terminus of β1-AR, leading to 
AKAP79-bound PKA-dependent phosphorylation of the receptor, which is important for 
receptor recycling (Gardner et al., 2006). Subsequent work from the same group showed 




addition, the Dlg1-AKAP79 interaction was responsible for targeting PKA to the β1-AR, 
creating a PDZ-signalosome important for PKA phosphorylation of β1-AR at serine 312 
and subsequent receptor recycling (Gardner et al., 2007). 
Co-immunoprecipitation experiments in HFKs maintaining either wild type or ΔPDZE6 
genomes showed that only wild type E6 interacted with both AKAP95 and hScrib and this 
interaction was lost in cells maintaining ΔPDZE6 genomes. These data suggest that the 
E6-AKAP95 interaction requires an intact PBM as well as the presence of hScrib. This 
experimental approach cannot, however, exclude that other PDZ domain-containing 
proteins that are the targets of the E6 PBM also play a part in mediating the E6-AKAP95 
interaction. To examine whether this is the case, siRNA knockdown of cellular PDZ 
domain-containing proteins in the context of the wild type E6 protein, combined with 
either GST pull-down or co-immunoprecipitation experiments to examine the E6-AKAP95 
interaction, would provide further proof of the identity of the PDZ domain-containing 
protein responsible for mediating the E6-AKAP95 interaction. In addition, while the 
co-immunoprecipitation experiments suggested a multiprotein complex of E6-hScrib-
AKAP95, they cannot confirm the presence of this tertiary complex in cells. To provide 
evidence for this complex, affinity purification techniques such as two-step 
co-immunoprecipitation could be employed. This technique involves sequential 
co-immunoprecipitations using antibodies against two members of the protein complex 
under study and results in the highly selective enrichment of stable protein complexes from 
cell lysates, which is thought to exclude non-specific binders and transient low abundance 
complex proteins (Sciuto et al., 2019). 
What remains unclear is, given that both HPV16 and HPV18 interact (as well as the other 




and Huibregtse, 2000), why AKAP95 binding appears to be restricted to HPV18 E6 and 
from the mass spectrometry data, HPV52 and 45, but not HPV16 and 33. The ability of 
these E6 proteins to target AKAP95 does not appear to be species specific, with the 
mass-spectrometry identified binders HPV18 and 45 in species 7 and 52 in species 9 and 
the non-binders HPV16 and 33 in species 9 (Bernard et al., 2010). Interestingly, analysis of 
the PBM sequence of the high-risk types identified in the mass spectrometry screen 
suggested two common features; the AKAP95 binders all contained a terminal valine 
residue (HPV18 E6: ETQV, HPV45 E6: ETQV, HPV52 E6: VTQV) and the non-binders 
contained a terminal leucine residue (HPV16 E6: ETQL, HPV33 E6: ETAL). As this 
terminal E6 PBM residue is important for dictating substrate specificity, with a valine 
residue preferring interaction with Dlg1 and leucine with hScrib (Thomas et al., 2005), 
perhaps the fact that all the AKAP95 binders contain a terminal valine residue suggests 
that this is an additional targeting mechanism for the virus to interact with hScrib. In 
addition to these carboxyl-terminal sequences, differences in other sequences, such as 
those upstream of the PBM, may also be relevant for this binding (Luck et al., 2012). 
However, for the beta HPV E6 proteins identified in the mass spectrometry screen, there is 
no evidence that these proteins encode PBMs. If these are true interacting partners of 
AKAP95 then this interaction must occur via a different mechanism. It is possible that for 
these E6 proteins, their interaction with AKAP95 is direct and not mediated by a cellular 
PDZ domain-containing proteins. Alternatively, E6 may bind to AKAP95 through a non-
PDZ domain-containing protein; re-interrogation of both the E6- and AKAP95-mass 
spectrometry data identified eight proteins common to both the beta E6- and AKAP95-
immunoprecipitates, including regulators of actin-dependent ATPase activity, cytoskeletal 




Extending this approach, we next determined the E6-binding region on AKAP95. Using 
various AKAP95 mutant expression constructs, these experiments showed that amino acids 
1-100 and the PKA-RII binding site were involved in mediating the HPV18 E6-AKAP95 
interaction. AKAP95 through these amino-terminal residues interacts with a variety of 
proteins known to be involved in RNA processing and transcription, including several 
hnRNP proteins and RNA polymerase II (Hu et al., 2016), although what influence this has 
on mediating the E6-AKAP95 interaction is at present unclear. The finding that the PKA 
binding site was required for this interaction was interesting given that hScrib is a known 
substrate of PKA. Therefore, one possible function of this hScrib-AKAP95-PKA complex 
may be to regulate phosphorylation either of hScrib itself or other downstream substrates. 
In addition, phosphorylation of hScrib by PKA alters hScrib interactions with its major 
binding partner, protein phosphatase 1γ (PP1γ; Kawana et al., 2013; Nagasaka et al., 
2010), and therefore this complex may modulate the hScrib interactome. The change in the 
hScrib-PP1γ interaction mediated by PKA likely results in the formation of a feedback 
loop to control hScrib phosphorylation, although what effect this has on other hScrib 
functions (such as its ability to downregulate ERK activation and regulate 
oncogenic-associated cell transformation) is unclear (Kawana et al., 2013).  
Overall, the data presented in this chapter identified a novel interaction between HPV18 
E6 and the nuclear PKA-anchoring protein AKAP95. Domain mapping experiments 
showed that this interaction was dependent on the integrity of the E6 PBM. Analysis of 
AKAP95-PDZ interactions highlighted a novel interaction between AKAP95 and hScrib, 
which may mediate the binding of E6 to AKAP95. The reverse domain mapping 
experiments showed that the first 100 amino acids and the PKA-RII binding site of 




presence of a multiprotein complex composed of HPV18 E6, hScrib, AKAP95 and PKA-










Figure 4.22: Schematic of the proposed E6-AKAP95 complex. The data 
presented in this chapter identified E6 complexes containing hScrib and AKAP95, 




CHAPTER 5 FUNCTIONAL CHARACTERISATION OF 
THE HPV18 E6-AKAP95 INTERACTION  
5.1 Introduction 
While the full repertoire of signal transduction pathways targeted by E6 is not known, what 
is clear is that these E6 interactions with the host signalosome make significant 
contributions to the completion of the viral life cycle. Thus, the use of HPV life cycle 
models has been very insightful into understanding the role of specific E6-host interactions 
in the infectious life cycle of the virus. One of the best researched E6 interactions is the 
ability of E6 to target the tumour suppressor p53, which is upregulated in response to 
unscheduled cell cycle re-entry in E7-expressing cells.  
As described in section 1.2.4 in the introduction of this thesis, the ability of E6 to target 
p53 is important during the virus life cycle where it contributes to replication of viral DNA 
and episomal maintenance (Flores et al., 2000; Kho et al., 2013; Lorenz et al., 2013; Park 
and Androphy, 2002; Thomas et al., 1999; Wang et al., 2009). Other E6 interactions are 
also important however in regulating viral genome and DNA amplification.  
In an HPV18 life cycle model in primary foreskin keratinocytes in which viral episomal 
establishment is not dependent on E6 immortalizing functions, an E6 null mutant genome 
displayed high levels of p53, a less hyperproliferative phenotype, loss of late protein 
expression and amplified poorly on organotypic raft culture compared to the wild type 
genome. Knockdown of p53 or expression of a wild type E6 protein partially restored viral 
genome amplification in raft culture. In the same study, the effect of various E6 missense 




phenylalanine at position 4 to a valine (F4V; unable to destabilise p53) or leucine (F4L; 
partial degrader of p53). Another mutant containing a substitution of F45, F47 and aspartic 
acid (D) 49, to tyrosine (Y), Y and histidine, the corresponding residues in low-risk E6 
proteins, was used, which does not destabilise p53. Expression of these missense mutants 
could not restore the phenotype of the wild type protein. Unexpectedly, two of these 
missense mutants (F4L, F4V) amplified in raft culture, albeit to a lesser extent than the 
wild type protein, and only in cells lacking p53. Together, these observations indicate that 
additional virus-host interactions are important for viral DNA amplification (Kho et al., 
2013).  
One such host interaction critical for viral DNA amplification is STAT3. HPV18 
replication in monolayer primary HFKs induces the dual phosphorylation of STAT3 at 
Y705 and S727 residues, compared to control cells. In addition, this enhanced STAT3 
phosphorylation is maintained throughout differentiation only in HFK-18 cells. 
Overexpression experiments using the viral oncoproteins E5, E6 and E7 in C33A cells 
showed that E6 could promote this dual phosphorylation and activation of STAT; this 
dependency on E6 for STAT3 phosphorylation was also confirmed in the primary HPV18 
life cycle model. In addition, expression of E6 in C33A cells, but not E5 nor E7, induced 
the activation of two STAT3-dependent reporter plasmids (β-casein, pro-
opiomelanocortin), and this was reduced in E6-expressing cells treated with STAT3 
inhibitors. Furthermore, E6 also induced the transcription of the STAT3-dependent genes, 
including Bcl-XL and cyclin D1. The same study also analysed the effect of several E6 
mutants on STAT3 phosphorylation, with STAT3 phosphorylation increased by E6 in a 
p53 and PDZ-independent manner through the actions of Janus kinases and members of 




phosphorylation site dominant-negative form of the protein or STAT3 inhibitor, showed 
that it was involved in cell cycle progression and maintenance of the viral genome in 
undifferentiated keratinocytes as well as viral genome amplification during differentiation. 
Finally, transduction of keratinocytes with lentiviruses expressing either control or the 
dominant-negative mutant grown in 3D showed that STAT3 was required for expansion of 
the suprabasal compartment and delayed differentiation in cells maintaining HPV18 
genomes (Morgan et al., 2018). Overall, the data indicate that the E6-STAT3 interaction is 
critical for both viral DNA maintenance and genome amplification on keratinocyte 
differentiation. 
In addition to the above E6 interactors, other E6-host interactions such as the PDZ 
domain-containing proteins Dlg1 and hScrib are also relevant for HPV DNA replication. 
Studies in cells harbouring high-risk HPV genomes showed that this PDZ targeting ability 
contributes to the establishment, maintenance and amplification of viral episomes for 
several oncogenic HPV types (Delury et al., 2013; Lee and Laimins, 2004; Nicolaides et 
al., 2011). Furthermore, there is some co-operation between the E6 p53 and PDZ targeting 
functions, with knockdown of p53 by siRNA rescuing episomal maintenance in cells 
lacking the E6 PBM (Brimer and Vande Pol, 2014). E6-PDZ interactions such as hScrib 
are important for regulating E6 oncoprotein expression (Kranjec et al., 2016; Nicolaides et 
al., 2011). 
In the previous chapter, a novel interaction between HPV18 E6 and the nuclear 
PKA-anchoring protein AKAP95 was identified. Given that E6 functions play crucial roles 
at many stages of the virus life cycle, it was of interest to determine the functional 





5.2.1 Influence of HPV18 E6 on AKAP95 expression and localisation 
5.2.1.1 E6 does not direct the degradation of AKAP95 
One of the best-characterised features of high-risk E6 is to induce degradation of a subset 
of host proteins by association with E6-AP, including the tumour suppressor p53 
(Huibregtse et al., 1991) and cellular PDZ domain-containing proteins such as Dlg1 
(Gardiol et al., 1999; Kiyono et al., 1997). Therefore, whether E6 could direct degradation 
of AKAP95 was investigated in transient overexpression experiments. HPV negative 
cervical cancer C33A cells were transfected with HPV18 E6 and AKAP95 (Myc-
AKAP95) expression vectors, individually or in combination and then residual AKAP95 
expression determined by Western blotting 48 hours later. In Figure 5.1 A, expression of 
E6 did not significantly alter levels of endogenous (cf. vector and E6) or overexpressed 
AKAP95 (cf. E6 and E6 and Myc-AKAP95). To ensure that the overexpressed E6 was 
functional in the degradation of known targets, lysates used in experiments shown in 
Figure 5.1 A were examined for p53 levels as an indicator of E6 degradation activity. In 
Figure 5.1 B, expression of E6 results in a decrease of endogenous p53 levels by 
approximately 50% compared to control transfections, suggesting that the exogenously 
expressed E6 is functional. Quantification of three independent experiments of the data 
shown in panel A is given in Figure 5.1 C, indicating that there are no significant 
differences in the expression of either endogenous or overexpressed AKAP95 in cells 
expressing HPV18 E6. 
Further examination of the data showed that overexpression of AKAP95 did not alter E6 
levels, suggesting that the interaction between these two proteins does not lead to 




5.1 A). The interaction also did not affect the ability of E6 to degrade p53; in the presence 
of both E6 and Myc-AKAP95, the level of p53 protein was reduced to a similar level as E6 
alone. These data indicate that AKAP95 levels are not affected by E6, suggesting that this 









Figure 5.1: HPV18 E6 does not degrade endogenous or overexpressed AKAP95 in transient overexpression experiments. A: C33A 
cells were transfected with the indicated expression vectors and AKAP95 protein levels determined by Western blotting 48 hours later. B: 
Lysates taken from panel A were examined for p53 levels as an indicator for E6 degradation activity. C: Quantification of AKAP95 
expression from cells expressing HPV18 E6, taken from three independent experiments. Note that endogenous AKAP95 expression 




To examine the E6-AKAP95 interaction in a more physiological context, lysates were 
prepared from donor matched HFK cells or those maintaining HPV18 genomes and levels 
of AKAP95 were determined by Western blotting. In Figure 5.2 A, there was no 
significant difference in AKAP95 expression between HFK or HFK-18 cells, shown with 
quantification from two independent foreskin donors in Figure 5.2 B. Additionally, 
HFK-18 cells show no differences in AKAP95 protein expression between vehicle 
(DMSO) and treatment with the proteasome inhibitor MG132, whereas the p53 protein 
expression was rescued (Figure 5.2 C). Quantification of three independent MG132 
experiments is shown in Figure 5.2 D, together with levels of p53 as a positive control for 
MG132 inhibition of the proteasome. These data show that E6 does not direct the 
degradation of AKAP95 in primary HFK cells maintaining HPV18 genomes. The 
experiment was repeated using HeLa cells that harbour HPV18 integrants and, as observed 
in the HFK-18 cells, p53 expression was rescued upon treatment with MG132 but 






Figure 5.2: Endogenous HPV18 E6 does not direct degradation of AKAP95. A: Donor matched HFK or HFK-18 cells were 
immunoblotted for AKAP95 expression levels with relative quantification of two donors shown below in panel B. C: HFK-18 cells were 
treated with the proteasome inhibitor MG132 for four hours and AKAP95 protein levels determined by Western blotting. Levels of p53 




5.2.1.2 E6 does not induce subcellular relocalisation of AKAP95 in monolayer 
grown cells 
The data presented in Figures 5.1 and 5.2 indicate that E6 does not direct the degradation 
of AKAP95 either in transient overexpression studies or in cells immortalised or 
transformed by HPV18. While E6 can target several host proteins for degradation, it can 
also induce redistribution of host proteins, such as the PDZ polarity protein Par3 (Facciuto 
et al., 2014). Whether the expression of HPV18 E6 was associated with subcellular 
redistribution of endogenous AKAP95 was examined using a combination of 
overexpression experiments and more physiological experiments using primary 
keratinocytes maintaining HPV18 genomes. 
In Figure 5.3, C33A cells were transiently transfected with HPV18 E6 and the subcellular 
localisation of endogenous AKAP95 determined by indirect immunofluorescence using 
specific antibodies. In these experiments, cells were also stained for p53 as a surrogate 
marker for E6 expression as E6 antibodies are poor at detecting E6 by immunostaining. In 
control C33A cells, AKAP95 was predominantly nuclear with a diffuse uniform 
localisation pattern and excluded from nucleoli. There was also a low level of staining in 
the cytoplasm. In cells expressing E6 (C33A-E6: indicated by white arrows and negative 
for p53 expression), AKAP95 localisation remained nuclear and excluded from nucleoli 
with a low level of cytoplasmic staining, suggesting that exogenously expressed E6 does 
not redistribute endogenous AKAP95. 
Next, primary HFK or HFK-18 cells were used to examine AKAP95 localisation in a 
physiological cell system (Figure 5.4). As in C33A cervical cancer keratinocytes, in 
primary keratinocytes, AKAP95 was largely confined to the nucleus in a uniform staining 




similar in HFK-18 cells except that the nuclear staining was less uniform and more patchy 
in appearance. A low level of AKAP95 staining occurred in the cytoplasm of both HFK 
and HFK-18 cells. These data suggest that the subcellular localisation is of the AKAP is 
not grossly affected by either overexpression of E6 or in cells harbouring intact HPV18 
genomes and expressing physiological levels of the E6 oncoprotein. The less uniform 
nuclear staining pattern (cf. cells indicated by white arrows in HFK and HFK-18 images) 
may indicate that there is some intranuclear redistribution of the AKAP in cells 







Figure 5.3: Expression of E6 does not induce subcellular redistribution of endogenous AKAP95 in C33A cells. C33A cells 
either mock transfected or transfected with an expression vector for HPV18 E6 (C33A-E6) were fixed in 4% paraformaldehyde 
and processed for indirect immunofluorescence, before staining with the indicated antibodies. White arrows in C33A-E6 figures 
represent C33A cells expressing E6, judged by loss of p53 signal. Scale bar: 10 µM. Merge represents all channels. Identical 





Figure 5.4: AKAP95 subcellular distribution is not grossly altered in HFK cells maintaining HPV18 genomes. Donor matched 
HFK or HFK cells maintaining HPV18 genomes (HFK-18) were fixed in 4% formaldehyde, permeabilised in 0.1% Triton-X100 
incubated with an anti-AKAP95 antibody. Images were taken at identical exposure times. Scale bar represents 10 µm. Note that the 





To confirm the lack of clear redistribution of AKAP95 in cells maintaining HPV18 
genomes compared to control cells, biochemical fractionation of both HFK and HFK-18 
cells was carried out. Markers for specific fractions were used to demonstrate successful 
fractionation: GRB2 (cytoplasm), E-Cadherin (membrane/organelle associated), p53 
(nuclear) and cytokeratin 18 (cytoskeletal). Figure 5.5 shows that each of the marker 
proteins was enriched in their expected fraction, demonstrating successful fractionation. 
Next, lysates were examined for AKAP95 and E6 localisation. In HFK cells, AKAP95 
localised to the nuclear (F3) and cytoskeletal (F4) compartments and this was not altered in 
HFK-18 cells. Note that the buffer used to extract F4 (cytoskeletal fraction) contains SDS, 
which solubilises both chromatin and the nuclear matrix; AKAP95 is known to associate 
with both of these structures (Akileswaran et al., 2001; Eide et al., 1998). E6 was present 
in all fractions in HFK-18 cells, but with an apparent preference for the cytosolic and 
cytoskeletal fractions. Taken together, these data suggest that HPV18 E6 expressed from 
intact HPV18 genomes does not redistribute endogenous AKAP95 in primary 
keratinocytes. In addition, the data show that E6 and AKAP95 are both present in nuclear 
and cytoskeletal compartments, suggesting that the E6-AKAP95 complex may occur in 





Figure 5.5: HPV18 E6 does not redistribute AKAP95 in primary human foreskin 
keratinocytes maintaining HPV18 genomes. Donor matched HFK or HFK-18 cells were 
fractionated using the ProteoExtract Subcellular Proteome Extraction Kit from monolayer 
grown cells and each fraction examined by Western blotting for the indicated target 
protein. F1: cytosol, F2: membrane/organelle associated, F3: nuclear and F4: cytoskeletal. 







5.2.1.3 AKAP95 localisation is not altered by HPV18 replication in differentiating 
epithelium 
The data presented so far showed that E6, either overexpressed in isolation or expressed 
from the complete viral genome, does not redistribute AKAP95 in monolayer grown cells. 
However, it was important to determine whether there was any effect on AKAP95 
expression or localisation during the complete viral life cycle. The productive stages of the 
viral life cycle are dependent upon keratinocyte differentiation and therefore HFK and 
HPV18-HFK cells were grown in 3D organotypic raft culture, which accurately 
recapitulates epithelial differentiation and supports the complete HPV18 life cycle (Knight 
et al., 2011; Wilson et al., 2007).  
As shown in Figure 5.6, raft cultures of parental HFKs (top panel) showed the typical 
pattern of keratinocyte differentiation, with each layer clearly identifiable. These layers 
feature the cuboidal cells that make up the basal layer (stratum basal), slightly larger cells 
of the lower suprabasal (stratum spinosum) and upper suprabasal (stratum granulosum) layers 
along with cells of a granular appearance that make up the stratum granulosum. The most 
superficial layer contains the enucleated cells that make up the cornifying layer (stratum 
corneum). In cells containing HPV18 genomes (lower panel), a similar morphological 
appearance is apparent except that there is a significant expansion of the suprabasal 
compartment and retention of cell nuclei throughout the layers.  
Formalin-fixed sections were immunostained for AKAP95 (Figure 5.7). In HFK cells, 
AKAP95 localised to bright nuclear foci throughout all layers of the differentiating 
epithelium and there was no marked difference in localisation in HFK-18 cells, suggesting 





Figure 5.6: Morphology of HPV18 genome containing cells on organotypic raft culture. Donor matched HFK (top panel) or 
HFK cells maintaining HPV18 genomes (HPV18; bottom panel) were grown in organotypic raft culture for 13 days before 
fixation and sectioning. Raft sections were then stained with haematoxylin and eosin to show differences in morphology. The 





Figure 5.7: AKAP95 expression and localisation are not affected by the late stages of the viral life cycle. Donor 
matched HFK or HFK cells maintaining HPV18 genomes (HPV18) were grown in organotypic raft culture for 13 
days before fixation and sectioning. After epitope retrieval, sections were stained for AKAP95 expression and DAPI 
was used to highlight cell nuclei. All images were taken at identical exposures. Representative of staining gathered 

















5.2.2 Functional analysis of loss of AKAP95 in the HPV18 life cycle model  
5.2.2.1 Generation of shAKAP95-containing HFK-18 cells 
Having shown that AKAP95 is not degraded or relocalised during the virus life cycle, it 
was then necessary to determine a functional role for this novel E6 interacting partner. For 
this, human keratinocytes maintaining episomal HPV18 genomes were infected with 
lentiviruses expressing both single and pooled shRNA constructs against AKAP95 under 
the control of a doxycycline-inducible promoter. After drug selection, stable cell lines were 
generated where expression of the shRNA could be activated by adding doxycycline into 
the cell culture media. Figure 5.8 shows AKAP95 knockdown following induction of 
shRNA expression in these cells over a 96-hour experimental time course. The success of 
AKAP95 knockdown varied at 48 hours between the different shAKAP95 constructs 
(~40-60% reduction in AKAP95 expression compared to uninduced cells), but by 72 and 
96 hours knockdown was >80% compared to uninduced cells for all shAKAP95 constructs 
tested, indicating that the shAKAP95 constructs successfully reduced protein expression of 
the AKAP at these time points. 
Unfortunately, during this analysis, the HFK-18 shRNA cells developed a mycoplasma 
infection and so were destroyed. We were not able to repeat these experiments due to time 
constraints and so the data presented here in the HFK-18 shRNA cells should be 
considered preliminary until further experiments in additional foreskin donors and/or using 




Figure 5.8: AKAP95 expression in HFK-18 cells maintaining shControl or shAKAP95 constructs. HFK-18 cells transduced 
with the indicated shRNA constructs were uninduced (UI) or induced with doxycycline for the indicated times and levels of 







5.2.3 Silencing of AKAP95 leads to changes in expression of E6 and E6-PDZ 
targets 
As several viral-host targets are important for regulating the expression of the oncoproteins 
(Kranjec et al., 2016; Nicolaides et al., 2011), the effect of loss of AKAP95 on E6 and E7 
expression, as well as several E6 targets, was examined in HFK-18 cells maintaining the 
shRNA constructs after a 96 hour induction period with doxycycline (Figure 5.9). 
Lysates derived from the cells expressing two of the most effective shRNA AKAP95 
constructs displayed a significant reduction in AKAP95 protein levels compared to control 
cells, showing successful induction of the shRNA. Analysis of viral oncoprotein 
expression in these cells showed that there was a small increase (1.6-fold compared to 





Figure 5.9: Loss of AKAP95 resulted in a slight increase in E6 oncoprotein 
expression. Lysates prepared from HFK-18 cells expressing the indicated shRNA 
constructs were examined for E6 and E7 oncoprotein expression by Western blotting. 





Even though the increase in E6 protein upon AKAP95 silencing was slight, there might be 
a biological effect. Therefore, to determine whether these changes in E6 levels were 
biologically relevant, the expression of known E6 targets, p53, and PDZ proteins Dlg1 and 
hScrib was determined in shRNA-expressing cells.  
The results (Figure 5.10) show that silencing of AKAP95 in HFK-18 cells is associated 
with increased expression of both Dlg1 (2-fold) and hScrib (4-fold), both targets of the E6 
PBM, compared to cells expressing the control shRNA. In addition, there was almost a 
complete loss of p53 protein in AKAP95-shRNA expressing cells. These data show that in 
HFK-18 cells, silencing AKAP95 expression correlates with changes in expression levels 





Figure 5.10: Changes in protein expression of hScrib, Dlg1 and p53 in 
AKAP95-shRNA expressing cells. Lysates prepared from HFK-18 cells expressing 
the indicated shRNA constructs were examined for E6 target protein expression by 






5.2.4 E6 binds to PKA-RII via the E6 PBM 
AKAPs provide a high level of specificity to cAMP-PKA signalling by localising the PKA 
holoenzyme to specific subcellular sites, conveying tight spatiotemporal control to these 
signalling events. The majority of AKAPs (including AKAP95) interact with PKA-RII; 
however, some bind to the RI subunit and some are dual specific (Eide et al., 1998; Pidoux 
and Taskén, 2010). To understand whether E6 binds to the same PKA isoform as 
AKAP95, E6-IP experiments were carried out from HFK-18 cell lysate expressing epitope-
tagged PKA-RI or -RII holoenzymes. The holoenzymes used were tagged with Renilla 
luciferase as the endogenous proteins run close to the molecular weight of the antibody 
heavy chain, which would obscure detection by Western blotting.  
The data shown in Figure 5.11 shows that E6 binds to specifically to both the PKA-RII 
regulatory subunit and the PKA-Cα catalytic subunit, suggesting that it can bind to the 
complete type II holoenzyme. There was no noticeable binding to the PKA-RI regulatory 
subunit. These data show that E6 binds to specifically to PKA-RII.  
Next, whether the interaction with PKA-RII was mediated via the E6 PBM was 
investigated, reasoning that if E6 interacts with PKA-RII via AKAP95 (which requires the 
E6 PBM) then disruption of the PBM should result in a defect in E6-PKA-RII binding. 
Indeed, the data presented in Figure 5.12. shows that wild type E6 (as expressed in 
HFK-18 cells) interacts with PKA-RII and this binding is markedly decreased in cells 
expressing ΔPDZE6 (HFK cells harbouring mutant HPV18 genomes that lack the E6 
PBM; Delury et al. 2013), indicating a requirement of the E6 PBM in mediating the 





Figure 5.11: HPV18 E6 specifically binds the PKA-RII holoenzyme. E6 was 
co-immunoprecipitated from lysates prepared from wild type HPV18 genome 
containing cells expressing the indicated tagged PKA subunits. Data representative of 





Figure 5.12: HPV18 E6 interacts with PKA-RII through its PBM. E6 was 
immunoprecipitated from lysates prepared from HFK-18 cells expressing wild type 
(WT genomes) or ΔPDZE6 (mutant genomes) as well as epitope tagged PKA-RII. 






5.2.5 Activation of the PKA catalytic subunit in HFK and HFK-18 cells 
Since the data presented thus far suggested the presence of an E6-AKAP95-PKA complex, 
mediated via the E6 PBM, organotypic rafts sections from HFK and HFK-18 cultures were 
stained with an antibody that detects the phosphorylated (Thr 197) form of the catalytic 
subunit of PKA, which is a prerequisite for activation of the kinase (Steinberg et al., 1993; 
Yonemoto et al., 1993). The data presented in Figure 5.13 shows that in HFK cells, 
localisation of the phosphorylated catalytic subunit is present in the cytoplasm and nucleus 
of cells throughout all layers of the differentiating epithelium, although the intensity of the 
cytoplasmic signal in the suprabasal layers is somewhat lower than that in the basal and 
uppermost superficial layers. Of note, in the superficial layers, there are cytoplasmic 
aggregates of PKA that may represent keratohyalin granules, which are structures that are 
thought to bind together keratin filaments. In HFK-18 (HFK HPV18) cells, localisation is 
again seen in the cytoplasm and nuclei of cells throughout all layers of the epithelium, 
albeit without any major changes in suprabasal signal intensity. The aggregated staining is 
also present in cells of the uppermost layers. Examination of the nuclei in the HPV18 
genome containing cells showed that activated PKA appeared in more intense 
microdomains compared to HFK cells. Finally, there may be an overall more intense 
staining throughout the epithelium of HPV18 containing cells compared to HFKs, but this 
is a little variable between foreskin donors. Together, these data show that the activated 
PKA catalytic subunit (and hence active PKA signalling) is present in both the cytoplasm 




Figure 5.13: Expression of the activated PKA catalytic subunit in HFK and HFK cells maintaining HPV18 genomes. Donor matched 
HFK or HFK cells maintaining HPV18 genomes (HFK HPV18) were grown in organotypic raft culture for 13 days before fixation and 
sectioning. After epitope retrieval, sections were stained for the activated PKA catalytic subunit (phospho-T197) and DAPI was used to 







5.2.6 E6 modulates AKAP95-PKA-RII interactions  
The binding of AKAP95 to its interacting partners is dynamic and expression of different 
interacting partners in cells leads to alternative AKAP95-complexes (Arsenijevic et al., 
2006). Given that E6 binds to  PKA-RII specifically, the same PKA isoform that binds to 
AKAP95, the next logical question was whether E6 can regulate AKAP95 binding to 
PKA-RII. To investigate this, AKAP95-immunoprecipitates were examined for the 
presence of tagged PKA-RII subunits in C33A cells expressing vector or HPV18 E6 
(+HPV18 E6). The interaction data in Figure 5.14 show that in the absence of E6, 
AKAP95 binds to the complete PKA-type two holoenzyme (as indicated by binding of 
PKA-RII and PKA-Cα), as expected. However, when E6 is co-expressed in these cells, 
there is a substantial loss of PKA-RII and PKA-Cα bound by AKAP95, suggesting that E6 





Figure 5.14: HPV18 E6 regulates the AKAP95-PKA-RII interaction. 
AKAP95-immunoprecipitates were isolated from C33A cells expressing tagged PKA 
subunits as well as HPV18 E6 (+HPV E6), where indicated, prior to Western blotting 








Multiple studies have outlined the important role of E6 interactions for the regulation of 
both replication and maintenance of viral DNA in undifferentiated cells as well as viral 
genome amplification in differentiating epithelium. In addition, these interactions play key 
roles in regulating viral oncoprotein expression and growth of HPV genome containing 
cells. Therefore, examining how exactly the virus interacts with the host cell is critical for 
our understanding of the viral life cycle. The previous chapter demonstrated a novel 
virus-host interaction between the HPV18 E6 oncoprotein and the cellular PKA anchoring 
protein AKAP95, which was mediated by the E6 PBM. In this chapter, the functional 
consequence of this interaction was examined in a mixture of immortalised cells 
expressing HPV18 E6 and primary cells harbouring viral genomes. 
Several HPV18 E6 interacting partners, including p53 and several PDZ domain-containing 
proteins, are targeted for degradation via its association with the cellular E3 ubiquitin 
ligase E6-AP. Using both immortalised and primary cells expressing E6, either in isolation 
in overexpression experiments or from complete HPV18 genomes in physiologically 
relevant cell models, there was no evidence that E6 directed the degradation of AKAP95. 
In addition, other viral targets, such as the PDZ protein Par3, are mislocalised in cells 
expressing E6. In analogous experiments, we found no evidence of a gross redistribution of 
AKAP95 in cells in immortalised cells expressing HPV18 E6, although in the HPV18 life 
cycle model the nuclear staining of AKAP95 was more patchy in appearance than the 
donor matched HFKs, which may suggest some intranuclear redistribution in the presence 
of the complete viral genome. In cells grown in 3D organotypic raft culture, which 




evidence of virus-induced redistribution of AKAP95, with its nuclear localisation in these 
cells identical to control HFKs.  
Of note, rafts from both HFK and HFK-18 cultures had bright nuclear AKAP95 foci and, 
since AKAP95 is linked to regulation of splicing and transcription (Hu et al., 2016; Jiang 
et al., 2013), organotypic raft sections were stained with markers of various nuclear 
domains to ask whether there was any change in virus-induced AKAP95 relocalisation in 
these nuclear subdomains. Staining of raft sections with markers of PML bodies, splicing 
factories (SRP20) or DNA damage (γH2AX) showed no obvious colocalisation (data not 
shown) so it was not possible to fully examine this possibility. Future experiments using 
additional nuclear markers, such as UBF, RPA43 and fibrillarin, which would indicate an 
association with the nucleolus (Marstad et al. 2016) as well as markers of viral replication 
factories (Swindle et al., 1999), would be useful to determine the identity of these 
AKAP95 nuclear foci. Once the identity of these nuclear foci is known, additional 
experiments could be carried out to investigate whether there is any virally-induced 
redistribution of AKAP95 in these nuclear microdomains. 
Next, to examine the function of this novel E6 interactor, HFK-18 cells maintaining 
shRNA constructs against AKAP95 were developed. Loss of AKAP95 in these cells was 
associated with a slight increase in protein expression of E6 but not E7. In addition, 
silencing of AKAP95 was associated with increased protein expression of the E6 targets 
Dlg1 and hScrib, and an almost complete loss of p53. While the loss of p53 protein 
expression may be due to the increased expression of E6, it is likely that, at least for Dlg1 
and hScrib (whose expression increased in shAKAP95 cells, rather than decreased, which 
was unexpected in the light of increased E6), but also for p53, these changes relate to an 




AKAP95 has a known role in regulating gene expression and alternative splicing of its 
targets, the changes in protein expression may relate to alterations at the level of RNA 
processing. To understand whether this is possible, analysis of publicly available splicing 
data from MDA-MB-231 cells showed that loss of AKAP95 was associated with increased 
alternative splicing of Dlg1, which may account for changes in protein expression (Wei et 
al., 2019). As MDA-MB-231 cells are triple-negative breast cancer cells, these results may 
not be representative of the changes in the HPV18 life cycle model established in primary 
HFKs, but these data do give an indication of the potential for AKAP95 to control Dlg1 
gene expression. There was no information on p53 or hScrib in this database, although this 
may represent alterations in gene splicing inherent in these cancer cells. Alternative 
explanations would be that, for hScrib, that the increase in protein expression is 
post-transcriptional and so would not be captured in the alternative splicing data and, for 
p53, that the loss is due to protein degradation. Future experiments using quantitative real-
time polymerase chain reaction to measure changes in RNA transcript levels and 
proteasome inhibition using MG132 coupled with Western blotting in the HPV18 life 
cycle model will provide further insight into the mechanism underlying these changes in 
AKAP95-depleted cells. In addition, knockdown of AKAP95 expression in HFK cells will 
provide information as to whether there is any influence of the HPV18 genome on the 
changes seen here. 
As the data presented in chapter 4 highlighted the importance of the RII binding site for the 
E6-AKAP95 interaction, we wished to determine whether PKA-RII, the PKA holoenzyme 
that associates with AKAP95, was physically associated with HPV18 E6 in HFK-18 cells. 
Using epitope-tagged PKA holoenzymes, these experiments indicated that PKA-RII, but 




one step further, experiments using viral genomes expressing a mutant E6 protein that no 
longer binds to cellular PDZ domain-containing proteins (ΔPDZE6) showed that this 
interaction, like the E6-AKAP95 interaction, was mediated by the E6 PBM. Together, 
these data suggest the presence of an E6-hScrib-PKA-AKAP95 complex in cells 
maintaining HPV18 genomes. The function of this signalling complex was not explored 
due to time constraints but it is plausible that it would regulate PKA phosphorylation of 
downstream substrates. This would be consistent with the work on the β1-adrenergic 
receptor, which showed that a complex composed of Dlg1-AKAP79-PKA was required for 
phosphorylation of the third intracellular loop of the receptor, regulating receptor recycling 
back to the cell membrane (Gardner et al., 2007). Identifying the targets of this E6-hScrib-
PKA-AKAP95 complex is key to understanding the impact of this signalling complex. As 
the E6 PBM mediates the E6-AKAP95 interaction, E6 immunoprecipitations from cells 
maintaining wild type or mutant (ΔPDZE6) genomes followed by identification of PKA 
phosphoproteins by phosphopeptide enrichment prior to mass spectrometry should give an 
indication of what proteins are phosphorylated by this complex (Shohag et al., 2015).  
One interesting target to examine would be CREB. Analysis of chromatin 
immunoprecipitation data from the papillomavirus genome database showed CREB 
binding to the early promoter in HeLa cells (data not shown). As CREB is phosphorylated 
on serine 133 by PKA (and other kinases such as MAPK; Alberini 2009) and this 
phosphorylation event is critical for recruitment of CREB binding protein and subsequent 
activation of transcription, changes in PKA phosphorylation may, therefore, be relevant for 
CREB-dependent transcription from the viral early promoter.  
An alternative hypothesis is that E6 regulates the function of the hScrib-AKAP95-PKA 




various interacting partners leading to alternative AKAP95-complexes in cells (Arsenijevic 
et al., 2004), thus E6 may regulate the formation of AKAP95 protein complexes. As E6 
binds to PKA-RII, the same PKA isoform that binds to AKAP95, E6 may recruit PKA-RII 
from AKAP95-PKA complexes. Consistent with this idea, transient overexpression 
experiments combined with co-immunoprecipitation showed that E6 negatively regulated 
the ability of AKAP95 to interact with PKA-RII. This is consistent with data from Pirson 
group who showed that expression of CDK4 recruited cyclin D3 from AKAP95-cyclin D3 
complexes (Arsenijevic et al., 2004). Thus, E6 may destabilise AKAP95-PKA complexes 
to downregulate nuclear PKA signalling in the HPV genome containing cells. Similar to 
the experiments outlined above, identifying changes in AKAP95-bound PKA 
phosphosubstrates in cells expressing either empty vector or an E6 expressing construct 
would allow for the identification of differentially regulated phosphosubstrates in the 
presence of E6. 
Whether the E6-AKAP95 interaction regulated E6 phosphorylation by virtue of AKAP95’s 
PKA binding ability was investigated. The interaction data presented in the previous 
chapter suggested that this was not the case, as phosphorylation of the E6 PBM would 
inhibit its interaction with hScrib through steric hindrance and, as the data shown indicated 
a requirement for the E6 PBM in mediating this binding, this would, therefore, inhibit 
E6-AKAP95 binding. To demonstrate this directly, E6 was co-immunoprecipitated from 
cells either expressing empty vector or AKAP95 and binding to the known PDZ target 
Dlg1 as well as 14-3-3 (which only recognises the phosphorylated form of the E6 PBM) 
investigated. This preliminary data showed no difference in E6-Dlg1 binding in the 
presence of overexpressed AKAP95 and no enrichment of 14-3-3ζ bound by E6, implying 




Overall, the data presented in this chapter showed that HPV18 E6 did not direct 
degradation or induced gross mislocalisation of AKAP95, either in E6 transient 
overexpression experiments or when expressed from the complete viral genome in a 
physiologically relevant model of HPV18 replication. Instead, there is a signalling 
complex composed of E6-hScrib-AKAP95-PKA in HFK-18 cells, which may regulate the 
phosphorylation of cellular and/or viral PKA substrates. Interestingly, E6 can also 
negatively regulate the interaction of AKAP95 with PKA-RII, which may have profound 





CHAPTER 6 DISCUSSION 
6.1 Overview of findings 
The work presented in this thesis sought to address the hypothesis that HPV18 interacted 
with and modulated the activity of the host cell signalling pathway mediated by the 
cAMP-dependent PKA. Here, using BRET technology in two model systems of HPV18 
replication, there was a consistent activation of the type two PKA holoenzyme (PKA-RII) 
in cells maintaining HPV18 genomes. Transient overexpression experiments found that 
HPV18 E5 regulated PKA-RI signalling in C33A cells and this negatively affected the 
ability of PKA-RI to activate CRE-dependent luciferase transcription. Whether the virus 
interacted with regulators of the PKA pathway was also examined. Using publicly 
available virus-host interaction data, a potential interaction between diverse HPV E6 
proteins, including HPV18 E6, was found with the nuclear PKA anchoring protein, 
AKAP95. This interaction was confirmed in vitro and in vivo using a variety of cell 
systems, including a physiologically relevant model of HPV18 replication in primary 
human keratinocytes and HPV18 cancer cells, suggesting a physiologically relevant 
interaction. Intriguingly, this interaction was mediated by the E6 PBM and, consistent with 
this, we identified a novel interaction between AKAP95 and hScrib that may mediate the 
E6-AKAP95 interaction. In addition, domain mapping experiments showed that the 
amino-terminal 100 amino acids and the PKA-RII binding site on the AKAP were 
important for its interaction with E6. Initial functional analysis of this interaction in cells 
expressing HPV18 E6, either in transient overexpression experiments or in the HPV18 life 
cycle model, showed that E6 did not degrade or induce gross relocalisation of AKAP95, 




constructs against AKAP95 in HFK cells maintaining HPV18 genomes, silencing of the 
AKAP was associated with a slight increase in E6 oncoprotein expression, without changes 
in E7. This was associated with changes in E6 target expression; Dlg1 and hScrib 
expression were increased in cells maintaining shAKAP95 constructs compared to control 
and there was almost a complete loss of p53 in addition in these cells. Furthermore, using 
HFK-18 cells, E6 was found to bind to the same PKA isoform as AKAP95, PKA-RII, and 
this too occurred via the E6 PBM, suggesting a signalling complex of E6-hScrib-AKAP95-
PKA in these cells. Consistent with this, we saw the activation of the PKA catalytic 
subunit, which is a prerequisite for kinase activation, in cells maintaining HPV18 genomes. 
Interestingly, however, E6 was also found to modulate AKAP95-PKA interactions. 
Therefore, the function of this complex may be either for phosphorylation of cellular 
and/or viral PKA substrates or the virus may modulate AKAP95-PKA interactions to 
control the phosphorylation status of host substrates that are relevant for the viral life 
cycle. 
6.2 Regulation of PKA activity by HPV18 
Given that PKA regulates multiple facets of the HPV life cycle through modification of 
HPV and/or host protein function, the activity of the pathway was determined in cells 
harbouring HPV18 genomes.  
The BRET data showed consistent activation of PKA-RII, occurring concomitantly with 
increased levels of cAMP, in HPV18 genome containing cells in two model systems of 
viral replication, which are not due to changes in PKA regulatory subunit expression or 
localisation. As PKA is activated by cAMP, it would first be prudent to examine whether 




methods to examine cAMP levels in cells, including fluorometric enzyme-linked 
immunosorbent assay based methodologies that can quantify cAMP in cell lysates. Using 
assays such as these, whether the virus can induce cAMP could be examined. In addition, 
as cAMP and PKA signalling are compartmentalised within cells, the data may suggest 
that the virus modulates the cAMP dynamic at a specific site (or sites) within infected 
cells, forming an HPV-specific cAMP-PKA-RII microdomain for local regulation of PKA 
substrates. A key experiment, therefore, would be to identify the exact subcellular site(s) 
where this alteration in PKA-RII activity occurs. For this, additional sensors that take 
advantage of the targeting ability of AKAPs (termed A-Kinase Activity Reporters) could 
be used. These sensors have been successfully used to measure the cAMP landscape at 
several subcellular locales, including the plasma membrane, mitochondria, cytoplasm and 
nucleus (reviewed in Paramonov et al., 2015). Alternatively, the fact that the virus appears 
to specifically targets the RII isoform may suggest that manipulation of PKA-RII 
dependent signalling is important for the virus life cycle. Unfortunately, studies examining 
the role of PKA in HPV18 life cycle events do not clarify the exact PKA isoform involved 
and so it is difficult to hypothesize which viral events specifically require PKA-RII over 
PKA-RI. Nevertheless, the use of isoform-specific PKA inhibitors combined with analysis 
of known PKA-dependent processes in the HPV18 life cycle model, such as PKA 
phosphorylation of E6, would be important in delineating the function of PKA isoforms for 
HPV18; Rp-8-Br-cAMPS preferentially inhibits PKA-RI whereas Rp-CAMPS inhibits 
both PKA-RI and -RII holoenzymes (Gjertsen et al., 1995).  
As the BRET data were gathered only in cells grown in monolayer, which represent 
basally infected keratinocytes, it would be interesting to determine whether the same 




through suspension of cells in methylcellulose (Wilson and Laimins, 2005). An alternative 
method to differentiate cells would be through supplementation of cell media with calcium 
(Yuspa et al., 1989). Initial attempts to carry out the BRET assay in calcium-differentiated 
cells, however, were unsuccessful in our hands. 
Experiments to determine the viral protein responsible for the observed PKA alterations 
did not recapitulate the BRET results; however, they did show that the HPV18 E5 protein 
specifically increased PKA-RI and cAMP sensor activity only in cells pre-treated with the 
AC inducing agent forskolin. These data disagree with that of Oh et al., 2009 who showed 
higher basal cAMP levels in E5-expressing cells, although this may reflect differences in 
the sensitivities of the assays used (BRET versus direct measurement of cAMP). 
Nevertheless, these data are consistent with the ability of E5 to active cAMP and PKA in 
C33A cells. Furthermore, the same study showed that E5 induced expression of the EP4 
receptor via a variant CRE site in its promoter via PKA and CREB. In this study, 
experiments using complete PKA holoenzymes showed that PKA-RI activated 
transcription of a CRE-dependent luciferase reporter which, surprisingly, was inhibited by 
co-expression of HPV18 E5. The negative regulation of HPV18 E5 on CRE-dependent 
luciferase transcription occurs via an unknown mechanism and was not explored further 
due to time constraints. Key experiments would be to identify whether the same effect of 
E5 is evident in a more physiological cell system, including HPV18 E5 knockout cells, and 
to identify differentially expressed CREB target genes in cells expressing HPV18 E5. 
6.3 Identification and validation of a novel HPV-host interaction 
At the same time as exploring whether HPV18 replication affected PKA signalling, a novel 




AKAP95 was identified through publicly available HPV-host interaction data. This 
interaction was confirmed both in vitro and in vivo using lysates derived from both 
E6-expressing immortalised and primary cells and was found to be mediated by the E6 
PBM. Furthermore, we identified a novel AKAP95 interactor in the form of hScrib, 
suggesting that the interaction between E6 and AKAP95 is not direct and instead is 
mediated by the polarity protein.  
The binding of hScrib to AKAP95 is particularly interesting given that the two proteins are 
thought to occupy different subcellular locales; AKAP95 is predominantly nuclear and 
cytoskeletal associated and hScrib is thought to primarily localise to sites of cell to cell 
contact. Biochemical fractionation experiments, however, revealed that a significant 
proportion of hScrib protein is in the nucleus of keratinocytes (Kranjec et al., 2016) and in 
liver cancer (Kapil et al., 2017). There is limited information on the function of nuclear 
hScrib; however, one possible nuclear function involves the orientation of the mitotic 
spindle.  
In HPV18 genome containing cells expressing the ΔPDZE6 protein, there is an increase in 
spindle-associated abnormalities in late mitosis (Marsh et al., 2017). As AKAP95 is known 
to form multiprotein scaffolds for the regulation of diverse cellular processes, PKA is 
important for mitotic spindle formation (Matyakhina et al., 2002), and hScrib is involved 
in spindle positioning in mitosis (Zigman et al., 2011), it would be worthwhile examining 
whether the hScrib-PKA-AKAP95 complex was important in maintaining correct spindle 
orientation in the presence of replicating viral DNA. For this, identification of a mutant 
hScrib protein that cannot bind to AKAP95 would be instrumental in establishing whether 




Work on the β1-adrenergic receptor showed that another PDZ protein, Dlg1, is crucial in 
organising AKAP-PKA complexes (Gardner et al., 2007). Therefore, it would be 
interesting to examine the effect of loss of hScrib on the integrity of the complete E6-
AKAP95 complex identified here, reasoning that if hScrib is key for E6 binding to 
AKAP95 then the loss of hScrib will disrupt this complex as well as possibly E6 binding to 
PKA, which may occur via the AKAP.  
The E6 mass spectrometry database suggested that one determinant of E6-AKAP95 
binding, at least for the high-risk types, may be the precise sequence of the E6 PBM, with 
sequence alignment of the mass spectrometry predicted AKAP95 binders showing two 
common features. All predicted AKAP95 binders (HPV18, 45 and 52) contained a 
terminal valine residue while the non-binders contained a terminal leucine residue 
(HPV16, 33). There is currently no data on whether HPV45 and HPV52 E6 proteins bind 
to hScrib so it would be interesting to determine whether these proteins are capable of 
doing so, although a recent report identified hScrib binding as a marker of oncogenicity, 
suggesting that these high-risk E6 proteins do interact with hScrib (Thomas et al., 2016). In 
addition, as additional sequences outside of the E6 PBM are also important for regulating 
E6-PDZ interactions, a key experiment would be to test all predicted AKAP95 binders, 
which not only will help identify whether E6-AKAP95 is a conserved binding event 
among all alpha HPVs, but also whether differences in sequences upstream of the PBM are 
relevant for this novel interaction (Luck et al., 2012; Thomas et al., 2016). 
6.4 Functional analysis of the E6-AKAP95 interaction  
Functional analysis showed that HPV18 E6 did not degrade or induce a gross 




recapitulates the productive phase of the viral life cycle), which is unusual given that E6 
generally targets its substrates through one of these mechanisms. To characterise this 
interaction in HFK-18 cells, cell lines maintaining shRNA constructs against AKAP95 
were developed. Silencing of the AKAP was associated with a slight change in E6 
expression, as well as changes in E6 targets Dlg1, hScrib and p53. The data presented here 
is preliminary and therefore should be repeated using additional methods of AKAP95 
knockdown, such as siRNA, as well as in additional foreskin donors. Furthermore, whether 
these changes are specific to HPV18 genome containing cells needs to be determined. For 
this, knockdown of the AKAP in donor matched HFK cells followed by expression 
analysis of Dlg1, hScrib and p53 needs to be carried out.  
As AKAP95 plays a key role in regulating cellular DNA synthesis through its interaction 
with MCM2 (Eide et al., 2003), it would be interesting to examine whether changes in 
AKAP95 expression are relevant for viral DNA replication and/or amplification during 
keratinocyte differentiation, especially as multiple host proteins are required for efficient 
replication of viral DNA (McBride, 2017).  
An alternative hypothesis is that E6 modulates the activity of the AKAP towards its 
substrates, possibly regulating viral and/or cellular proteins that are phosphorylated by 
PKA. The totality of the data presented in this thesis suggested a multiprotein complex 
composed of E6-hScrib-AKAP95-PKA in HFK-18 cells. While the function of this 
complex is unclear at present, it is likely that it functions as a signalling complex for the 
regulation of viral and/or cellular PKA substrates, akin to the Dlg1-AKAP79-PKA 
complex identified through work on the β1-adrenergic receptor (Gardner et al., 2007). 




In addition, the data showed that E6 physically interacted with the same PKA isoform that 
binds to AKAP95, PKA-RII, and in doing so removes PKA from AKAP95-PKA 
complexes. The functional importance of this modification of AKAP95 behaviour is not 
known; however, a likely consequence would be the downregulation of PKA signalling in 
AKAP95 mediated signalosomes. Indeed, recent evidence has shown that AKAP95 
coordinates a signalling hub composed of AKAP95, PKA and PDEs in the nucleus for the 
regulation of nuclear cAMP. Thus, E6 may disrupt the integrity of this complex, resulting 
in alternations in nuclear PKA signalling, such as those involving the transcriptional 
regulator CREB (Clister et al., 2019).  
Consistent with this newly identified role for AKAP95 in mediating nuclear PKA 
signalling, staining of raft sections using an antibody that detects the activated form of the 
PKA catalytic subunit showed that active PKA was present in both the cytoplasm and 
nucleus of HFK and HFK-18 cells throughout the differentiating epithelium. As the 
nuclear active PKA staining may indicate AKAP95-PKA complexes, and the staining 
results in the rafts show bright nuclear microdomains in the HPV genome containing cells 
compared to HFKs, it would be interesting to examine whether the virus is able to 
modulate these complexes during infection. For this, changes in PKA activation could be 
examined by staining raft sections derived from HFK-18 cultures expressing the ΔPDZE6, 
which no longer binds to AKAP95 nor PKA, compared to the wild type E6 protein. 
Furthermore, similar to the experiments suggested above, identification of PKA substrates 
bound by AKAP95 in cells expressing vector or E6 constructs would be instrumental in 
identifying the consequence of this E6-AKAP modification.  
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• ‘Human papillomavirus type 18 E6 oncoprotein interacts with the protein kinase A-
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• ‘Oncogenic HPV18 interacts with multiple components of the host protein Kinase 
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